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SUMMARY
Resistance to antituberculosis agents became evident soon after antituberculosis
treatment was introduced for the first time. Combined drug therapy seemed to resolve
this problem. Animal experimental studies, which showed that isoniazid (INH)-resistant
strains of Mycobacterium tuberculosis were less infectious and pathogenic than drug-
susceptible strains, gave further reassurance that drug resistance was not a major issue.
Transmission of INH- and multiple-drug-resistant strains did, however, occur.
Studies in children, who develop mainly primary drug resistant tuberculosis (TB),
showed that drug resistance in adults was followed by a similar rise in drug-resistant
(TB) in children, and that tuberculous infection rates in childhood contacts of INH-
resistant and drug-susceptible adult TB cases were the same.
It was however, only after the significant rise in the incidence of TB and large
outbreaks of multidrug-resistant (MDR) TB cases in developed countries (mainly
because of the human immunodeficiency virus epidemic) in the early nineties that
sufficient attention was again focussed on the problem of drug-resistant TB. Drug-
resistant tuberculosis, and more in particular MDR TB, posed a serious threat to global
TB control programmes.
Despite this renewed interest, childhood drug-resistant TB remained neglected. The
incidence of drug-resistant TB among children, which could give a good indication of
currently circulating strains in a community, is hardly known. The management of
childhood contacts of adults with infectious MDR TB or children with MDR TB has also
not been studied prospectively.
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All confirmed childhood TB cases from a specific geographic drainage area over a
3.5-year period were prospectively included in a drug resistance surveillance study. The
incidence of drug resistance in children was comparable to the incidence of initial
(primary plus undisclosed previous treatment) drug resistance documented in adults in
the same area. The findings show that the incidence of drug-resistant TB in children in
the Western Cape province is low, and probably reflects the level of primary drug
resistance amongst organisms currently circulating in this community.
The short- and long-term outcome of children <5 years of age in contact with
infectious adult MDR TB cases was determined by prospective follow-up for 30 months.
The initial evaluation showed an infection rate significantly higher in MDR TB contacts
compared with contacts of drug susceptible cases, but the disease rate was lower. On
follow-up, many more children became infected or developed disease. The finding that
90% of those who developed disease did so within the first 12 months, indicates that
follow-up beyond 12 months is probably not cost-effective in resource poor countries.
The results demonstrate that MDR TB is not less infectious than drug susceptible TB.
Despite the fact that some children received chemoprophylaxis, 24% of the children
eventually developed disease. This is not different from the expected prevalence of
disease in childhood contacts <5 years of age of infectious drug-susceptible adult
pulmonary TB cases.
Restriction fragment length polymorphism analysis confirmed transmission from an
adult source case to a child contact in 5 of 6 adult-child pairs in whom both isolates were
available. If therefore an isolate of M tuberculosis for susceptibility testing cannot be
obtained from a child in close contact with an infectious MDR TB case, the child should
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therefore be treated according to the drug susceptibility pattern of the source case's
strain.
Treatment of children with confirmed and probable MDR TB included 2 or 3 drugs
to which the adult source case's isolate was susceptible in addition to pyrazinamide and
high-dose INH. Duration of treatment ranged from 6 to 12 months depending on the
severity of the disease. INH was included in the treatment regimen because low-level
resistance to INH was present in about half the cases of primary INH resistance. The
pharmacokinetics of INH in children confirmed that an adequate concentration and
exposure time could be achieved for this purpose. Ethionamide often caused
gastrointestinal adverse events, but these could be overcome in most cases by temporary
dose adjustments. The fluoroquinolones, which are not generally recommended for use in
children, possibly caused arthralgia in 1 of the17 children treated for ~6 months. This is
in accordance with previous reports of the safety of these drugs in children for short- and
medium-term treatment.
TB disease occurred significantly less often in children who received appropriate
chemoprophylaxis (according to the drug susceptibility pattern of the adult source case's
isolate). Although this was not a randomised controlled trial, the group that received
chemoprophylaxis was at higher risk for developing disease. This implies that prevention
of TB in MDR contacts is possible. A prospective, randomised controlled study is
necessary to evaluate the best drug combinations and the optimal duration of such
chemoprophylactic regimens.
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OPSOMMING
Middelweerstandigheid het na vore gekom kort nadat antituberkulose behandeling
vir die eerste keer in gebruik geneem is. Die gekombineerde gebruik van middels het
klaarblyklik die probleem oorkom. Diere eksperimente wat getoon het dat isoniasied
(INH)-weerstandige stamme van Mycobacterium tuberculosis minder infektief en
patogenies IS as vatbare stamme, het verdere gerustelling gegee dat
middelweerstandigheid nie 'n groot probleem is nie.
Die oordrag van INH- en multi-middelweerstandige stamme het egter wel
plaasgevind. Studies in kinders, wat hoofsaaklik primêre middelweerstandige tuberkulose
(TB) ontwikkel, het getoon dat middelweerstandigheid in volwassenes gevolg is deur 'n
soortgelyke toename in middelweerstandige TB in kinders en dat die voorkoms van
tuberkuleuse infeksie in kinderkontakte van INH-weerstandige en middelvatbare
volwasse TB gevalle dieselfde is.
Dis egter eers toe daar 'n beduidende toename in die insidensie van TB en groot
uitbrake van multimiddelweerstandige (MDR) TB gevalle in die ontwikkelde lande
(hoofsaaklik as gevolg van die menslike immuungebrek virus epidemie) in die vroeë
negentigerjare was dat daar opnuut aandag aan die probleem van weerstandige TB
geskenk is. Middelweerstandige TB, en in besonder MDR TB, hou 'n ernstige bedreiging
vir globale TB beheerprogramme in.
Tenspyte van die nuwe belangstelling in middelweerstandige TB is die probleem in
kinders steeds afgeskeep. Die insidensie van weerstandige TB in kinders is onbekend
alhoewel dit 'n goeie weergawe van die huidig sirkuIerende stamme in 'n gemeenskap
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sou gee. Die hantering van kinderkontakte van volwassenes met infektiewe MDR TB of
kinders met MDR TB is ook nog nie prospektiefbestudeer nie.
Alle bevestigde kinder-TB gevalle van 'n spesifieke geografiese gebied is oor 'n
3.5 jaar tydperk prospektief in 'n middelweerstandige waarnemingstudie ingesluit. Die
insidensie van middelweerstandigheid in kinders was vergelykbaar met die insidensie
van inisiële (primêre weerstandigheid plus onbekende vonge behandeling)
middelweerstandigheid in volwassenes van dieselfde gebied. Die bevindinge toon dat die
insidensie van middelweerstandige TB in kinders in die Weskaap provinsie laag is. Dit
weerspieël waarskynlik die vlak van primêre middelweerstandigheid in organismes wat
tans in hierdie gemeenskap sirkuleer.
Die kort- en langtermyn uitkoms van kinders <5 jaar oud wat in kontak met
infektiewe volwasse MDR TB gevalle was, is prospektief tydens 'n 30-maande opvolg
bepaal. Die aanvanklike evaluasie het 'n beduidend hoër infeksiekoers in die MDR TB
kontakte in vergelyking met kontakte van middelvatbare gevalle getoon, maar die
siektekoers was laer. Tydens die opvolgperiode het baie meer kinders infeksie of siekte
ontwikkel. Aangesien 90% van dié wat siekte ontwikkel het, dit gekry het binne die
eerste 12 maande, is opvolg ná 12 maande waarskynlik nie koste-effektief in hulpbron-
beperkte lande nie. Die bevindinge toon dat MDR TB nie minder infektief is as
middelvatbare TB nie. Tenspyte daarvan dat sommige kinders chemoprofilakse ontvang
het, het 24% van die kinders uiteindelik siekte ontwikkel. Dit verskil nie van die
verwagte siekte-insidensie van kinderkontakte <5 jaar oud wat in kontak met infektiewe
volwasse middelvatbare pulmonale TB was nie.
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Restriksie fragment lengte polimorfisme analise het oordrag van volwasse
brongeval na kinderkontak in 5 uit 6 volwasse-kind pare, van wie beide isolate
beskikbaar was, bevestig. Indien daar dus nie 'n isolaat van M. tuberculosis vir
vatbaarheidstoetse van 'n kind met nabye kontak met 'n infektiewe MDR TB geval
beskikbaar is nie, behoort die kind volgens die middelvatbaarheidspatroon van die
brongeval se stam behandel te word.
Behandeling van kinders met bevestigde of waarskynlike MDR TB het 2 tot 3
middels waarvoor die volwasse brongeval se isolaat vatbaar was, ingesluit, tesame met
pirasinamied en hoë-dosis INH. Die duur van behandeling het gewissel van 6 tot 12
maande op grond van die omvang van die siekte. INH is in die behandeling ingesluit
omdat dit getoon is dat ongeveer die helfte van die gevalle met primêre INH-
weerstandigheid lae-vlak weerstandigheid het. Die farmakokinetika van INH in kinders
het bevestig dat genoegsame vlakke en blootstellingstyd aan INH vir hierdie doel bereik
kan word. Etionamied het dikwels gastrointestinale newe-effekte veroorsaak, maar dit
kon in die meeste gevalle oorkom word. Die fluorokwinolone, wat nie oor die algemeen
in kinders aanbeveel word nie, het moontlik artralgie veroorsaak in 1 uit 17 kinders wat
vir ~6 maande behandel is, wat vorige verslae oor die veiligheid van hierdie middels in
kort- en medium-termyn behandeling bevestig.
TB-siekte het beduidend minder dikwels voorgekom in kinders wat toepaslike
chemoprofilakse (volgens die middelvatbaarheidspatroon van die volwasse brongeval se
isolaat) ontvang het. Alhoewel dit nie 'n ewekansig gekontroleerde studie was nie, het
die groep wat chemoprofilakse ontvang het die hoogste risiko vir die ontwikkeling van
siekte gehad. Dit dui daarop dat voorkoming van TB in MDR TB kontakte moonlik is. 'n
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Prospektiewe, ewekansig gekontrolleerde studie is nodig om die beste middel
kombinasies en die optimale duur van so 'n chemoprofilaktiese behandeling te bepaal.
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1CHAPTERl
LITERA TURE REVIEW
The history of drug-resistance in tuberculosis
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2Literature Review: The history of drug-resistance in tuberculosis
1.1 The discovery of streptomycin
Soon after the discovery of streptomycin (SM) in 19441 and the introduction of this
anti-tuberculosis agent in the treatment of tuberculosis (TB), the problem of drug
resistance became evident.' Although not the first agent to be used in the treatment ofTB
in man, SM was the one with the most promise, showing the best clinical response. In
1946 Buggs 3 and colleagues showed that other bacteria rapidly acquire resistance to SM.
In the case of Mycobacterium tuberculosis (M tuberculosis) resistance emerged soon
after in vivo and in vitro exposure to SM.2
A small number of tubercle bacilli with relative resistance to SM were thereafter
demonstrated to be present in the sputa of patients who had tuberculosis but had had no
previous chemotherapy, and had probably not been in contact with other patients who
previously had chemotherapy with SM. Levels of resistance were low (no growth on a
medium containing ~ 25 ug/ml SM) and relative resistant organisms occurred
infrequently i.e one in several thousand organisms. The conclusion of this early study
was that "any large number of tubercle bacilli may be expected to contain organisms
which are relatively resistant to SM without having been exposed to the drug"."
The presence of naturally resistant variants in stock cultures of the control M.
tuberculosis strain H37RV was also demonstrated.l' 6
Resistance gradually increased (number of resistant organisms and degree of
resistance) in 6 of 8 patients within 1 to 4 weeks of starting SM chemotherapy but only
became predominantly resistant at 6 to 13 weeks." It was speculated that SM did not
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3cause resistance, but was responsible for selective propagation of the relatively resistant
organisms. Drug resistance to SM had been shown to persist after subculture and after
passage through animals.Ï: 8 This led the investigators to conclude already in 1947 that
SM resistance was an inherited genetic change and the importance of understanding the
mechanism of resistance was evident."
The initial reports on results of trials with SM in pulmonary TB were "encouraging
but inconclusive". 9 The first case control study of SM in the treatment of pulmonary TB
was undertaken by the British Medical Research Council (MRC) from 1946 and the first
report was published at the end of the initial6 months." Treatment with SM was shown to
be of some benefit in about half the patients but no clinical cures were effected and only
15% became bacteriologically negative. The observation that therapeutic results were
related to the degree of drug resistance that developed was probably a more important
finding. In 35 of 41 patients in whom data was available, resistance was >10 times (up to
2000 times in 13 cases) that of the original strain of the patients or control (H37RV)
strain. Some essential points were raised in the discussion that would have an effect on
future antituberculosis management: 1.) Emergence of SM-resistant strains may be
prevented by adding another drug to SM treatment or by a special rhythm of treatment;
2.) SM resistance develops within 2 to 3 months of SM treatment in a patient with open
(cavitary) TB and further treatment or a repeat course later is unlikely to be effective
(The time it took to determine resistance was too long to establish whether to continue
SM or not); 3.) The danger to public health of dissemination of SM-resistant strains was
realised." The far greater frequency of emergence of resistance during treatment of
cavitary TB compared with noncavitary TB was confirmed as early as 1949.10,11
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4The first reports of transmission of SM-resistant M tuberculosis in man came in
1949. Bogen was quoted with regards to the case of a nurse working with SM treated
patients who contracted TB and the M. tuberculosis strain recovered from her sputum
was resistant to 1000 ug/ml on original isolation.V A further two individual cases of
"primary" (i.e. no previous treatment with antituberculosis drugs) SM-resistant
pulmonary TB in healthcare workers were described during the same year.13, 14 Both
patients had direct contact with source cases who had pulmonary TB and had received
SM treatment. None of the cases themselves had received previous chemotherapy,
although in one patient a calcified nodule was present prior to the confirmation of TB.
High level SM resistance was present before initiation of any treatment. These ominous
cases confirmed the potential public health problem of drug-resistant TB.
In a study of the origin of resistance to penicllin and streptomycin amongst bacteria
other than M. tuberculosis, Demerec15 offered evidence that bacterial resistance
originates from spontaneous gene mutations and that the way to prevent the development
of resistance was to use two antibiotics (when such were available) that affect the same
pathogen, but are independent in their actions. Although this study did not include M
tuberculosis organisms, it supported what previous investigators suspected.v"
By 1948 it was generally agreed that resistance to SM arises by a process of
spontaneous mutation." Why was it that only some patients developed SM-resistant TB
while on SM-treatment? In a quantitative study with different M. tuberculosis strains
(H37RV, and strains from two patients with pulmonary TB, one of whom developed SM-
resistance on treatment) Yegian and Vanderlinde 6 noted that an increase in the
population of one parent strain was accompanied by an increase in the number of variants
resistant to a specific concentration of the drug but that populations in different cultures
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5showed a great variation in the number of resistant variants present. This was explained
by chance selection. The clinical significance of their findings was that: 1) sample size
can determine whether resistant forms will be observed, 2) conclusions on drug
resistance from a single sample (e.g. a single sputum sample) should be interpreted with
care, because all variations in resistance of the bacterial population in the diseased areas
of the patient are probably never represented. This could also be influenced by uneven
penetration or concentration of SM (or other drugs) to different areas which could lead to
differences in selective propagation of resistant organisms. One of these highly resistant
variants was found in every 108_109 bacilli in the original inoculum but proportions
varied considerably with different strains and in different experiments with the same
strain."
1.2 Para-aminosalisylic acid (PAS)
The problem of drug resistance received much attention in early studies and some
possible solutions were suggested, one of which was the use of more than one drug in the
treatment of TB. In the same year that SM was introduced as treatment for TB, a second
promising antituberculosis drug was being experimented with in animal models and
man.16, 17 Para-aminosalicylic acid (PAS) was discovered by Lehman in 1943 (after work
done on sodium benzoate and sodium salicylate by Bernheim 18) and showed in vitro
activity against tubercle bacilli. The first patients were treated in 1946 with a favourable
effect on clinical TB, one month before SM was administered for the first time."
A randomised placebo controlled trial in Swedish sanatoriums showed considerable
improvement in patients' condition treated with PAS compared to a placebo control
group. I7 No susceptibility tests were reported in this study. In in vitro studies SM
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6resistance had no effect on the bacteriostatic effect of PAS.19 Several studies showed an
added effect of PAS and SM when given together, as long as the strain was not resistant
to SM.19-21Combining SM with PAS in in vitro studies demonstrated that this
combination prevented the development of SM resistance. The addition of PAS to SM
treatment as a relatively non-toxic drug would therefore be advantageous to the use of
SM_22The true value of combining PAS and SM in the treatment of pulmonary TB was
confirmed in a controlled trial which showed that the association of these 2 drugs
substantially reduced the risk of developing drug resistance.r'' 24 Due to the gastro-
intestinal side effects of PAS, already observed in animal model.l" a follow-up
controlled trial was performed to determine whether a smaller dose of PAS would be as
effective in preventing the development of SM resistance. Although the clinical results of
treatment were similar in all 3 groups (5, 10, and 20g PAS daily by mouth with 19 SM
intramuscularly daily), the SM susceptibility tests showed a clear difference with
resistant strains remaining low only in the group on high-dose PAS.25
PAS resistance seemed to be much less common and took much longer to develop.
Early reports determined the shortest period of single drug PAS treatment resulting in
PAS resistance to be 157-184 days (22-26 weeksj.i': 26This lack of development of PAS
resistance was also observed in in vitro studies.22
1.3 Early surveillance of drug resistance
By 1951 fifteen published cases of primary (transmitted) SM-resistant TB were
collected, six of whom had TB meningitis.F: 28The first cases of primary PAS-resistant
TB were described by Thomas et al.29In the same report they documented the first case
of primary multiple resistant TB (SM & PAS), although the source case was not
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7identified. The risk of treating with a single antituberculosis drug was again emphasized,
since this often leads to the development of drug resistance and may be responsible for
contacts being primarily infected with such strains. In their study 3 or 4 patients were
most likely superinfected with a drug-resistant M tuberculosis strain. This possibility
was confirmed by DNA fingerprinting many years later.3o
In 1952 isoniazid (!NH) was introduced for the treatment of TB. In the series of
Thomas et a1.29two patients developed resistance to !NH while on treatment with a
combination of two drugs (including !NH), for one of which the infecting strain was
already resistant. Giving two drugs therefore did not prevent the development of !NH
resistance if the strain was already resistant to the second drug. Adding one drug to a
failing regimen is now well recognised as a dangerous practice.
The first thorough survey of SM resistance was done during a seven-month period
in 1952 in the USA.31 Results of SM susceptibility tests of 5526 consecutive admissions
to 30 hospitals were analysed. Primary SM resistance occurred in 30 of 1166 (2.6%)
patients, while acquired resistance was present in 20.4% of 1360 patients with known
susceptibility results of their M tuberculosis strains." In an editorial at the time it was
concluded that, except for contact within a TB hospital (12 of the 30 patients with
primary drug-resistant TB most likely contracted it in hospital), primary drug resistance
did not seem to be a serious public-health hazard.32 A survey on primary drug resistance
between July 1953 and January 1955 among patients with pulmonary TB in New York
yielded a prevalence of 1.6% and 2.3% for SM and !NH resistance respectively, a result
which gave further "reassurance" that primary drug resistance was not a major problem"
Beck,34 who studied primary drug resistance in one TB hospital in New York from 1948,
found an incidence of 2%. Of the 10 patients with drug resistance all had SM-resistant
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8tubercle bacilli and 2 of them were multiply resistant (SM & PAS).34 In this report he
also described for the first time the transmission of drug-resistant tuberculous infection at
a post-mortem examination. Furthermore he concluded that the incidence of infection
with drug-resistant tubercle bacilli would become more infrequent as a result of multiple-
drug treatment, surgical procedures and the availability of more antituberculosis drugs.
Fox et a1.35were much more cautious in their verdict on the public health hazard
after a national survey of primary drug resistance in the United Kingdom during 1955-
1956. The prevalence of primary drug resistance to one or more of the commonly used
drugs (SM, PAS, and INH) was 5,1% (95% confidence interval: 4.1-6.5%) with SM
resistance at 2.3%, PAS at 2.2%, and the recently introduced INH already at O.7%_35
Contrary to the previous investigators they found the prevalence of drug resistance high
enough "to make it a problem of some importance". They suggested that patients with
cavitary pulmonary TB should begin treatment with all three the common
antituberculosis agents simultaneously until susceptibility results were available" The
adoption of this initial triple drug regimen already took place between 1956 -1959 in the
United Kingdom."
In an International Union against Tuberculosis survey during 1957, drug resistance
was confirmed to be a worldwide problem.V Acquired drug resistance in hospital
admissions in several countries was 42% and primary drug resistance was 6.5%. Crofton
37 called for not only the correct drug combinations to be used but specifically for
enthusiastic cooperation between all branches of TB services (public health services) to
be able to defeat TB.
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9By the end of the initial era of SM and PAS, it was clear that treating patients with
either of these drugs or a combination of both agents showed results much better than
those in groups treated by bed rest only" Although high dose PAS (20g/day) in
combination with SM decreased the development of SM resistance dramatically, even
lower doses of PAS (5 & IOg/day) had considerable effect on the reduction of SM
resistance."
1.4 Thiacetazone
A third antituberculosis drug was developed in Germany in 1946 by Domagk et
a1.39 Thiacetazone or Conteben (4-acetylaminobenzaldehyde thiosemicarbazone) was
selected as the best drug for human therapeutics from a group of compounds called
thiosemicarbazones. These compounds were developed from studies with sulfonamides
and sulfones (the first antibiotic agents) as well as the sulfathiazole and sulfathiodiazole
series.39-41 The drug was employed to treat patients with TB in Germany from 1947 but
its evaluation was hampered by many post-war changes and problems such as increased
weight of returning soldiers because of improved diets, and the unavailability of adequate
chest radiograph facilities.V' 43 Thiacetazone showed good clinical promise from
observations in more than 7000 patients treated with this drug but it fell into disuse
because of its relative toxicity at the high dosages given at the time and the discovery of
the antituberculous activity of!NH in 1951.43
Itwas only when a cheap effective drug was sought as a companion drug to !NH to
prevent the emergence of resistance for the use in low income countries when
thiacetazone was brought back into treatment regimens in the early 1960s.44 After a
number of pilot studies to determine the optimal dose of both drugs, a controlled clinical
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trial using INH 200mg (100mg twice daily) plus thiacetazone 150mg as a single daily
oral dose proved to be as effective as the standard combination of !NH and PAS in
producing sputum conversion and in preventing the emergence of !NH-resistant strains.f
(In follow-up studies the dose of!NH was increased to 300mg per day.46,47)An initial
supplement of 8 weeks of SM improved these results, with significantly less !NH
resistance developing in the SM-group and a considerably higher rate of bacteriologically
negative sputa at 6 and 12 months in the latter groUp.46,47
1.5 Isoniazid (IND)
In 1952 Bernstein et a1.48described the antituberculous activity of isoniazid (INH),
or isonicotinic acid hydrazide (Nydrazid) as it was originally named, for the first time.
!NH and its derivatives had a great specificity for mycobacteria." The drug was a highly
active antituberculosis agent in mice at low oral dose and had a wide therapeutic index."
There was complete and rapid absorption after oral administration of !NH to mice and
dogs, and it was well tolerated.Ï''
Investigations in man of the antituberculous activity of !NH started in November
1951.51 Pharmacokinetic studies confirmed rapid absorption and low potential for
toxicity after oral administration of Jmg/kg/day.t' High concentrations of !NH were
attained in cerebrospinal fluid. This first report was, however, too soon to make
statements on the effectiveness of !NH in tuberculosis treatment in humans or the
development of drug resistance. The addition of another new antituberculosis agent was
viewed with some reserve by the Executive Committee of the American Trudeau
Society.52
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The first report of !NH resistance developing during treatment of patients came in
April 1952.53,54 Steenken et a1.53,who also described in vitro !NH resistance in some
variants of drug susceptible cultures of tubercle bacilli together with others, 55-57
demonstrated resistance in 4 of 6 patients treated with hydrazines of isonicotinic acid
(including !NH). Their conclusion was that patients should receive treatment with !NH in
such a way as to not encourage resistant organisms to appear, i.e. combination therapy.53
An additive (synergistic) effect of SM and !NH was documented in vitro.49, 58 It
was further shown that tubercle bacilli resistant to SM were still susceptible to !NH and
vice versa." Middlebrook 55isolated !NH resistant variants (mutants) of M tuberculosis
with 4 different in vitro methods from !NH-susceptible cultures. Untreated cultures of
tubercle bacilli contained a higher proportion of !NH-resistant mutants than of SM-
resistant mutants. 55,57,59Middlebrook 55could not, however, get any organisms to grow
from these same cultures in mediums containing both SM and !NH at low concentrations.
He suggested that combination therapy would probably be essential for the public health
control of the disease. 55
1.6 Combination therapy vs. single drug treatment
After a series of randomised controlled studies comparing different options of TB
treatment, the British MRC compared !NH treatment with SM and PAS, the best
antituberculosis treatment at the time. 59It was now established that !NH resistance does
develop in patients, the rate at which this occurred was, however, still unclear.ï" Clinical
and radiological improvement was similar in both groups after 3 months of treatment
although weight gain was better with !NH alone. Resistance to !NH developed early in
the !NH alone treatment group. Within a month, two months and three months after
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initiating the latter treatment, 10%,50% and 70%, respectively, of cultures obtained were
resistant to INH.59 The second report of the British MRC 61 on INH treatment confirmed
this development of resistance to INH but also clearly showed that a combination of SM
and INH, if the initial culture was susceptible to both, prevented the development of drug
resistance to either of these drugs in the majority of cases. A combination of INH and SM
was also shown to be the best treatment for TB.61 Some important lessons on the
development of drug resistance were now evident: 1.) No antituberculosis drug should be
used alone in the treatment of pulmonary TB; 2.) Treatment regimens should contain 2
drugs to which the organism is susceptible, therefore drug susceptibility tests should be
done before therapy is started. If not, resistance to one drug in an unsuitable combination
may lead to resistance developing to the second drug, and; 3.) Taking a history of
previous use of antituberculosis drugs before initiating treatment could be of great value
in considering which drugs to use in a combination, since culture/susceptibility results
are not always immediately available. A history of previous treatment with any (single)
drug or contact with a person who received previous TB treatment and the results of this
source case's susceptibility tests may be a guide in making the correct choice of
treatment."
The fourth report of the British MRC 62 on the treatment of pulmonary TB with
INH, SM and PAS addressed the specific issue of emergence of drug resistance up to six
months of treatment. In the group treated with INH alone, 58% of the total number of
patients were INH-resistant at the end of the six month period (that is 100% of all
cultures obtained at six months). Combinations of SM plus INH and SM plus PAS,
however, restricted the development of resistance to SM and/or INH to between 0 to 5%
of the total number of patients in each group confirming the value of these combinations
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in preventing drug resistance.f In vitro evidence suggested that strains resistant to !NH
may revert to susceptibility when contact with !NH was stopped.t" 63 Although its
occurrence was considered in some patients after !NH treatment was stopped/" the
British MRC study did not show a general reversion to susceptibility over a 3 month
period after discontinuing !NH which suggested that resistance to !NH is not usually
transient. 62
Despite a recommendation by members of the Twelfth Chemotherapy Conference
held in 1953 at Atlanta, Georgia, that studies with !NH alone should be abandoned
because of emergence of resistance with single drug therapy, Phillips 65 compared
treatment with !NH or !NH plus PAS in groups of patients with noncavitary pulmonary
TB. He found both groups to do equally well with little !NH-resistance developing. This
was probably because of the low number of bacilli in these lesions and therefore the risk
of drug-resistant mutants being present was small (see section 1.12). The same results
were obtained with !NH alone by Lauckner 66 in primary TB in Nigeria.
Due to cost constraints in developing countries, !NH alone was again compared to
combination treatment in patients with extensive pulmonary TB in these countries and
was shown to be definitely inferior to combination therapy even despite high dose
!NH.66,67 After 8 years of trials it was finally recommended that!NH should not be used
alone in these patients and that combination therapy should be preferred even in low-
income countries." This was where thiacetazone, one of the first antituberculosis agents,
re-entered the scene. (see section 1.4)
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1.7 Pyrazinamide (PZA)
At about the same time when INH was introduced as an effective antituberculosis
agent, McKenzie and her co-workers reported the effect of nicotinamide on experimental
TB of mice." Kushner and associates then developed pyrazinamide (Aldinamide) and
evaluated its effect on experimental TB in mice over the next three years." The
antituberculous activity of pyrazinamide (PZA) in mice and guinea pigs was
demonstrated to lie between that of SM and PAS, being superior to the latter.69,7oPZA
had no effect on Mi bovis. 69
Treatment with PZA was started in the first patients in 1949.7! It appeared that PZA
had a moderate degree of antituberculous activity with initial clinical improvement in
most patients. Resistance emerged rapidly, in some cases within 15 days of initiating
treatment. Itwas again noted that resistant tubercle bacilli appeared more rapidly in those
patients who had large pulmonary cavities and expectorated large quantities of sputum
with high bacillary contents." The method for determining resistance to PZA was,
however, complex and development of other methods was desirable.f The determination
of resistance to PZA has remained a serious technical problem.
Combinations ofPZA and INH were more effective than either drug used alone.Ï"
75More important was that this combination was the only regimen capable of sterilizing
the organs of mice after a 12-week treatment period, an observation at first ignored by
the TB community but which later contributed to the development of short course
chemotherapy.76-78
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1.8 Other antituberculosis drugs developed in the 1950s
Several other antituberculosis drugs were developed during the period 1950 to
1960. Many were derived from different Streptomyces species, e.g. viomycin (1950;
Streptomyces puniceus)/9 cycloserine (1955; Streptomyces orchidaceus),8o kanamycin
(1958; Streptomyces kanamyceticusï." and capreomycin (1960; Streptomyces
capreolus).82 They were all less effective, had to be used in combination with existing
antituberculosis drugs, and caused more pronounced toxic effects."
Ethionamide (alpha-ethyl-thioisonicotinic acid), another second line
antituberculous drug, was derived from isonicotinic acid in 1958. It exerted a bactericidal
effect on growing cells and was reported to be more effective than SM but less effective
than INH.84 As with all previous antituberculosis drugs, clinical trials indicated that it
should not be used alone. Toxic effects, which were more common in adults than in
children and restricted its use, were gastric intolerance and reversible liver damage/"
1.9 Ethambutol (EMB)
In 1961 a new synthetic compound, ethambutol (EMB), was described. It was
chemically unrelated to any of the known antituberculosis drugs and shown to be active
in vivo and in vitro against mycobacteria.f" 86 It acts only on actively proliferating cells,
and is specifically antimycobacterial.P''" Development of resistance in vitro was slower
and smaller in magnitude than with SM or INH, and EMB was fully active against SM-
and INH-resistant mycobacreria.f'' 86 Studies in monkeys with experimental TB showed
that although EMB had substantial antituberculous activity, it was inferior to INH but
that the therapeutic outcome of a low dose combination of the two drugs was strikingly
better than either compound given alone." Studies in humans began in 1961.89 It was
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initially used with good effect as a single oral drug in retreatment cases, but resistance
developed in about 35% of cases." The only apparent side effect was visual disturbance.
This was dose related.89, 91 When EMB was used in combination with other
antituberculosis drugs to which the infecting strain was susceptible, clinical responses
were good with bacteriological relapses and bacterial resistance being mostly
prevented. 90, 92, 93 Specifically in combination with INH with or without SM, EMB has
shown to be superior to PAS, mainly because of less side-effects and better acceptance. 90,
94,95
1.10 Rifampicin (RMP)
Rifampicin (RMP) was the last of the current "first line" antituberculosis drugs to
be discovered. It remains the most important component of short course
chemotherapeutic regimens. It was developed by Maggi et a1.96 in 1965 as a
semisynthetic derivative of the rifamycins, a group of antibiotics isolated from
Streptomyces mediterranei in 1957.97 In the first clinical studies reported in 1967 and
1968, 120 adults who had chronic cavitary pulmonary TB and were excreting bacilli
resistant to primary and most secondary drugs or were intolerant to these, were treated
with RMP, either alone or in conjunction with other drugs." In the pooled results
summarized in the review, 72 patients showed bacteriologic evidence of sputum
conversion after 2 to 6 months, but in 11 cases RMP resistance appeared after 6 weeks to
4 months." Virchowand Flemming'" noted that when RMP was given alone, it soon lost
its efficacy and selectively induced resistant mutants. Although not mentioned as such in
an extensive review on rifampicin in Drugs," some of the many chronic pulmonary TB
patients with drug resistance who subsequently received RMP alone, must have
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developed multidrug-resistant (MDR) TB (i.e. resistance to !NH and RMP with or
without resistance to other drugs). In a randomized controlled trial of new TB cases,
treatment with RMP in combination with !NH or EMB compared with RMP alone was
very effective.l'" RMP resistance emerged in only one of 30 patients in the RMP-alone
group.
After all the lessons learned from previous experience, and a generally accepted
rule that at least two drugs to which the infecting strain is susceptible should be used in
the treatment of TB, RMP was again often initially used alone or as a single drug added
to an already failing regimen, with the result that resistance often emerged. Canetti et
al.lol confirmed that, although the rate of resistant mutants against RMP was low in most
wild strains (in the order of 107 or less), this did not justify treatment of cavitary TB with
RMP alone. However, when RMP was used in combination with EMB as a second new
drug in a failing regimen, the results were promising.l'"
It soon became clear that the efficacy of RMP was comparable to that of !NH.lol
Even more important was its sterilizing effect when given in conjunction with !NH.lo3-lo5
Sterilisation in this context referred to not being able to culture any bacilli from infected
mice after treatment, a result that had not been obtained in mice after 4 months of
treatment with any other combination of antituberculosis drugs.l'" This was of
fundamental importance in the subsequent development of six-month short-course
chemotherapy for patients with primary TB.lo6
1.11 A eaU for revival of active interest in drug-resistant tuberculosis
About 20 years after the discovery of the first antituberculosis drugs, Canetti called
for a revival of active interest in drug resistance in TB.I07 The main biological facts of
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TB drug resistance were all discovered in the first 10 years of chemotherapy and in the
following 10 years a decline in the general interest in research in this area was apparent.
The main reason for this lack of interest was that optimal chemotherapy reduced the
emergence of resistance so drastically that it was thought to be of only historical
importance. Canetti 107warned that although the problem might be small for advanced
countries, although primary drug resistance was relatively high in France at the time,108
developing countries did not have the resources to apply the new methods of preventing
drug resistance and would therefore still produce a considerable amount of drug
resistance.
1.12 Bacillary populations and drug resistance
Resistance is a phenomenon linked to large bacillary populations. In human TB the
greatest populations, in the order of 107 to 109 bacilli, are found in cavities, whereas
those found in hard caseous foci, such as found in extrapulmonary TB (and primary TB
in children), usually do not exceed 102 to 104 bacilli.l07 Wild strains of M. tuberculosis
do contain a few resistant mutants for almost all drugs among 106 bacilli.l'" Hugo David
109calculated that the highest proportion of mutants that can be expected in unselected
populations of the tubercle bacilli was observed to be as follows:
3.5 X 10-6 and 3.1 x 10-6 to 0.2 and l.Oug ofINHlml, respectively;
3.8 x 1O-6t02.0Ilg ofSMlml;
3.1 X 10-8to l.Oug ofRMP/ml;
0.5 X 10-4to 51lg ofEMB/ml.
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The mutation rates to resistance to the drugs were determined to be:
2.56 x 10-8mutations per bacterium per generation for INH;
2.95 X 10-8 mutations per bacterium per generation for SM;
2.25 X 10-10 mutations per bacterium per generation for RMP;
1.0 x 10-7mutations per bacterium per generation for EMB. 109
These naturally occurring drug resistance mutation rates were later established to
be as follows:
1 in 108 for RMP;
1 in 106 for INH, EMB, SM and PAS;
1 in 103 for ethionamide, capreomycin, cycloserine and thiacetazone.l'"
Both the number of organisms present and the possibility of resistant mutants being
present have important implications for treatment of patients. In latent TB infection, with
low numbers of bacilli, there is an almost negligible chance of eliciting resistance by
using INH as a single chemoprophylaxis agent.107 An even more important question was
whether an initial phase of treatment with multiple antituberculosis drugs and a
continuation phase with fewer drugs for a longer period would be sufficient treatment
and still prevent emergence of resistance.107, III The rationale behind this was that the
bulk of the bacilli are killed with the initial treatment, and the low number of remaining
bacilli held a low risk for the development of resistance during the continuation phase.
This had been experimentally confirmed in mouse studies 112, 113 and in humans in the
first International Union against TB trial. 114 This principle is now generally accepted.
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1.13 Cross-resistance
Cross-resistance is rare among the unrelated antituberculosis drugs. Some cross-
resistance occurs between related agents. Cross-resistance is a rare cause of the
emergence of resistance.!" The therapeutic consequence of the latter observation and the
number of organisms present in cavitary lesions, makes the presence of mutants which
are double-resistant to any two drugs unlikely in any previously untreated patient.'?' A
doubly resistant mutant should only occur once if the total bacillary population were
about 1012, an occurrence rate higher than expected, even in extensive pulmonary TB."5
This reasoning confirms the well known fundamental prerequisite for antituberculosis
treatment of at least two drugs to which the strain is susceptible.
Knowledge of cross-resistance such as that between ethionamide and thiacetazone
and some of the aminoglycosides is important for selecting acceptable drug-regimens for
specifically multidrug-resistant tuberculosis (MDR TB).116
1.14 Virulence of drug-resistant M. tuberculosis strains
The virulence of INH-resistant strains of M. tuberculosis has been a subject for
debate since the early 1950s. Many researchers clearly demonstrated that INH-resistant
tubercle bacilli lost no virulence for mice or guinea pigs.60, 117, 118 Subsequently, however,
reports from reputable investigative laboratories claimed a decrease or loss of virulence
of these strains in experimental models.119-123 Although a loss of virulence in catalase-
negative strains is expected to have its counterpart in human TB, it is also known that this
must be limited, as cases of primary drug resistant TB with highly INH-resistant catalase-
Stellenbosch University http://scholar.sun.ac.za
21
negative strains do exist.107 This loss of virulence was not found in M. tuberculosis
strains resistant to SM.7, 8
Canetti 107 and Tripathy et al.I24 showed that INH-resistant strains obtained from
patients with primary INH-resistant TB had considerable lower levels of INH resistance
than those obtained from patients with acquired INH-resistant TB. Two possible
explanations were given: 1.) the resistance may have dropped in the newly infected host
through prolonged multiplication of the resistant strain in the absence of INH, or 2.)
higher experimental virulence of the low INH-resistant, catalase-positive strains may
have caused the infection rather than the highly INH-resistant, catalase-negative strains
with lower virulence.107, 125 Both of these mechanisms may be relevant. This observation
of low-level INH resistance in primary INH-resistant TB may have the implication that
INH could still be of value in the treatment of these patients, including all children with
INH-resistant TB.124, 126-128
1.15 A change in the focus of TB treatment from drugs to management
Once effective antituberculosis drugs were available, and drug resistance could be
prevented, the focus of the management of TB started to change.
The number of TB cases sent for treatment increased to such an extent that
sanatoria could no longer cope and such institutions were in any event unaffordable and
impracticable in developing countries." Available oral antituberculosis drugs made
outpatient treatment possible. This option was usually not considered, since it was
believed that patients needed to rest, should be free of emotional stress, receive a
nutritious diet, and not be allowed to infect their household contacts. In a randomized
controlled trial in Madras, India, home treatment and treatment in a sanatorium was
Stellenbosch University http://scholar.sun.ac.za
22
compared, both groups receiving !NH plus PAS for one year.129 Efficacy of
chemotherapy was not increased by giving treatment in a sanatorium nor was the risk of
infecting household contacts decreased.P" 130 For effective ambulatory treatment and to
suppress the emergence of drug resistance, good patient compliance with drug-taking
was essential. This could be improved by fully supervised drug-taking, 13l more recently
renamed directly observed treatment (DOT).132
Not all drugs are equally good in suppressing the emergence of resistance to
another drug. A highly potent drug is able to prevent the growth of, and usually kills, all
the organisms in the lesion, and continues to do so despite slight irregularities in drug-
taking by the patient. Examples of potent drugs are !NH and RMP, and less potent drugs
are SM, PZA and EMB. In clinical studies thiacetazone and PAS were much less
effective.I''' In the 1970s it became normal practice to start treatment with three drugs
because even the most effective pair (!NH plus RMP) does not always prevent the
emergence of resistance. I IS Furthermore initial !NH resistance may lead in effect to
monotherapy.
Developments to decrease the frequency and duration of drug-taking followed to
make supervised therapy more practicable. These were; 1.) intermittent therapy and; 2.)
short-course chemotherapy (SCC). Intermittent (2 or 3 times weekly) treatment was first
tried in 1955 as part of a British MRC controlled trial.133 SM was administered twice
weekly together with daily !NH but in comparison with daily treatment of both drugs
permitted an increase in emergence of drug resistance probably because dosages were not
adjusted.!" A randomized controlled trial in India comparing SM plus !NH twice weekly
to PAS plus !NH showed both regimens to be equally effective as treatment and in
preventing drug resistance.i" Growth of tubercle bacilli was inhibited for several days
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after varying periods of exposure to different antituberculosis drugs such as INH, SM and
RMP with in vitro studies.134,136These drugs are therefore suitable for use in intermittent
therapy regimens and several randomized controlled studies have confirmed this.135,137
New hope came for shorter treatment regimens when RMP was discovered. In
1970 the sterilizing effect of both PZA and RMP in combination with INH in animal
experiments eventually led to the first controlled clinical trials of 6-month short course
regimens of chemotherapy.P'''!" A comparison was made between four 6-month daily
regimens, all containing SM plus INH, with a third drug added in 3 of the regimens -
RMP, PZA, or thiacetazone (T) and a standard 18-month regimen
(3SM,INH,T/15INH,T) in the treatment of newly diagnosed smear-positive extensive
pulmonary TB. The SCC regimens containing RMP or PZA were highly effective and
comparable to the standard 18-month regimen. The few patients that did relapse, nearly
all still had drug susceptible organisms.139-140SCC regimens of 6 to 9 months are now
used worldwide for nearly all new TB cases, at least in developed countries. Intermittent
SCC has also been introduced reducing the number of observed doses to be administered
to as little as 62 without increasing the risk of drug resistance.F'
1.16 Resurgence of TB and renewed interest in drug resistance, mainly MDR
tuberculosis
Although therapeutic TB studies continued after the early 1970s they were on a
much smaller scale than before, as it was believed that the available drugs and effective
combinations of these drugs had overcome this disease. Despite the warnings from
experts such as Canetti 107and Home 142that research and surveillance of drug resistant
TB should continue, this was to a large extent ignored. TB case numbers were steadily
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decreasing mainly in developed countries, where effective regunens could be
implemented, and the United States was even contemplating the elimination of the
disease.143 In many developing countries, chemotherapy had, however, failed to have a
significant impact on TB morbidity during these years, mainly because the commonly
used treatment regimen of 12-18 months often failed due to patient non-adherence.v"
In 1989 Rieder et al.143 focused the attention on the rising incidence of TB in the
USA from 1985. This trend was also observed throughout the world and in 1993 the
WHO reported that, more than 40 years after the introduction of chemotherapy for TB,
there were more new cases (8 million per year) than ever.144 The main reason for the
increasing number of TB cases throughout the world was the growing epidemic of human
immunodeficiency virus (HIV) infection, which is now known to be the most potent
facilitator ofTB infection and disease. 144, 145
Outbreaks ofMDR-TB, originally described in HIV-infected persons, were in large
measure responsible for focusing the attention of the industrialized countries on TB for
the first time in decades.l'" The global resurgence in TB, the association of HIV and TB,
and MDR- TB was described as the three epidemics of TB.147 Drug-resistant TB was
always a global problem and to start with developing countries had higher rates of
primary and acquired resistance than developed countries.Y MDR- TB was, however,
mainly a problem in countries making use of the more expensive RMP-containing sec
regimens. This was reflected in data from several global reviews on drug resistance
surveillance.P'" 148, 149
The outcome ofMDR-TB patients has been notoriously bad. The mortality ofHIV-
infected individuals with MDR- TB during nosocomial outbreaks in the USA was 72-89%
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within six months. ISO Even in HIV-negative patients with MDR-TB 48% died within 5
years and only 33% were cured, an outcome not dissimilar to TB patients before the
development of antituberculosis treatment 151,152or patients not receiving these drugS.153
Of particular concern is the prolonged duration of infectiousness, since the diagnosis of
drug resistance is often delayed and up to 20% of patients' sputa remain smear positive
for as long as 5 years or more. MDR- TB is transmissible and transmission of MDR- TB
was responsible for outbreaks among institutionalized HIV-infected patients,150 and has
also been confirmed in HIV-negative patients.P" ISS
The persistent problem of drug-resistant TB has been attributed to several factors of
which the most important was the failure to adhere to effective drug regimens.145. 148.156
This failure is because of inappropriate regimens being prescribed, irregular drug supply,
or poor compliance with treatment by the patients.148. 157A second important problem
was the failure of governments to supply and maintain community based health care
services in order to permit directly observed therapy.145,158-160In developed countries the
problem of drug resistance was exacerbated by an influx of immigrants from countries
with a poor TB control programme.l'"
1.17 HIVand drug-resistant TB
Although HIV infection was associated with an increase in drug resistance in
studies, mainly from the USA,145, 161this was not the case in several other studies,
specifically from Africa,162-165where the incidence of HIV is extremely high. Mono-
resistance to RMP is generally rare.145,166Recently it was noted that mono-resistance to
RMP was on the increase and restriction fragment length polymorphism (RFLP)
fingerprinting found the strains to be of independent origin.l'" Most of these strains were
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obtained from HIV -infected patients, and one of the possible explanations was selective
malabsorption of RMP in some HIV-positive patients. Malabsorption of other
antituberculosis drugs was also suggested by a number of studies,167-169but reports to the
contrary have been published.l " This has important implications for the management of
HIV -infected patients with TB as well as for TB control programmes, since
malabsorption of one or more drugs could in effect lead to monotherapy and therefore to
the emergence of drug resistance. This aspect regarding TB treatment in HIV -infected
patients needs further clarification.l"': 172
1.18 Treatment strategies in the global era
The global resurgence of TB, its close association with HIV/AIDS and especially
the epidemic of MDR- TB has been largely responsible for an influx of resources into TB
research and public health care. A further impetus was given when the WHO in 1993
declared TB a global emergency.i" Directly observed treatment, short-course (DOTS),
was strongly advocated in the management of TB. 132, 174Where DOTS was practiced it
resulted in a dramatic decline in the prevalence of drug-resistant TB.175-178Good National
TB Programmes that included the implementation of DOTS did not, however, succeed in
lowering TB incidence rates in countries with a very high prevalence of HIV
infection.V" 178
Regimens with an initial intensive phase of four drugs were introduced in the
treatment of new TB cases, because of high rates of primary drug resistance.V" Previous
studies found that four-drug sec regimens containing INH, RMP, PZA, and SM or
EMB, whether given 5 times weekly or three times weekly, achieved excellent results
even if patients were initially resistant to INH and/or SM.180 In 1993 the Advisory
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Council for the Elimination of Tuberculosis in the United States recommended that a 4-
drug regimen (INH, RMP, PZA, and SM or EMB) should be introduced in any area if the
prevalence of !NH resistance is ~4%, and that only PZA should be discontinued at 8
weeks, thus continuing with three drugs for a total of 6 months.179 The WHO guidelines
adopt a similar approach except that the continuation phase of four months includes only
!NH and RMP.181
1.19 Treatment of MDR TB cases and their contacts
New antituberculosis drugs have not been readily forthcoming since the
development of RMP in 1965. Amikacin, an aminoglycoside with a structure closely
related to kanamycin, was added in 1982, and another aminoglycoside, paromomycin,
has been shown to have antituberculous action. The fluoroquinolones, the only new
bactericidal compounds, were introduced in 1983.182-185 The development of further
drugs is urgently needed to enlarge the armamentarium of drugs for the treatment of
MDR TB and to further shorten the duration of treatment.
Principles for the management of MDR TB treatment have been formulated. Most
important is the prevention of drug resistance by prescribing and supplying correct drug
regimens and ensuring that directly observed treatment takes place in every new patient.
Patients who are MDR should be managed in specialized units, since the reserve drugs
are more expensive, less effective and have more side effects.!" These units must have
access to reliable susceptibility testing and reliable drug supplies. Principles that need to
be observed in the treatment of these patients are: 1) employ at least 3 drugs with proven
in vitro susceptibility, including one injectable drug (or 2 bactericidal drugs); 2) when
possible, use drugs that are active in vitro and have not been employed previously, and 3)
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try to put together a regimen with tolerable side effects.l'" 186 Treatment should continue
until 12-18 months after the last positive culture.
In developed countries the individualized treatment regimens for MDR TB patients
are used as described, but this is not always possible for developing countries. The WHO
has recently launched the "DOTS Plus" strategy, making use of standardized regimens
for patients with retreatment or treatment-failure TB, to address the MDR TB problem in
these countries, since it became clear that all patients with active TB, including MDR
patients, should be treated.187, 188
Until a decade ago INH was the only medication proved to be efficacious and
recommended for the prevention of TB in latent TB infection.i" Recently several
combinations of INH, RMP and PZA have been compared to INH alone for 6 to 12
months for their efficacy to prevent TB in mainly tuberculin skin test positive HIV-
infected adults. In a prospective randomized trial Gordin et al.I89 demonstrated a 2-month
regimen of daily RMP plus PZA to be similar in efficacy and safety to a 12-month
regimen of INH. Halsey et al.I90 compared a 2-month intermittent RMP plus PZA
regimen to a 6-month course of INH and showed the same outcome. Other studies
compared a 3-month regimen of RMP alone and 3 months of INH plus RMP to INH
alone for 6 months in mainly HIV -infected adults and showed them to be as efficacious,
although the numbers in these studies were too small to come to a definite conclusion.V"
191 RMP plus PZA for two months or RMP alone for 4 months is now recommended as
preventive treatment in latent TB infection in HIV-infected adults and in contacts of
INH-resistant pulmonary TB cases.192, 193
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Persons exposed to MDR TB pose a special problem. There has been no controlled
trial to evaluate any treatment regimen for chemoprophylaxis of contacts of MDR TB
cases. 154, 194 The American CDC has developed a set of guidelines for the management of
such exposed persons. 194 The probability of infection with MDR M tuberculosis among
contacts thought to be newly infected has to be estimated and thereafter the likelihood
that such an infected person will develop TB disease should be determined before
starting any prophylactic regimen. If the risk of infection is intermediate to high and risk
of disease is relatively low, two options are available: a.) administer no preventive
therapy and provide careful clinical follow-up, or b.) consider multidrug preventive
therapy with drugs other than !NH and RMP. In the latter group as well as those with
high risk of developing disease preventive therapy with at least two antituberculosis
drugs to which the possible infecting strain is susceptible for a period of 6-12 months
should be considered. A Delphi-technique survey to determine which drugs experts
would use for preventive treatment for high-risk contacts of patients with MDR- TB
resulted in support for PZA and otloxacin or ciprofloxacin.l'"
1.20 New technology in the battle against drug-resistant TB
In the 1980s phage typing and drug susceptibility testing were used to trace the
epidemiological route of transmission of drug-resistant bacilli to contacts.l'" More
recently powerful molecular strategies have been developed that permit rapid and
accurate bacterial strain characterization for use in molecular epidemiology.V': 198 One
such method is DNA fingerprinting. The presence of repetitive genetic insertional
elements in M tuberculosis permits the identification of individual strains by DNA
fingerprinting with restriction-fragment-length polymorphism (RFLP) analysis.!" The
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technique was developed in the early 1990s and a standardized method for the IS6110
band was described by van Embden et al.200 Additional probes were developed to
enhance the accuracy of strain typing especially in cases of low IS611 0 copy numbers.i'"
This DNA fingerprinting technique has been used to demonstrate the transmission of
particular M. tuberculosis strains in outbreaks of disease and, together with conventional
epidemiologic investigations, has improved our knowledge of the epidemiology of
tuberculosis in communities.l'f 199,202 and our knowledge of the dynamics of the disease.
The genetic origin of drug resistance in tubercle bacilli was already suspected
shortly after the emergence of drug resistance to the first antituberculosis drugs. Only
recently was the molecular genetics of resistance determined for several antituberculosis
dru 203 204 M . . delen f .fi drua resi tigs.' utations in, or etenons 0 speci IC genes cause g resistance, or
example: mutations in the katG gene or inhA gene cause !NH resistance, mutations in the
rpoB gene confers resistance to RMP, and mutations affecting the strA and 16S
ribosomal RNA have been identified in SM-resistant isolates of M. tuberculosis.203 The
identification of these genes and their mutations are valuable tools in molecular
epidemiology which assist the rapid identification of drug resistance using a polymerase
chain reaction-based (PCR-based) technique, single-stranded conformation
polymorphism (SSCP) to enable the detection of single-base substitutions, as well as
small deletions and/or insertions.i'" These techniques are, however, often unavailable in
those countries that most need them in their fight against drug-resistant TB. It is therefore
necessary that countries should work together to be able to tum the tide against TB.
Developed countries will not be safe from the threat of tuberculosis and drug resistance
until the disease has been controlled in developing countries.
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Literature Review: Drug-resistant tuberculosis in children.
2.1 Epidemiology of drug-resistant tuberculosis in children:
2.1.1 The first case report of drug-resistant TB in a child.
An ll-week-old infant who presented with streptomycin (SM)-resistant miliary TB
in 1948 was probably the first childhood case of drug-resistant TB to be documented.'
The mother was diagnosed with TB when the infant was aged 2 weeks and the two were
immediately separated. Neither of them had received previous SM-treatment. Although
this was most likely primary SM resistance, no isolate of M. tuberculosis was obtained
from the mother, and few people in the community could have had SM-treatment at the
time. Nevertheless, attention was drawn to the desirability of drug-susceptibility tests on
all diagnostic cultures obtained from new TB patients on entry to hospital or at the start
of treatment.
2.1.2 Primary INH resistance in childhood - the first reports.
Although Debré et al.2 gave Murdoch and Grant 3 the credit for reporting the first
case of primary isoniazid (INH)-resistant TB in a child, this was not correct. The sibling
to whom the INH-SM-resistant tubercle bacilli were transmitted was already more than
20 years of age at the time. The next case report by Noufflard et al.,4 described a French
child admitted in 1954 with tuberculous cervical adenitis. Culture from aspirated
material, however, revealed a strain of M. bovis resistant to INH. No human TB source
case was identified.
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It seems likely, therefore, that the first case of primary INH-resistant TB due to M
tuberculosis in a child was that reported by Klemm and Meissner from Germany. 5 They
described a child 16 months of age with tuberculous pneumonia, infected by her father
who had been treated with INH. Both father and child had tubercle bacilli resistant to
INH at the same concentration (MIe 50 ug/ml), which were catalase negative and of
attenuated pathogenicity for guinea pigs.
2.1.3 Early monitoring of childhood drug resistance.
Wilking et a1.6 reported the first comprehensive study on childhood drug-resistant
TB from New York. SM-susceptibility tests were done on M. tuberculosis isolates from
152 of 193 children <13 years of age between 1946 and 1951.6 Seventeen (11%) had one
or more SM-resistant isolates of whom 5 of 115 (4%) had primary drug resistance.
However, as acknowledged by the authors, this study could not report on incidence,
because of inherent problems with the study methods. The study did show that primary
and acquired drug-resistant TB could occur in children, both of which could have a fatal
outcome.
In 1959 Debré et al? realised that the incidence of primary drug resistance in
children is an important reflection of the presence in the community of sources of
infection with bacilli resistant to SM and INH. In their laboratory, Debré and co-workers
had used the same method for drug susceptibility testing from 1950 onwards, and in the
survey they included only children who had received less than a week's treatment thus
identifying strains that actually infected the children.' This report was therefore probably
the first to give some evidence of incidence of primary drug resistant TB in childhood.
Their first case of SM-resistant TB that responded poorly to SM-treatment was a child
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seen in 1949 with TBM. Primary SM resistance continued to increase until effective
multiple-drug treatment was introduced in 1952. The first primary INH-resistant M.
tuberculosis strains obtained from children in this study were identified in 1957, and 2 of
4 strains were also resistant to SM. Primary drug resistance was usually reported 3 to 5
years after acquired resistance to a drug became evident and primary drug resistance
usually remained much less frequent than acquired resistance. The incidence of primary
SM- resistant TB in children was 4.6% (18/394) and primary INH-resistance was 6-9%
(4-6/65). Despite encouraging earlier observations from animal experiments that INH-
resistant strains were less virulent than INH-susceptible strains, Debré et a1.2 found them
to be as infectious as SM-resistant strains. There was also no difference in the clinical
presentation of drug-resistant and drug-susceptible TB in children in this study.
2.1.4 Primary drug-resistant TB in childhood in the United States and other
countries.
After 1959 the few reported surveys of drug-resistant TB among children almost all
came from the United States of America (USA). Furthermore, these surveys were mainly
hospital or clinic-based, since it is difficult to obtain proper specimens for culture of M.
tuberculosis from children. This could lead to selection bias, as children with TB are
often referred to hospital because of more severe disease, poor response to treatment or
other risk factors for having a drug-resistant organism.
The first report of drug-resistant TB in children from the USA was published in
1961.7 In this retrospective survey 7 of 33 clinics did regular drug-susceptibility testing
on isolates obtained from children. Of 325 strains tested before any treatment, 11 (3.4%)
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were resistant to SM, and of235 strains tested after the introduction ofINH, 7 (3%) were
resistant to INH. Five of the latter patients were also resistant to SM and therefore had
multiple-drug resistance [i.e. resistance to two or more drugs without resistance to
rifampicin (RMP)].
Steiner and Cosio 8made the point that studies on disease due to primary resistant
organisms are of great importance and that primary drug resistance could best be studied
in children before the institution of any drug therapy, as primary TB in children
represents recently acquired infection. This would afford a more accurate assessment of
the incidence of primary drug-resistant TB infection in a community. Many years later,
Rieder," an epidemiologist, confirmed that cross-sectional appraisal of prevalence of drug
resistance in adults provides little information on the susceptibility patterns of currently
circulating strains. TB in children, however, is a sentinel event for TB transmission in the
community. Therefore the frequency of drug-resistant TB in children, and especially
those under 5 years of age, reflects a precise evaluation of the currently circulating
strains." Unfortunately such studies are rare, because specimens from children for
culturing M. tuberculosis are difficult to obtain and the cultures are frequently negative.
Steiner and colleagues started the first of a series of 4-yearly surveys of primary
drug-resistant TB in children (1 month to 13 years of age) at the Kings County Hospital
in Brooklyn, New York in 1961.8 The SM and para-aminosalicylic acid (PAS) resistance
(3% each) rates were stable compared to Zitrin's findings before 1961, and the rates were
similar to that of strains in adults in New York City. The incidence of primary INH-
resistant TB in children (6.3%) defined as resistance at a minimal inhibitory
concentration of 1.0 ug/ml, however, was unexpectedly higher than that reported in
adults (2.6%).8 The explanation offered was that the children in this study were drawn
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from a socio-economic deprived area with a high TB incidence while the adults were
drawn from the greater New York area.
On completing six 4-year surveys of primary drug resistance in children at Kings
County Hospital from 1961 through 1984, Steiner et aLlOshowed that SM resistance was
on the decrease, INH resistance was stable at 9.9% and that since the introduction of
RMP in the early seventies, the resistance to RMP had increased significantly. This
followed the marked rise in RMP resistance found in adults in the same area. Only a
single case of childhood MDR TB was, however, found during this period. (Steiner et al.
1986)
After 1984 primary INH resistance increased to 18.2% (8/44) for 1989 through
1992 and RMP resistance rose to 15.9% (7/44).11 However, the most disturbing finding
was the rise in primary MDR TB in children from 0% in 1973 through 1976 to 13.6%
(6/44) in 1989 through 1992. Resistance rates in strains isolated from adults at the same
medical center for 1989 through 1991 were 20.2%, 13.0% and 11.4% respectively for
INH, RMP and INH plus RMP.II The children's strains therefore reflected a similar
increase in resistant strains isolated from the adult population. This was to be expected if
INH-resistant strains were as infectious and cause as much disease as drug-susceptible
strains because children contract TB from adult source cases.
An interesting observation from the surveillance of primary drug resistance in the
USA was that resistance rates varied inversely with age.12 Bloch et al. 13 confirmed this in
a nationwide survey of drug-resistant TB in the USA during the first quarter of 1991.
They again showed a decreasing incidence of drug resistance with increasing age, with
21.6% of children :::;14years of age resistant to one or more drugs compared to 9.4%
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adults ;;::65years of age. Although children ~14 years of age were not included, age was
however, not shown to be significantly associated with drug resistance in developing
countries.J" IS
Except for the early studies mentioned already, only a few surveys from countries
other than the USA reported on the prevalence on drug-resistant TB in children, or
included children in their surveys. A report on 10 years' experience of paediatric
intrathoracic TB from British Columbia in Canada showed a positive culture yield in 45
(22%) of 202 children. Eight (17.7%) of these children had drug-resistant strains, 4 of
which were INH-resistant and 4 strains were multiple drug-resistant."
The only recent survey on the prevalence of childhood drug-resistant TB from
outside the North American continent was from Turkey. Dilber et al.17 reported the
prevalence of primary drug resistance among children at their hospital from 1975 to 1995
to be 26.7% (16 of 60 children). INH resistance was present in 4/60 (6.7%) and RMP
resistance in 3/46 (6.5%), but there were no MDR cases. They report all cases in whom
susceptibility tests were done, but do not say how many culture confirmed cases they had
during the same period that were not tested. No studies on the prevalence of drug
resistance in children from developing countries could be found.
2.2 Infectiousness (virulence) and pathogenicity of drug-resistant M. tuberculosis
strains.
2.2.1 Infectiousness of drug-resistant strains
As discussed in Chapter 1, there is some experimental evidence of reduced
virulence for laboratory animals of those strains of tubercle bacilli that are resistant to
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INH.18-20 The studies of Riley et al.21 on the risk of infection for guinea pigs breathing air
from a tuberculosis ward showed that untreated patients excreting INH-resistant
organisms were infectious for guinea pigs but less infectious than untreated patients
excreting susceptible organisms. This, and other data on reduced catalase production of
such strains led to the assumption that INH-resistant M. tuberculosis organisms are much
less infectious and cause less disease than INH-susceptible strains." This postulate was
already challenged by Oebré et al.2 and thereafter by several reports of outbreaks of TB
caused by INH- and multiple drug-resistant strains even before the HIV -era. In some of
these outbreaks high tuberculin skin test conversion rates were docnmeated.i" 23
In a study of drug-resistant contacts compared with a control group of drug-
susceptible contacts Snider et al.24 found the infection rate to be even higher in the
contacts of drug-resistant TB patients than in the contacts of drug-susceptible TB
patients. Furthermore both Steiner et al.25 and Snider et al.24 showed no difference in the
rate of disease development in children infected with INH-resistant and INH-susceptible
strains.
2.2.2 Pathogenicity of drug-resistant M. tuberculosis strains.
Evidence in the 1950's indicated that INH-resistant organisms were attenuated in
both virulence and pathogenicity for laboratory animals. It was postulated that these
strains might be attenuated for humans, too, with regard to their ability to cause
significant disease.
The same could not, however, be said of SM-resistant strains. Already in 1949 a
case of childhood tuberculous meningitis (TBM) was caused by a SM-resistant M.
tuberculosis strain? Of 19 children diagnosed with SM-resistant TB from 1949 to 1956,
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no less than 10 (53%) had TBM with or without miliary TB, 8 of whom died, and 9
(47%) had primary TB?
Only 4 cases of M tuberculosis resistant to !NH (plus SM resistance in 2) were
identified in this study. One child had a pleural effusion and 3 had primary TB. No
specific conclusion was drawn regarding the pathogenicity of !NH-resistant strains, but
they came to the conclusion that there is no clinical difference in disease caused by drug-
resistant and drug-susceptible tubercle bacilli in general.'
In the first official childhood drug-resistant TB surveillance study from the USA, 7
cases of!NH resistance with or without SM resistance were identified. Of these, 1 had
TBM, 1 had progressive primary TB, 2 had bone TB and 3 had primary TB. 7 Again no
comment was made regarding pathogenicity, but the severity of the disease is obvious
and 1 child, resistant to both !NH and SM, died.
Steiner and Cosio by implication queried the significance of drug-resistant TB
disease in the first of their surveys." They found no difference in response to treatment
with !NH and SM in the children who had !NH and/or SM resistant TB compared to that
of children with drug-susceptible TB. No deaths occurred although the expected death
rate of children with untreated TB was as high as 20%.8 However, in the follow-up
survey 1965 through 1968, 2 of 14 children deteriorated on treatment, one of whom died
of TBM and the second child responded only when treatment was changed according to
the susceptibility pattern of the organism."
In further studies comparing drug-resistant disease to drug-susceptible disease, both
Steiner et al.27 and Snider et al.24 concluded that from a clinical point of view, there was
no difference in the type or severity of disease caused by either isoniazid-resistant or
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susceptible strains of tubercle bacilli. Furthermore there was no difference in either the
rate of infection or disease found on contact investigation.i"
In a study comparing the rates of infection and progression to disease between
household contacts (both adults and children) of patients with MDR TB and drug-
susceptible TB, Teixeira et a1.28 found the prevalence of infection and progression to
disease to be similar in the two groups. Although this study included both adult and
childhood contacts, no specific data on the outcome of the children were presented. To
date, no similar studies have been done for MDR TB in children.
2.3 Epidemiologic proof of transmission of drug-resistant M. tuberculosis.
2.3.1 Correlation of susceptibility patterns of children and their adult source
cases.
In a remarkable study of the correlation of susceptibility patterns of M. tuberculosis
strains isolated from children with those isolated from identified adult source cases,
Steiner et a1.29 showed that strains of M. tuberculosis highly resistant (MIe >5J.lglml) to
!NH can be transmitted. Furthermore these strains caused disease indistinguishable from
that produced by !NH-susceptible strains. In a follow-up study correlating susceptibility
patterns in matched child and adult source case strains, 20 (69%) of 29 matched resistant
strains had identical susceptibility patterns, and in 14 (93%) of 15 adult-child matched
with pairs with !NH resistance the susceptibility tests were identical.f None of these
children had previously received antituberculosis treatment therefore transmission from
the source case is likely. It further alerts the physician to the fact that !NH prophylaxis
might fail in these cases. Probably the most important information derived from these
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studies is that the susceptibility pattern of the adult source case, when available, is a
useful guide in planning the child's treatment. 25
These early studies included only children with mono- or multiple-drug-resistant
TB and no cases of MDR TB. Furthermore only epidemiologic measures and
susceptibility patterns were used to compare strains of contacts and source cases. The
development of new technological methods to aid epidemiology, such as phage typing
and DNA fingerprinting, and the rise in drug-resistant TB called for further studies.
2.3.2 Phage typing and DNA fingerprinting as aids in the epidemiology of
drug-resistant tuberculosis cases.
In the early eighties outbreaks of TB caused by multiple-drug-resistant strains were
considered rare events. The only report of such an outbreak prior to the community
outbreak described by Reves et aI., 23 was that of Steiner et a1.22 which occurred in a
family. All 23 members of the immediate household of the source case, from whom a
strain of M. tuberculosis resistant to INH, SM plus PAS was isolated, were infected and 6
of the family members had active disease. Of those with active disease, M. tuberculosis
was cultured from 3, 2 of whom were children. The susceptibity pattern was identical to
that of the source case.22
Although the first community outbreak with multiple-drug-resistant M.
tuberculosis involved high school children of> 14 years of age, this was of epidemiologic
importance. In 8 of 22 cases that were epidemiologically linked by case histories and the
unusual (for that time) drug-susceptibility patterns, phage typing of the isolates could
confirm the same strain type.23
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In the early nineties several outbreaks of MDR TB among mainly HIV-infected
patients in institutions in the USA were described.30-32 Confirmation of transmission in
these outbreaks was aided by the development of DNA fingerprinting methods for the
identification of M. tuberculosis strains and the development of specific probes such as
1S6110.33 Ridzon et a1.34 reported an outbreak of multiple-drug-resistant (INH-SM-ETH)
tuberculosis in a high school in which DNA fingerprinting by restriction fragment length
polymorphism (RFLP) analysis and polymerase chain reaction (PCR) were used to
confirm the epidemiologic link between cases. Eighteen TB cases were identified at the
school from 1991 to 1993 and DNA fingerprinting was done on Mttuberculosis strains
obtained from 120fthese students. Eight of these had an identical fingerprint pattern and
in 7 of these the drug-susceptibility pattern was also identical. Four strains had both
different susceptibility patterns and distinct DNA fingerprinting."
DNA fingerprinting has become an important epidemiologic tool in the evaluation
of transmission of tubercle bacilli. Studies involving the epidemiologic evaluation of
children with MDR TB, or children in contact with adult pulmonary MDR TB source
cases are rare. Teixeira et a1.28 identified six paired M. tuberculosis isolates from adult
MDR TB index cases and their contacts during contact tracing follow-up. Although their
study included child contacts, no indication was given whether any of the culture-
confirmed cases were children. Nevertheless DNA fingerprinting showed all pairs to be
identical even though one contact patient had a fully susceptible M. tuberculosis strain.
2.4 Multidrug-resistant tuberculosis in children.
RMP was the last of the major antituberculosis drugs to be discovered. Together
with INH it forms the cornerstone of antituberculosis treatment through its unique ability
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to rapidly sterilise TB lesions. The development of, and the dramatic increase in, MDR
TB throughout the world over the last two decades, therefore poses a major threat to
effective TB control.
The first cases of primary MDR TB in children were reported soon after the
development of acquired multidrug resistance in adults,27 and a marked increase in
numbers occurred following the rapid rise of MDR TB in adults in the same areas. 10, 35
The first community outbreaks of MDR TB were reported in adults 30,36 and outbreaks in
children 31 and infants, who acquired infection in a nursery during 1992-1993, soon
followed.V Further experience with MDR TB in children is derived mainly from case
reports. I I, 38, 39 The single cases of HIV associated MDR TB in children did not differ
clinically or radiologically from HIV -seronegative cases. II
2.5 Children at risk for drug-resistant TB.
The vast majority of children with drug-resistant TB have not been previously
treated with antituberculosis drugs and therefore have primary drug-resistant TB. II This
emphasises the importance of source case tracing in every case of childhood TB and the
importance of determining the drug susceptibility pattern of the source case's strain.
Source cases are, however, only identified in about 40% 11,40 to 70% 41 of children with
TB. This depends to a certain extent on the way that these children present to the health
care setting, either as contacts of adult TB cases or with symptoms, and the age of the
children because it is easier to trace a source case in younger children. Furthermore,
because source cases are often not traceable, or children live in communities with high
prevalence rates of drug-resistant TB, or there are more than one adult TB source case in
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the household.Y' 43 every effort should be made to culture the organism from the child
and determine the drug susceptibility of the strain. II
On the other hand, M tuberculosis is isolated from gastric aspirates or other
sources such as sputa and broncho-alveolar lavage in less than 50% of cases.'?' 44 It is
therefore critically important that a clinician treating a child with TB infection or disease
be familiar with the resistance patterns of the M. tuberculosis strains of the community in
which the child resides."
The type of TB lesions found in children with primary TB disease is such that they
normally contain relatively low numbers (103 - 105) of tubercle bacilli. Drug resistance
to a single drug is present in about 105_108 organisms depending on the drug. (See
section 1.12) This implies that development of acquired drug resistance is less likely in
children than in adults, unless the child has either extensive pulmonary TB or cavitary
disease.
Except for those children from whom a drug-resistant M tuberculosis strain is
isolated, the following children are at high risk and the possibility of drug resistance
should be considered in the management of these children:
a) Known adult source case with drug-resistant TB.
b) No known source case, but the community (or country) in which the child resides
(or had resided) has a high prevalence of drug-resistant TB.
c) Adult source case is a treatment defaulter (not compliant), a treatment failure
(compliant but sputum still positive at end of treatment), a retreatment case (second
episode of TB) or a chronic case (TB despite 2 previous treatment courses) with
unknown drug susceptibility pattern."
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d) Child does not respond satisfactorily or deteriorates while on TB treatment and is
compliant.
e) Child with pulmonary TB relapses after incomplete or incorrect TB treatment.
2.6 Differences in childhood and adult TB: How it could influence drug
management.
2.6.1 A major microbiologic determinant of the success of antituberculosis
treatment is the size of the bacillary population within the host." Adults and children
with cavitary pulmonary TB or children with extensive pulmonary infiltrates have large
bacillary populations and these may contain many single-drug-resistant bacilli. However,
for children with infection only (positive tuberculin skin test) or slight changes on chest
radiograph (i.e. lymphadenopathy or small infitrates) or moderate extra-pulmonary TB,
bacterial populations are small to medium-sized and are not metabolically very active.
This may influence both the number of drugs and the duration of treatment necessary to
treat children effectively, and it is believed that children are generally overtreated."
2.6.2 Extra-pulmonary TB is more common in children. Although the populations
of organisms in these lesions are medium-sized, the sequestered localisation of these
bacilli (e.g. osteo-articular or in the central nervous system) may influence drug
treatment and specifically if there is drug resistance e.g. to INH. Other first line
antituberculosis drugs penetrate obstacles such as the blood-brain barrier poorly and the
use of a fourth drug such as ethionamide is often recommended.47-49
2.6.3 Children often have a different response to antituberculosis drugs than their
adult counterparts. On the one hand, adverse reactions such as hepatotoxicity with INH,
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RMP and PZA, and gastro-intestinal side effects with ETH may be less common in
children. On the other hand, some drugs are not generally recommended for use in
children because of the difficulty of evaluating adverse reactions e.g. optic neuritis with
the use ofEMB and arthropathy with the use of the fluoroquinolones."
2.6.4 Antituberculosis drugs are difficult to administer to children because of the
lack of paediatric formulations. Combinations of the first line drugs specifically designed
for paediatric use have recently become available for use in South Africa. Often it is
necessary to use second line drugs in the treatment of resistant TB. Except for
ciprofloxacin, however, no paediatric formulations are available. Furthermore, the
dosages recommended for children have often not been prospectively evaluated in
children, but have been extrapolated from dosages used in adult studies.
2.7 Management of drug-resistant TB in children.
Although no meaningful clinical trials have assessed the effectiveness of treatment
for drug-resistant TB infection or disease." the following basic principles for drug
management of drug-resistant TB are important:
a) Never add a single drug to a failing regimen.
b) Drug-resistant strains of M. tuberculosis should be treated with at least 2 or
preferably 3 drugs to which the strain is susceptible.V' 50
~~~~~~~~~~~~~~~~~
previously. Continuation of previously used drugs even if the relevant isolate is
reported to be susceptible to them, is of uncertain value. 50 Use bactericidal drugs as
far as possible."
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d) If M tuberculosis strains are resistant to !NH and/or RMP, treatment duration
should be prolonged in order to attain the necessary sterilisation of the lesions.
Although guidelines based on experience in adult drug-resistant TB exist, optimal
duration of treatment in children is unknown. 11,45
e) If the child's culture for M. tuberculosis is not available or the susceptibility pattern
is not known, the adult source case's strain can be used as an initial guide for
constructing an effective treatment regimen.f
f) Only daily (5 times a week or more) treatment and not intermittent therapy is
advised.
g) All treatment must be directly observed.
h) Children treated for drug-resistant TB should be carefully monitored specifically
with regard to adverse reactions."
i) Cases should be managed by specialised units only, because treatment involves
second line reserve drugs which are more expensive, less effective and have more
side effects than standard drugs/" 51
j) Trace and effectively treat all adult source cases.
k) Combinations of drugs that produce similar toxic effects, such as deafness or liver
or renal damage should be avoided unless no other combination is possible. 52
2.8 Antituberculosis drugs in the management of drug resistant TB.
The basic principles of managing drug-resistant TB have been discussed. (See
section 2.7) A summary of available first line, second line and newer antituberculosis
drugs has been compiled in tables 1 to 3 (Addendum).
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The use of INH in INH-resistant patients is controversial and needs further
clarification. Uncertainty remains whether old (previously used) drugs should be
continued once the diagnosis of drug resistance is confirmed in adults, since their
effectiveness is doubtful and their use may increase the risk of adverse reactions.r'
However, children develop mainly primary resistant TB and a case can be made for using
INH in primary INH-resistant or MDR patients."
Many studies have shown that more than half of the M. tuberculosis isolates from
primary resistant patients have low-level (MIC <Sug/ml) resistance to INH.55-5sIn early
studies some benefit was derived from adding INH, some in double dosage, to treatment
regimens in adults with primary INH-resistant TB.55,59,60An International Union against
Tuberculosis (IUAT) study, however, indicated no advantage in adding a normal dose of
INH to a regimen for INH-resistant cases.?' Moulding." reviewing the literature at the
time, also argued that an increased INH dosage of 16-20 mg/kg/day might be
advantageous even in patients with acquired INH resistance since the bacilli vary in their
degree of resistance to INH. More recently, a mouse model study suggested that INH
might be useful in combination therapy of M tuberculosis infection caused by low-level
INH-resistant organisms (INH MIC 0.2-5.0 j.lglml).62Donald et a1.63showed some early
bactericidal effect in adults with INH-resistant TB. Short course chemotherapy regimens
have now been shown to be effective in some MDR TB cases and the likely explanation
is a low-level resistance to INH in those individuals who responded to treatment.64,65
The question remains: what is the optimal dosage of INH to reach effective INH
serum-levels in children, those with faster as well as with a slow acetylator status, who
have low-level INH resistance. The International Union Against Tuberculosis and Lung
Disease's (IUATLD) guidelines recommend an INH dosage of 4-6 mg/kg/day for
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childhood TB cases while the American Academy of Pediatrics (AAP) recommends lO-
15 mg/kg/day.66,67 Donald et a1.68showed that even cerebro-spinal fluid concentrations
of 5 ug/ml could easily be surpassed in most children with TBM by administering a dose
of!NH of 20 mg/kg.
In addition to the reasons given above, in high TB incidence areas, adding !NH to
drug regimens for contacts of MOR or !NH-resistant TB cases may be of value, because
some contacts may have more than one possible source case and may therefore have
drug-susceptible TB.43,69 !NH alone is, however, insufficient for chemoprophylaxis in
such cases, because failure of!NH prophylaxis after exposure to !NH-resistant strains has
repeatedly been reported.22, 69,70
2.9 Management of children in contact with adults with drug-resistant
tuberculosis. (Preventive treatment)
!NH alone is the only drug proven to be efficacious for the treatment of TB
infection in children.71-74In the case of!NH resistance, however, !NH prophylaxis might
fail and several such failures have been reported.r" 69, 70 A need for alternative
prophylactic regimens with other antituberculosis drugs and of shorter duration was
appreciated.
Both experimental evidence 75and studies in mainly HIV -infected adults showed a
2-month regimen of RMP plus PZA or a 3-month regimen of RMP alone to be
comparable in efficacy to !NH alone for 6 to 12 months. 76,77 The only alternative
paediatric regimen that was published, is a 3-month regimen of!NH plus RMP evaluated
retrospectively, which seemed to be as efficacious as treatment with the same drugs for
up to 12 months."
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In 1992 the AAP recommended treating children infected with an INH-resistant
strain with RMP for 9 months." Recent randomised controlled studies in adults showed
markedly shorter courses of RMP plus PZA or RMP alone to be efficacious in preventing
TB, but these regimens are not yet generally recommended in children. These regimens
can, however, be used in children who are contacts of INH-resistant source cases."
Although the optimal duration of chemoprophylaxis with RMP in children has not been
established, the AAP now recommends a treatment course of at least 6 months.67
The chemoprophylaxis of children infected with a MOR M. tuberculosis strain is a
challenging problem. No regimen has proven efficacy and there are no data on how long
such prophylaxis should be taken.45, 80 Many experts agree on the need for
chemoprophylaxis in persons who have contracted infection from a MOR TB patient. I I, 45
Others, however, consider regular clinic follow-up of individual cases without
chemoprophylaxis an alternative strategy until more data are available.Ï" 80, 81 Infants
have a very high risk (up to 40%) of developing disease after infection and are at special
risk for developing disseminated disease and should therefore receive chemoprophylaxis
when infected.Ï"
The drugs that could be used for the prophylaxis of MOR infected persons have not
been prospectively evaluated. Use of a regimen containing other agents to which the
source case's strain is susceptible and that are active against M. tuberculosis should be
considered. No single antituberculosis drug is recommended for preventive therapy. I I In
adults who are at high risk of developing TB, PZA plus EMB or PZA plus a
t1uoroquinolone for 6 to 12 months has been recommended if the index case's strain is
susceptible to these agents. All persons with suspected MOR infection should be
followed for at least 2 years irrespective of treatment. 74 In children the combination of
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PZA plus EMB for 9 to 12 months is recommended if the isolate is susceptible to both
drugs. Resistance to PZA is, however, difficult to determine. Several other combinations
of drugs to which the source case's strain is susceptible have been recommended such as
PZA plus cycloserine, ETH and cycloserine and, if the potential benefits justify the
potential side effects, PZA plus a fluoroquinolone.'!' 45,81,82
The optimal duration of chemoprophylaxis in children has not been determined, but
most experts recommend a 6 to 12 month course. II, 45, 80
2.10 Conclusion
2.10.1 Drug-resistant TB in children reflects the prevalence of drug resistance in
the adult population.
2.10.2 Infection and subsequent disease occur with similar frequency following
exposure to sputum smear positive adults who are drug-resistant as following exposure to
drug susceptible index cases.
2.10.3 The principles of prophylaxis and treatment of drug-resistant TB are
similar in adults and children, although children may be more tolerant of higher drug
dosages and less likely to develop adverse effects. Some antituberculosis drugs are, on
the other hand, not yet recommended for use in children.
2.11 Setting of planned study
The different components of the study will be done in the Western Cape Province of
South Africa, an area with a reported TB notification rate of 589 new cases per 100 000
population per year in 1998 (data from Department of Health, Directorate Health Systems
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Research and Epidemiology). In this hyperendemic area, transmission of M. tuberculosis
is high, and the annual rate of TB infection in the suburbs surrounding the tertiary
hospital from where the study will be done, is 3.1% (Beyers et al. Unpublished data).
Many children have more than one adult TB source case living in the same house either
at the same time or over a period of time.42 These factors may have a role in the outcome
of the study.
2.12 AIMS OF THE STUDY
In the light of the problems discussed above and a number of uncertainties
regarding management and treatment, the following areas will be addressed in this thesis:
a) Drug-resistant TB in children is of great epidemiologic importance. No information
on the occurrence of drug-resistant TB in children is available from developing
countries. One of the aims of this thesis will be to determine the prevalence of
drug-resistant TB in children in a geographical area surrounding Tygerberg
Hospital, a secondary and tertiary referral centre in the Western Cape Province of
South Africa. Although the ideal is a population-based study, a hospital-based
study is of value when all problem cases in a geographical area are referred to that
hospital. 83
b) In animal studies INH-resistant M. tuberculosis strains had attenuated
pathogenicity and it was therefore postulated that INH-resistant bacilli might be
less able to establish infection or cause disease in humans. Transmission of drug-
resistant TB from adult index cases to their child contacts has been documented.
-
These studies involved mainly INH-resistant or multiple drug-resistant TB cases. In
this thesis the aim will be to document transmission of MDR TB from adult index
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cases to their child contacts in the short (first two months) and long term (30
months) and the frequency of development of disease in these children. A further
objective will be to compare M. tuberculosis isolates obtained from both the index
case and child contact not only by drug-susceptibility pattern, but also by DNA
fingerprinting and gene mutations.
c) The role ofINH in the treatment ofJNH-resistant TB is still controversial, but there
is some evidence that it has a place in the management of primary JNH-resistant
cases. The final aim of this thesis will be to determine the pharmacokinetics of JNH
in children and to determine whether sufficient concentrations of JNH could be
achieved to overcome low-level JNH-resistant tubercle bacilli in children.
Each chapter will have its own introduction, material and methods, results and
discussion. A final chapter will be included to summarise the findings of the thesis.
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Table 1: First line antituberculosis drugs: recommended dosage, effects and possible adverse reactions.
Antituberculosis Recommended Bactericidal or Adverse reactions Protective effect Continuation Maximum
Drug daily dosage Bacteriostatic against resistance phase drug daily dose
(paediatric)
Isoniazid" 10-20 mg/kg Bacteriocidal Hepatitis, hypersensitivity, Good Yes 300mg
WHO: 4-6 mg/kg peripheral neuropathy,
drowsiness, skin rash,
mood changes
Rifampicin 10-20 mg/kg Bacteriocidal Hepatitis, rash, orange Good Yes 600mg
discolouration of urine and
secretions, gastro-intestinal
upset, thrombocytopenia
Pyrazinamide • 20-40 mg/kg Bacteriocidal Hepatitis, arthralgia, Poor Specific 2g
hyperuricaernia indications
Ethambutol 15-25 mg/kg 15 mg/kg- Optic neuritis (dose related Good - moderate Yes 2.5g
bacteriostatic; and reversible),
25 mg/kg- rash
moderately
bacteriocidal
Streptomycin 20-40 mg/kg 1M Bacteriocidal Ototoxic, nephrotoxic Good - moderate No 19
--
• Good eSF penetration
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Table 2: Second line antituberculosis drugs: recommended dosage, effects and possible adverse reactions.
Antituberculosis Recommended Bactericidal or Adverse reactions Protective effect Continuation Maximum
Drug daily dosage Bacteriostatic against resistance phase drug daily dose
(paediatric)
Ethionamide" or 10-20 mg/kg Bacteriostatic; Gastric intolerance, hepatitis, Good Yes 19
prothionamide 2 or 3 divided bacteriocidal at convulsions, hypersensitivity
doses/day higher dose?
Kanamycin 15 mg/kgIM Bacteriocidal Ototoxic, nephrotoxic Good - moderate No 19
Amikacin 15 mg/kg 1M or IV Bacteriocidal Ototoxic, nephrotoxic Good - moderate No 19
Capreomycin 15 mg/kgIM Bacteriocidal Ototoxic, nephrotoxic Moderate No 19
Viomycin 15 mg/kgIM Bacteriostatic Ototoxic, nephrotoxic Poor No 19
Cycloserine • 10-20 mg/kg Bacteriostatic Psychosis, personality changes, Good Yes 19
depression, seizures, rash
Thiacetazone 4 mg/kg Bacteriostatic Gastrointestinal intolerance, Moderate - poor Yes 150mg
vertigo, rash, Stevens Johnson's
syndrome (HIV -infected
patients)
Para-aminosalicylic 150-300 mg/kg 4 Bacteriostatic Gastritis, hypersensitivity Moderate - poor Yes 12g
acid divided doses/day reactions, hepatitis,
• Good eSF penetration
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Table 3: New antituberculosis drugs: recommended dosage, effects and possible adverse reactions.
Antituberculosis Recommended Bactericidal or Adverse reactions Protective effect Continuation Maximum
Drug daily dosage Bacteriostatic against resistance phase drug daily dose
(paediatric)
Ofloxacin (not yet lO-IS mg/kg Moderately Arthropathy, arthralgia, Moderate? Yes 800mg
recommended) bacteriocidal headaches, insomnia,
gastrointestinal upset,
photosensitivity
Levofloxacin (not yet Moderately Arthropathy, arthralgia, Moderate? Yes lOOOmg
recommended) bacteriocidal headaches, insomnia,
gastrointestinal upset,
photosensitivity
Ciprofloxacin (not 20-30 mg/kg Moderately Arthropathy, arthralgia, Moderate? Yes 1500mg
yet recommended) bacteriocidal headaches, insomnia,
gastrointestinal upset,
photosensitivity
Azithromycin 10-20 mg/kg Gastrointestinal disturbance, 500mg
ototoxic
Clarithromycin 15-30 mg/kg Gastrointestinal disturbance, 19
rash
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Antituberculosis
Drug
Recommended daily
dosage
(paediatric)
Bactericidal or
Bacteriostatic
Adverse reactions Protective effect
against resistance
Continuation
phase drug
Maximum
daily dose
600mgRifabutin (up to 90% 10-20 mg/kg
cross resistance with
RMP)
Amoxicillin-
clavulanate
Clofazamine 1-2 mg/kg
Bacteriocidal Polyarthralgias, arthritis,
neutropenia, myositis, skin
hyperpigmentation, uveitis
Effect not known Headache, diarrhoea,
or no effect on M peripheral neuropathy, red
tuberculosis skin discoloration
Good Yes
lOOmg
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Primary drug-resistant tuberculosis in children
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Primary drug-resistant tuberculosis in children
Setting: The Western Cape Province of South Africa, an area with a high
tuberculosis (TB) incidence where initial isoniazid (INH) resistance and multidrug
resistance (MDR) among adults was 3.9% and 1.1%, respectively, during 1992-
1993.
Objective: To determine the drug resistance incidence among children as compared
to adults, to compare the clinical features of drug-resistant and drug-susceptible
TB, and the degree of INH resistance in isoniazid-resistant isolates.
Methods: All Mycobacterium tuberculosis cultures obtained from children (0-13
years) at a regional hospital were prospectively collected from August 1994 to April
1998 and susceptibility testing done on each child's specimens. Degree of INH
resistance was determined in available resistant isolates. The children's clinical
records were reviewed.
Results: Susceptibility results were available in 306/338 children with cultures of M.
tuberculosis; 21 isolates (6.9%) were INH-resistant, and seven were MDR. Taking
into account study limitations, the incidence of INH resistance was 5.6% and MDR
1% in children aged <5 years. Clinical features were similar in children with drug-
susceptible and drug-resistant TB.
Conclusion: The incidence of drug resistance in childhood tuberculosis in Western
Cape is low, and probably reflects the level of primary drug resistance amongst
organisms currently circulating in the community.
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INTRODUCTION
In the last decade there has been an increased awareness that drug-resistant
tuberculosis (TB) poses a major threat to patients as well as to tuberculosis control
programmes. Surveillance of drug resistance is therefore essential, because trends in
primary drug resistance (i.e., resistance in cultures from patients with no previous
tuberculosis treatment) or initial drug resistance (i.e., primary resistance plus undisclosed
acquired resistance) provide an indication of the effectiveness of treatment regimens,
while drug resistance rates in patients with a history of previous treatment (acquired
resistance) can indicate failures in the management of the disease. I Accuracy in
determining whether patients have initial/primary or acquired drug resistance is often
unsatisfactory, as obtaining a history of previous treatment is difficult.' Van Rie et al.'
demonstrated that some patients who previously had drug-susceptible TB and thereafter
presented with drug-resistant tuberculosis were reinfected with drug-resistant strains and
thus had primary drug-resistant tuberculosis, despite having had previous tuberculosis
treatment.
Children have mainly primary drug resistant TB, and previous treatment is easier to
exclude. They should therefore be a good source for surveillance of true primary drug-
resistant TB, and may accurately reflect the transmission of these organisms in the
community." There are few studies of drug-resistant TB in children or surveillance data
that include children in significant numbers.i'" and no data from developing countries
could be traced.
The use of isoniazid (!NH) in isoniazid-resistant TB patients is controversial. 7
There is reason to believe that adding !NH to the treatment of newly diagnosed children
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with INH-resistant TB would be beneficial, as the degree of INH resistance differs in
patients with primary and acquired resistance, and in early studies some benefit was
derived from adding INH to treatment regimens in adults with primary INH-resistant
TB.8•9
The aim of this study was to determine the prevalence of drug resistance among
children with tuberculosis and to compare the clinical and radiological features of drug-
resistant and drug-susceptible TB in these children. A secondary aim was to determine
the minimal inhibitory concentration of INH-resistant isolates.
PATIENTS AND METHODS
Setting
This prospective study was conducted between August 1994 and April 1998 at
Tygerberg Hospital, a secondary and tertiary referral centre in the Western Cape
Province of South Africa. This area had a reported TB notification rate of 589 new cases
per 100 000 population per year in 1998 (Department of Health: Directorate Health
Systems Research and Epidemiology). The rate of initial resistance to INH determined in
adult TB cases in the Western Cape Province during 1992-1993 was 3.9% (95%
confidence intervals [Cl]; 3.3-4.6%) and initial multidrug resistance (MDR-defined as
cultures resistant to INH and rifampicin [RMP], with or without resistance to other
antituberculosis drugs) was found in 1.1% of isolates (95% Cl; 0.7-1.4%).' Prevalence of
human immunodeficiency virus (HIV) infection in women attending antenatal clinics in
the Western Cape Province rose from 1.16% (95% Cl; 0.76-1.56) in 1994 to 5.21% (95%
Cl; 4.2-7.2) in 1998 (Department of Health: Directorate Health Systems Research and
Epidemiology).
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Drug susceptibility testing
All cultures of Mycobacterium tuberculosis obtained at Tygerberg Hospital from
children 0 to 13 years of age were collected prospectively. A single specimen from each
patient was sent to the South African Institute for Medical Research in Cape Town for
susceptibility testing. Initial screening was done for !NH resistance only, because RMP
resistance was seldom found without !NH resistance in primary (initial) drug resistance
in the Western Cape. t When resistance to !NH was found, susceptibility testing for RMP,
streptomycin and ethambutol was performed.
Laboratory procedures for determining drug resistance were as follows:
Middlebrook 7H12 (Bactec) culture medium was used for selective primary isolation of
mycobacterial strains. The niacin production test was used to identify M. tuberculosis.
Drug susceptibility testing was performed by the economic variant of the indirect
proportion method currently in use by the majority of laboratories in South Africa. This
method entails the incorporation of the required drug concentration into Lowenstein-
Jensen (LJ) egg-based medium before coagulation, while the slants were subsequently
inoculated with a standardized inoculum. The following drugs were tested at the
indicated concentrations: !NH 0.2 ug/ml LJ; RMP 30.0 ug/ml LJ; streptomycin 5 ug/ml
LJ and ethambutol 2 ug/ml LJ. The susceptibility of a strain was judged by determining
the proportion of bacilli resistant to a specific drug in comparison with growth on a
specific control, using international criteria. Resistance was defined as 1% or more
bacterial growth. Quality assurance for drug susceptibility results is done locally with
every batch and quarterly by the national tuberculosis reference laboratory. to
In addition, nme of the clinical isolates that were resistant to the critical
concentrations of !NH (0,2!lg/ml) and which were still available at the time, were
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processed to determine the degree of their resistance in MIC values (ug/ml), Briefly,
precultures were prepared in 7H9 Middlebrook medium and incubated at 37°C for
approximately 14 days before they were adjusted to an optical density of a No. I
McFarland standard, which is equivalent to 2 x 107 organisms/ml. The latter suspensions
were further diluted (1/20) to a concentration of about I x 106 colony forming units
(cfu)/ml and 20~1 aliquots were inoculated on to 7HIO Middlebrook medium, with or
without appropriate dilutions of INH, to yield final concentrations of approximately 2 x
104 cfu. INH was incorporated into 7HIO plates at final concentrations of2, 4, 5, 10 and
20~glml and M tuberculosis H37Rv (ATCC 27294) was used as a drug-sensitive
control. An organism was considered to be resistant to a specific concentration of the
drug if it failed to inhibit more than 99% of the bacterial population, indicating whether
the isolate has a high or low level of resistance to INH.
Clinical data
The clinical records of all children with positive cultures for M. tuberculosis were
reviewed, and all children with drug-resistant TB were recalled. A history was obtained
from all children regarding previous TB prophylaxis or treatment, and whether they had
close contact with adults with pulmonary TB. Weight at diagnosis and site of
tuberculosis were recorded. Results of tuberculin skin test (Mantoux test by intradermal
injection, 5 tuberculin units, Japanese purified protein derivative), HIV -serology, and
sites of positive M tuberculosis specimens obtained were noted where available. An area
of induration of ;;:::15mm after Mantoux skin testing was regarded as significantly
positive in accordance with World Health Organization criteria, as more than 90% of
children in this area receive BCG.II Chest radiographs were read according to a
standardized method.V All children with drug-susceptible TB were treated according to
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the National Tuberculosis Programme (NTP) policy with INH, RMP and pyrazinamide.
Children with drug-resistant TB were treated according to the drug susceptibility pattern
of their M.tuberculosis strain and followed up for 2 years.
Categorical data was analyzed using the '1: test to compare groups, and Fisher's
exact test was applied where appropriate. Statistical analysis was done using Epi-Info
version 6.04.
The study was approved by the Ethics Committee of the Faculty of Medicine of
the University of Stellenbosch.
RESULTS
During the 3 year 9 month period, 538 cultures of M. tuberculosis isolates were
obtained from 338 children. The children, 193 (57%) boys and 145 (43%) girls, had a
median age of 2.6 years (range 0.06 - 13 years). They were divided into two groups; < 5
years of age (n = 241) and 5 - 13 years of age (n = 97). In respectively 23 (9.5%) and 9
(9.3%) children, drug susceptibility testing was not done due to lost specimens (n = 13),
contamination (n = 15) or loss of viability (n = 4).
Susceptibility results
Susceptibility results were available in 90.5% of cases (Table 1). Of the 21 isolates
(6.9%) that were resistant to INH, seven (2.3%) were multidrug-resistant. Of 56 (19.6%)
M tuberculosis isolates that were susceptible to INH and also tested for RMP
susceptibility, none was resistant to RMP.
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Table 1: Susceptibility test results
<5 years old 5-13 years old All
n =218 n=88 n=306
Susceptible to H*t 202 (92.7%) 83 (94.3%) 285 (93.1 %)
Resistant to H only 5 4 9
Resistant to H + S 3 4
Resistant to H + E
Resistant to H + R 2 2
Resistant to H + R + S 3 3
Resistant to H + R + S + E + ETH 2 2
Total no. resistant to H 16 (7.3%) 5 (5.7%) 21 (6.9%)
Total no. MDR 7 (3.2%) 7 (2.3%)
* 56 (20%) also tested for R susceptibility; all were susceptible
t 24 (8%) also tested for Sand E susceptibility; all were susceptible
H = isoniazid; R = rifampin; S = streptomycin; E = ethambutol; ETH = ethionamide.
Study limitations
Thirty children whose M tuberculosis strains had been tested for drug
susceptibility received previous antituberculosis treatment. Of these, 16 defaulted from
treatment. Drug resistance was found in two: one child had received 5 months of INH,
RMP and pyrazinamide and did not respond to treatment. The initial culture was done
before the study began, but susceptibility testing was not done. Follow-up culture was
multidrug-resistant, No close contact could be identified. The second child had previous
TB and was treated for more than a year due to extensive pulmonary TB. Her father had
INH-resistant TB but died after her initial TB diagnosis. She again presented 4 years later
with culture-confirmed TB and bronchiectasis with no known TB source case. The M.
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tuberculosis strain was resistant to !NH only. Both of these cases could therefore still
have had primary drug-resistant TB.
The second limitation of the survey is that it was conducted concurrently with a
study of childhood contacts <5 years of age of adults with MDR pulmonary TB at the
same hospital. Four of seven children identified with MDR TB were part of the latter
study. If these children were excluded from the study, only 17 (5,6%) children had !NH-
resistant and three (1,0%) MDR-TB.
Clinical data
Clinical data of children with drug-susceptible TB, drug-resistant TB and those in
whom susceptibility testing was not done are compared and summarized in Table 2.
In 138 (46%) of 297 children an adult pulmonary TB source case could be
identified. Specific attention was paid to source cases of the 21 children with drug-
resistant TB. Six (28%) children (four from MDR contact study) had a known drug-
resistant source case, five of whom had the same drug susceptibility pattern. A further
five (24%) children had known adult source cases, but the drug susceptibility patterns of
the adults' M. tuberculosis strains were not known. Three of the 11 children had
additional contact with adults who had drug-susceptible TB. No source cases were found
in nine (43%) children, and one (5%) child could not be traced.
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Drug susceptibility results SusceptibleH*t
n=285
to Resistant to Not doneH ± other drugs*
n =21 n=32
Age (median [range]) in years
Sex: male
2.64 (0.15-13)
157 (55%)
Previous antituberculosis drugs (including
defaulters) 28 (10%)
Household TB contact
Weight for age <3rd percentile (NCHS)
Pulmonary TB
116/248 (47%)
116 (41%)
248 (87%)
Extra pulmonary TB (including pleural 171 (60%)
effusion and miliary TB)
Mantoux test z 1Omm
Mantoux test z 15mm
HIV -seropositive
CXR
done and read
hilar/mediastinallymphadenopathy
opacification lobar/segmental
bronchopneumonic opacification
perihilar opacification
cavities
miliary
pleural effusion
calcification
normal
Died in hospital
185/222 (83%)
168/222 (76%)
12/137 (8,8%)
275 (96%)
152 (55%)
112(41%)
43 (16%)
27 (10%)
32 (12%)
24 (9%)
30 (11%)
12 (4%)
40 (15%)
Il (4%)
2.67 (0.22-10.3)
14 (67%)
2 (10%)
11/20 (55%)
8 (38%)
21 (100%)
8 (38%)
13/18 (72%)
10/18 (56%)
1/20 (5%)
20 (95%)
9 (45%)
8 (40%)
3 (15%)
4 (20%)
3 (15%)
1 (5%)
2 (10%)
o
4 (20%)
o
2.43 (0.06-12.3)
22 (69%)
2 (6%)
11/29 (38%)
Il (34%)
32 (100%)
15 (47%)
17/22 (77%)
17/22 (77%)
0/9
32 (100%)
9 (28%)
12 (38%)
4 (13%)
6 (19%)
o
5 (16%)
6 (19%)
o
2 (6%)
3 (9%)
• The differences between drug-susceptible and drug-resistant groups were not statistically significant.
(P<0.05)
t Of 56 (20%) children tested for susceptibility to RMP, all were susceptible. As primary RMP monoresistance
in Western Cape 0.0-0.2%, RMP resistance is unlikely.
H = isoniazid; NCHS = US National Center for Health Statistics; HIV = human immunodeficiency virus; CXR
= chest X-ray; RMP = rifampicin.
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HIV test results were available in 166 (49%) children of whom 13 (7.8%) were
positive. Pulmonary TB was present in 89% of children. A diagnosis of pulmonary TB
was based on chest radiograph changes and/or culture of M. tuberculosis from gastric
aspirate, sputum or bronchial aspirate. Extra pulmonary TB (including miliary TB and
pleural effusion) was found in 57% of all of the children, and in seven of 13 (54%) HIV-
infected children.
Degree of isoniazid resistance
The MICs of INH against five of the nine M. tuberculosis isolates were between
0.2 and 2.0 ug/ml; these results imply that the specific strains were moderately
susceptible to the drug. However, as MIC values >20flglml were observed in the
remaining four isolates, this group was considered to be very resistant to INH.
DISCUSSION
Surveillance of antituberculosis drug resistance in a community provides a measure
of the success of the NTP and gives an indication of suitable drug regimens for future
use.13 Primary or initial resistance patterns reflect transmission of drug-resistant strains,
but as tuberculosis in children is a mark of recent TB transmission in a community, the
frequency of drug resistance in children, particularly those <5 years of age, reflects a
precise evaluation of the current situation." 13 Few surveillance studies are available,
however, on drug resistance in childhood TB.
This study was a hospital-based study, and therefore represents mainly children
referred for secondary or tertiary care problems. Specimens for culture of M. tuberculosis
are difficult to obtain in children, however, and will often be done only when children are
hospitalised. The most comprehensive study to date, by Steiner et aI., was also a hospital-
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based study over a 24 year period (1961-1984) conducted in King County Hospital
Center, New York.5,14 Of 374 children screened for primary drug resistance during this
period, 16,3% had resistance to one or more antituberculosis drugs. INH resistance was
relatively stable at 10%, but RMP resistance, which was introduced during this period,
was on the increase.i As far as we could determine, no studies on the prevalence of drug
resistance in children from developing countries are available.
Isolated RMP resistance is reported to be rare.I,15,16 Weyer et al. showed initial
RMP resistance and multidrug resistance both to be 1.1% in adult patients in their survey,
1 and Bohmer et al. found two of 808 (0.2%) cases with monoresistance to RMP in the
greater Cape Town area in 1990-1991. 17 Due to cost constraints we therefore tested
initially for INH susceptibility only; none of the 20% M. tuberculosis strains which were
susceptible to INH, and were tested for RMP susceptibility, was resistant to RMP.
Initial INH resistance is a sensitive indicator of the overall success of a treatment
programme in a country. 1 Failure to control its availability adequately will soon lead to
the appearance of INH resistance. The prevalence of primary INH resistance in this study
is below the median reported for the 35 countries in the global surveillance for
antituberculosis drug resistance from 1994 to 1997 (7,3%).18 This prevalence
nevertheless still requires the use of a four-drug regimen in newly diagnosed cases of
adult type pulmonary TB, as the level of primary INH resistance is more than the cut-off
of 4% recommended by the US Centers for Disease Control and Prevention." The
Western Cape Province had an initial INH resistance rate of 3.9% among adult
pulmonary tuberculosis patients during 1992-1993.1 The increase found with the current
survey may be due to several factors. Firstly, age is said to be inversely related to drug
resistance. A survey of drug resistance in the USA during the first quarter of 1991
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showed a decreasing incidence of drug resistance with increasing age, with 21,6% of
children $14 years of age resistant to one or more drugs compared to 9,4% adults ~65
years of age." Age was shown not to be significantly associated with drug resistance in
developing countries, however.P: 20 Secondly, hospital-based studies are biased towards
patients referred with problems such as possible drug resistance and will therefore
probably predict the worst case scenario." When the known study limitations were
removed, the prevalence of !NH and MDR is not different from the results obtained in
the adult study. Thirdly, primary resistance may be higher than determined by Weyer et
aI.,I as some of the patients in the acquired resistance group may well have had primary
drug-resistant TB.3 Lastly the possibility exists that the increase is a true increase in
prevalence of drug resistance in our community. Our results suggest that the observed
incidence of drug resistance in childhood tuberculosis, even though determined in a
hospital-based population, is a good reflection of the incidence of primary drug resistance
in a community.
The clinical presentation and chest radiograph results among those infected with a
resistant strain were not significantly different from those infected with a drug-
susceptible strain (Table 2). This is in agreement with findings from previous studies.14•22
An unexpected finding was the high rate of extra-pulmonary tuberculosis (57% overall),
which is higher than the expected 25% - 35% previously described in children.i" 24 This
can be explained by the fact that more complicated cases of suspected tuberculosis are
referred to our hospital, and that there is a higher yield from tissue cultures than from
pulmonary sources. IS Eighty-nine per cent of all our patients did, however, have
pulmonary tuberculosis on chest radiography and/or culture of M. tuberculosis from
gastric or bronchial aspirate or sputum.
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The use of INH for the treatment of INH-resistant M. tuberculosis infection is
controversial. 7 A distinction could probably be made between the use of INH in primary
or acquired (retreatment) cases of INH resistance. Canettr" and Tripathy et al.8 have both
shown larger numbers of low level INH-resistant strains (MIC <Sug/ml) in primary
resistance compared to acquired resistance. Several studies have shown some benefit by
adding INH to the treatment regimen. Devadatta et al." and Tripathy et al.8 showed an
initial improvement in patients with primary INH resistance treated with !NH alone or
with PAS, and Petty and Mitche1l26demonstrated significant benefit by the addition of
high dose !NH to a regimen of ethionamide and pyrazinamide in the retreatment of !NH-
resistant cases. An International Union Against Tuberculosis (IUAT) study, however,
indicated no advantage by adding !NH in conventional doses to a retreatment regimen for
INH-resistant cases." More recently, a mouse model study suggests that !NH may be
useful in combination therapy of M. tuberculosis infection caused by low-level INH-
resistant organisms (INH MIC 0.2-5)lglml).7 Our data showed that five of nine (56%)
strains from children with primary drug-resistant tuberculosis had low level INH
resistance. This is similar to findings in previous studies in primary INH-resistant
strains." 27These concentrations are attainable in children at normal to high dosages (10-
20 mg/kg/day) of INH. Further studies to evaluate a possible role of INH in primary
INH-resistant patients are needed.
In conclusion, our data suggest that the incidence of drug resistance in childhood
tuberculosis in the Western Cape is low, and probably reflects the level of primary drug
resistance amongst organisms currently circulating in a community.
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Evaluation of young children in household contact with adult multidrug-resistant
pulmonary tuberculosis cases
Background: The prevention and management of multidrug-resistant (MDR)
tuberculosis has received much attention, but little attention has been given to children
with MDR tuberculosis or children in contact with adults with MDR tuberculosis. The
aim of this study was to determine the prevalence of tuberculous infection and disease
in childhood contacts of adults with MDR pulmonary tuberculosis.
Method: All children <5 years of age in household contact with 75 recently diagnosed
adults with MDR pulmonary tuberculosis were evaluated. Evaluation included clinical
examination, tuberculin skin test, chest radiography and culture for Mycobacterium
tuberculosis from gastric aspirates.
Results: One hundred twenty-eight children, median age 27 months, were evaluated.
Fifty children had recent contact with other adult tuberculosis cases. Sixty-six children
previously had chemoprophylaxis or treatment of which 36 defaulted treatment or
received insufficient chemoprophylaxis. One child had HIV-infection. Forty-seven
children were classified as non-infected, 66 were considered infected only (Mantoux
test, ~15mm) and 15 had disease. Three children, who had not previously received
antituberculosis drugs, had positive cultures for M. tuberculosis; all were multidrug-
resistant.
Conclusion: This study documents the transmission of multidrug-resistant
M. tuberculosis to childhood contacts, the development of disease in these contacts and
the importance of knowing the index case's M. tuberculosis susceptibility pattern in
choosing a proper treatment regimen for the childhood contact.
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INTRODUCTION
In recent years there has been an increased awareness of drug-resistant tuberculosis.
Outbreaks and transmission of multidrug-resistant (MDR) tuberculosis have been
documented in both HIV-infected and noninfected adults.l" The risk factors for acquired drug
resistance such as previous tuberculosis (TB) treatment, noncompliance with antituberculosis
treatment (unsupervised treatment) and the incorrect prescription of antituberculosis
treatment by medical staff are well known.l"
The prevention and management of drug-resistant TB in adults has received much
attention, but relatively little attention has been given to drug-resistant tuberculosis in
childhood and the management of the childhood contacts of adults with drug-resistant TB and
specifically multidrug-resistant TB.4• 7-10 With the advent of the HIV era it is likely that more
children than in the past who are infected with drug-resistant Mycobacterium tuberculosis
will later develop disease if they are not properly managed as contacts. Furthermore any
program designed to control or eliminate TB must focus a greater effort on children because
they are a future reservoir for disease. II
The debate about whether drug-resistant TB is as infectious as drug-susceptible M.
tuberculosis in humans seems to be settled.12 Although there was some doubt in the past as to
whether drug-resistant M. tuberculosis bacilli were less likely to give rise to infection, there is
now little doubt that these organisms are transmitted, and in a controlled study the rate of
infection was even higher in the childhood contacts of drug-resistant index cases than in the
childhood contacts of a drug-susceptible group of index cases." Many children in
communities with a high incidence of tuberculosis are in contact with more than one adult
with pulmonary TB during their first 5 years of life, and it is still uncertain how these children
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should be managed regarding chemoprophylaxis.": IS Moreover if some of the index cases
have drug-susceptible and some have drug-resistant TB, the proper choice of
chemoprophylaxis becomes even more complex.l" There is also little doubt that drug-resistant
organisms can give rise to disease.P: 16
The purpose of this study was to determine the prevalence of tuberculous infection and
disease in young children in contact with newly identified adults with MDR pulmonary TB in
an area with a high incidence of TB.
PATIENTS AND METHODS
Primary resistance was defined as resistance in M. tuberculosis cultures from patients
with no previous TB treatment. Initial resistance is a term used for drug resistance in new TB
patients and allowing for undisclosed previous TB treatment (i.e. primary resistance plus
undisclosed acquired resistance). Acquired resistance is resistance found in cultures from
patients with one or more previous TB treatment episodes. MDR TB is defined as cultures
resistant to isoniazid and rifampin with or without resistance to other antituberculosis drugs.
This prospective study was conducted between April, 1994, and April, 1997, in the
Western Cape Province of South Africa, an area with a TB incidence of -700 new cases per
100000 population per year.17 The rate of initial resistance to isoniazid determined in adult
tuberculosis cases in the Western Cape Province during 1992-1993 was 3.9% [95%
confidence intervals (CI), 3.3 to 4.6%] and initial resistance to both isoniazid and rifampin
(multi drug resistance) was found in 1.1% of isolates (95% Cl 0.7 to 1.4).18 HN
seroprevalence in women attending antenatal clinics in the Western Cape Province rose from
1.16% (95% Cl 0.76 to 1.56) to 3.09% (95% Cl 2.34 to 3.84) from 1994-1996.19
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For the purpose of this study an index case was defined as an adult >15 years of age
with sputum culture positive for M. tuberculosis and resistant to at least isoniazid and
rifampin. Adult index cases were from suburbs surrounding the Tygerberg Hospital a tertiary
referral center for the area. They were identified as MDR cases by the South African Institute
for Medical Research (SAIMR) in Cape Town, which is responsible for the mycobacteriology
services in the Western Cape. Information collected regarding the adult index case included
gender and age, their relation to the childhood contact, whether they were previously treated
for TB (initial or acquired drug resistance), whether their sputa were smear- and/or culture-
positive for M. tuberculosis and the susceptibility pattern of the M tuberculosis culture.
Laboratory procedures for determining drug resistance were as follows: Middlebrook
7HI2 (Bactec) culture medium was used for selective primary isolation of mycobacterial
strains. The niacin production test was used to identify M. tuberculosis. Drug susceptibility
testing was performed by the economic variant of the indirect proportion method currently in
use by the majority of laboratories in South Africa.2o This method entails the incorporation of
the required drug concentration into Lëwenstein-Jensen (LJ) egg-based medium before
coagulation, and the slants were subsequently inoculated with a standardized inoculum. The
following drugs were tested at the indicated concentrations: isoniazid, 0.2 ug/ml LJ; rifampin,
30.0 ug/ml LJ; streptomycin, 5 ug/ml LJ; ethambutol, 2 ug/ml LJ; and ethionamide, 20 ug/ml
LJ. The susceptibility of a strain was judged by determining the proportion of bacilli resistant
to a specific drug in comparison with growth on a specific control using international criteria.
Resistance was defined as 1% or more bacterial growth." Quality assurance for drug
susceptibility results is done locally with every batch and quarterly by the national
tuberculosis reference laboratory.
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Childhood contacts were defined as children 5 years of age or less living and sleeping in
the same house or group of clustered houses/shacks on the same plot as the index case for at
least one month. Parents or guardians were asked to bring these children to the hospital for
evaluation, even if the parents considered the child to be asymptomatic. Transport was
arranged when necessary.
As part of the research protocol children were admitted for 3 days for assessment. A
history was obtained regarding previous TB prophylaxis or treatment and whether there were
any other adults in the same house who had or had recently had TB. This information was
verified with personnel at the local authority health clinics. Evidence regarding recent weight
loss or failure to gain in weight and documentation of previous bacillus Calmette-Guérin
(BCG) immunization was obtained from the patient's "Road to Health" clinic card when
available or from clinic records.
Each child had a clinical examination, tuberculin skin test [Mantoux test, 5 tuberculin
units (O.1ml) of Japanese purified protein derivative by intradermal injection read after 48 to
72 hl, anteroposterior and lateral chest radiographs and two gastric aspirates for M.
tuberculosis culture. Gastric aspiration was performed in the early morning before feeding
and without adding any lavage fluid. Sodium bicarbonate was added to the specimens to
neutralize gastric acid. Culture for M. tuberculosis was by a radiometric method (Bactec).
Erythrocyte sedimentation rate was determined, and HIV serology with enzyme-linked
immunosorbent assay (ELISA) was done on all children with informed consent and pre- and
posttest counselling of the parent. An area of induration ~ 15 mm after Mantoux skin testing
was regarded as significantly positive in accordance with World Health Organization criteria
given that >90% of children in this area receive BCG.21
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Bronchoscopy was performed only when the chest radiograph was abnormal and
showed persistent non-resolving opacification, but was not suggestive of TB.
The children were reevaluated after 2 months when all the relevant results including
gastric aspirate culture results and, where indicated, bronchoscopy and follow-up chest
radiograph were available. Children were classified as noninfected, infected or diseased. Non-
infected children were asymptomatic, had a non-significant «15 mm induration) Mantoux
test, normal chest radiograph and negative cultures for M. tuberculosis. Children with a
Mantoux test of ~15 mm who were asymptomatic had a normal chest radiograph or only
calcifications in the lung parenchyma or regional lymph nodes on the chest radiograph, and
negative cultures were regarded as having infection and not disease.22 Diseased children were
those who on chest radiograph had clearly visible, well defined hilar/mediastinal adenopathy,
miliary TB or endobronchial TB (as evidenced by hilar or mediastinal adenopathy with
bronchial compression or segmental/lobar consolidation or both), those with adenopathy
identified by bronchoscopy or those with a positive culture for M. tuberculosis. The chest
radiograph and bronchoscopy findings could be present with or without a positive Mantoux
test with or without positive cultures for M tuberculosis.
All infected children and all children <2 years of age who had received no previous
treatment or chemoprophylaxis of any kind for TB were given chemoprophylaxis with high
dose isoniazid 15 to 20 mglkg/day, pyrazinamide 25 to 35 mglkg/day, ethionamide 10 to 15
mg/kg/day and/or ethambutol 15 to 20 mglkg/day for 6 months, the latter two drugs
depending on the susceptibility of the MDR M tuberculosis strain of the adult index case.
Infected children who had received previous TB treatment or chemoprophylaxis with
isoniazid with or without rifampinlpyrazinamide were not prescribed another course of
chemoprophylaxis. Children who had TB were treated with at least two drugs to which the
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adult index case's organism was susceptible. They were treated with a 4 or 5 drug regimen
(isoniazid, pyrazinamide, ethionamide, ethambutol, and ofloxacin) for 9 to 12 months. All
children are included in a follow-up study to establish whether this treatment and duration of
therapy are sufficient.
Children older than 5 years of age and adults were not assessed as part of this study, but
were referred to the local authority health clinics in their area.
Categorical data were analysed by the chi square test to compare groups, and Fisher's
exact test was applied where appropriate. Chi square for trend was performed on data in
Table 4. Statistical analysis was done using Epi-Info version 6.03.
The study was approved by the Ethics Committee of the Faculty of Medicine of the
University of Stellenbosch, and informed written consent was obtained from the parent or
guardian for participation in the study.
RESULTS
During the three-year period of the study, 75 index cases with 128 childhood contacts <
5 years of age were identified and studied. The median age of the index cases was 30.5 years
(range, 16 to 63 years; mean age, 33.2 years) and the male:female ratio was 1:1.2. Index cases
were not routinely tested for HN, but 3 of the mothers (with 4 childhood contacts) were HN
infected. Only 13 (17%) index cases, all women, had primary drug resistance.
All 128 childhood contacts were evaluated. Of these, 116 (91%) lived in the same
dwelling and 12 (9%) stayed in the cluster of houses on the same plot. Ninety-nine children
(77%) were in contact with sputum smear positive index case and 29 (23%) with a smear
negative but culture positive MDR TB index case. Thirty nine percent of adult source cases
were resistant to isoniazid and rifampin only, whereas 44 (59%) were resistant to at least
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isoniazid, rifampin and streptomycin. Resistance patterns of the source cases and the number
of children in contact with them are summarized in Table 1.
In 47 (37%) children the index case was a parent, in 22 (17%) it was a grandparent and
other family members, mainly uncles, were the index case in 32 (25%) of children. Boarders,
caretakers and people living on the same plot were the index case for the remaining 27 (21%)
children.
Fifty (39%) children (34 of 75 households) had contact with other known adult
pulmonary TB cases in the same household at the same time. Of these, 17 (34%) were in
contact with known drug susceptible cases, 26 (52%) were in contact with another MDR TB
case and in 8 (16%) the susceptibility pattern was unknown.
Table 1: Drug resistance patterns of index cases and number of children contacts
Resistance Pattern to First Line Drugs No. of Index Cases No. of Children in Contact
(n = 75) (n = 128)
29 (39)* 46 (36)
31 (41) 54 (42)
2 (3) 2 (2)
13 (17) 26 (20)
Isoniazid, rifampin
Isoniazid, rifampin, streptomycin t
Isoniazid, rifampin, ethambutol!
Isoniazid, rifampin, streptomycin, ethambutoli
* Numbers in parentheses, percent.
t Additional resistance to second line antituberculosis drugs in 3 (10%) index cases (kanamycin 2; thiacetazone 1;
cycloserine 1).
t Additional resistance to second line antituberculosis drugs in 1 index case (kanamycin).
§ Additional resistance to second line antituberculosis drugs iniO (77%) index cases: 1 to 3 drugs (ethionamide 3,
thiacetazone 9, cycloserine 3, kanamycin 2, ofloxacin 2).
The children, 59 boys and 69 girls, had a median age of 27 months (range, 1 to 60
months, mean age 29.25 months). Of the 128 children 62 (48%) had received no previous
chemoprophylaxis or treatment and 46 (36%) had previously been given chemoprophylaxis,
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but 30 (65%) of these either defaulted within the first month or received isoniazid for only 3
months. In 20 children (16%) treatment for TB with isoniazid, rifampin and pyrazinamide
were previously prescribed for 6 months, but 6 (30%) defaulted after 3 to 4 months of
treatment.
One hundred nineteen children (93%) had received BeG [BeG scar on arm seen in 84
(71%), no BeG scar but administration of BeG noted on child's clinic card in 35 (29%)] and
1 child did not receive BeG. In 8 children no BeG scar was present and the Road to Health
clinic card could not be found.
All children were primarily evaluated because there was an adult household member
with MDR pulmonary TB. Some children, however, did have symptoms and these together
with the clinical signs and special investigations are summarized in Table 2. The Mantoux
skin test was done and read in all children and was positive (~15 mm) in 76 (59%). Chest
radiograph features were not statistically analysed because some features like
lymphadenopathy and opacification were used as criteria for diagnosis of disease. The lobar
and bronchopneumonie opacification in the children classified as noninfected and infection
only responded to antibiotics and was therefore considered to be pneumonia.
Bronchoscopy was done in six children and confirmed the presence of adenopathy in
three. M. tuberculosis was cultured from gastric aspirates in three children, none of whom had
received previous TB prophylaxis. Susceptibility testing of the M tuberculosis strains
cultured from the children's gastric aspirates was identical to that of the adult source case in
two instances. The third child's isolate was resistant to isoniazid, rifampin, streptomycin,
ethambutol and ethionamide whereas the isolate from the adult contact was resistant to
isoniazid, rifampin and streptomycin only.
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After investigation we classified 47 (37%) children as noninfected, 66 (51%) as
infected only and 15 (12%) as having disease. Ten children in the disease group had a
Mantoux result of z l S mm, in one the Mantoux test was ~10 to 14 mm and in 4 children, one
of which was HIV-infected who previously had a positive tuberculin skin test (Tine), the
Mantoux result was <5 mm. The diagnostic features in the diseased children were hilar or
mediastinal adenopathy in 10children (identified on bronchoscopy only in one child) and
endobronchial TB in 2 children. Three children who had not previously received
antituberculosis drugs had a positive culture for M. tuberculosis. Two of them had
adenopathy on chest radiograph and in the remaining child the chest radiograph appeared
normal. Because none of the children had received previous prophylaxis or treatment
appropriate for drug-resistant TB, the children were divided into 3 groups according to
whether they had received previous TB prophylaxis or treatment or not to detect any
difference in the prevalence of infection or disease. The final classification taking into
account previous TB chemoprophylaxis or treatment is summarized in Table 3.
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Table 2: Clinical features and special investigations in childhood contacts
Clinical Feature or Special Investigation Noninfected Infection Only Diseased
(n = 47) (n = 66) (n = 15)
Fever/sweating at night 2 (4)* 5 (8) 3 (20)
Cough> 14 days 8 (17) 7 (11 ) 6 (40)t
Documented failure to thrivej 10/41 (24) 12/57 (21 ) 7/12 (58)t
Weight <3rd centile§ 2 (4) 6 (9) 3 (20)
Lymphadenopathy 11 (23) 10 (15) 4 (27)
Respiratory signs (rhonchi, 4 (9) 7 (11 ) 4 (27)
crepitations, wheezes)
Hepatomegaly ~2 cm 4 (9) 5 (8) 3 (20)
Splenomegaly ~2 cm 3 (6) (2) (7)
Mantoux ~ 15 mm 0 66 (100) 10 (67)
ESR>50mmlh 4 (10) 7 (11) 5 (33)t
CXR features
Lymphadenopathy 0 0 12 (80)
Lobar/segmental opacification 0 (2) 3 (20)
Bronchopneumonic opacification (2) 2 (3) 3 (20)
Perihilar opacification (2) 9 (14) 3 (20)
Calcified parenchymal focus and/or nodes 0 10 (15) 0
• Numbers in parentheses, percent.
t P < 0,05; chi-square test with Fisher's exact. "Diseased" group compared with "noninfected" and "infection
only" groups combined. CXR features not compared (see text).
t Weight loss or failure to gain weight in >3 months.
§ NCHS centile chart.
CXR, chest radiograph; ESR, erythrocyte sedimentation rate.
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Table 3: Age and diagnosis according to previous TB prophylaxis or treatment
No Previous Previous Previous
Characteristic and Final Prophylaxis or Prophylaxis Treatment
Diagnosis Treatment (n = 46)
(n = 62) (n =20)
Defaulted or insufficient 0 30 (65%) 6 (30%)
prophylaxis/reatment
Median age in mo. (range) 22,5 (1-60) 22,5 (1,5-60) 48 (14-60)
Noninfected 27 (43%) 18 (39%) 2 (10%)
Infected only 24 (39%) 25 (54%) 17 (85%)
TB disease Il (18%) 3 (7%) (5%) *
Positive cultures 3 0 0
* HIV -infected patient.
There was no statistically significant difference between the number of patients with
disease in each group, but there was a trend towards more disease in those children who had
not received any previous antituberculosis drugs. Of further significance is that all 3 culture-
confirmed TB cases were from the group who received no previous chemoprophylaxis or
treatment. The one child with disease in the previously treated group was the only child in the
study who was HIV-infected.
Although the percentage of diseased children stayed constant with increasing age, the
number of infected children increased markedly (Table 4).
HIV infection was confirmed in only one child, with three different HIV enzyme-linked
immunosorbent assay serology tests positive at 36 months of age. Three other children
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initially had positive HN serologic tests, but they were clinically well and HN serology
became negative before 12 months of age.
Table 4: Mantoux result and diagnosis by age
No. with Mantoux Result Diagnosis
Age No. of 10-14 ~ 15 No. No. infected
( mo.) children mm mm non-infected Infected only Diseased
<12 29 5 (17)t 10(34) 18 (62) 8 (28) 3 (10)
12-<24 29 2 (7) 13 (45) 14 (48) Il (38) 4 (14)
24-<36 18 1 (6) Il (61) 7 (39) 9 (50) 2 (Il)
36-<48 25 1 (4) 19 (76) 4 (16) 18 (72) 3 (12)
48-60 27 0(0) 23 (85) 4 (15) 20 (74) 3 (11)
• Chi-square for trend test for tuberculin positivity by age categories: Mantoux ~10 mm, P <0,00 1;
Mantoux ~ 15 mm, P < 0,001; combining infected + diseased, P < 0,001.
t Numbers in parentheses, percent.
DISCUSSION
Several studies have shown that isoniazid-resistant and multidrug-resistant organisms
can be as infectious as drug-susceptible M. tuberculosis.3, 13,16,23 The presence of infection in
contacts is usually evaluated by tuberculin skin testing. In our study 81 (63%) childhood
contacts of adults with MDR pulmonary TB were infected or had disease. This is significantly
higher than (P <0.02) the 48% rate of infection and disease found in a similar study in
childhood contacts of mainly drug-susceptible adult TB cases in the same area." The disease
rate was, however, higher in the latter study (34% vs. 12%). No data on previous prophylaxis
or treatment in this drug-susceptible TB group were collected, and the number of households
with> 1 adult TB case was not systematically determined.
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The cutoff for a positive tuberculin test in South Africa and other developing countries
where BeG is routinely given is ~15 mm induration. This differs from the recommended
cutoff of >5 mm induration for children in contact with an adult with contagious TB and ~10
mm for all children <5 years of age used in the US. It is therefore possible that in our study
some children might have been misclassified as noninfected.
In a controlled trial Snider et al.13 also found the infection rate to be higher in the drug-
resistant TB contacts than in the drug-susceptible TB contacts. This higher rate of infection
could be explained in several ways, even in children younger than 5 years of age where a
positive tuberculin test usually indicates recent infection. In children living with adults with
MDR pulmonary TB, it is possible that the child was already infected before the adult
developed acquired drug resistance or that because of the delay in making a diagnosis of drug
resistance, the children had prolonged contact with adults chronically "expectorating" M.
tuberculosis organisms. In our study and earlier ones'?' 15 it is also clear that in an area with
high TB incidence, often more than one adult in a household has or recently had TB, and it
need not necessarily be drug-resistant TB.
The disease rate was relatively low in this study, possibly because there were children
who had previously received prophylaxis and treatment. Because of small numbers there was
no significant difference in the number of disease cases in those who previously received
antituberculosis drugs and those who did not. It is interesting, however, that all three culture-
proven cases arose among those children who had not received any previous treatment with
antituberculosis drugs. A disturbing finding is that even in those children in whom the index
case's drug susceptibility pattern was known, it was not considered in the choice of
antituberculosis drugs given to the children either as chemoprophylaxis or treatment. A
further problem was that the drug regimen used for prophylaxis (isoniazid for 3 months only)
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was inadequate for protection against TB disease and was further compromised by poor
compliance amongst the 36% of children receiving chemoprophylaxis.
Three children had a positive M tuberculosis culture, representing 20% of those who
had disease. All were drug-resistant and in two the drug resistance pattern matched that of the
adult index case, suggesting transmission of MDR M.tuberculosis from the adult index cases
to their child contacts. In the third patient the child's M. tuberculosis strain was not the same
as that of the index. The reason for this difference in drug susceptibility is unclear, and we
were unable to detect any other adults with MDR TB among the child's household contacts.
There was no difference in disease rate or infection rate in the children who were in
contact with smear-positive or culture-positive adult pulmonary TB cases. This could be the
result of low numbers in the study, other adults in the same household with smear-positive
TB (many adults were never screened) or the fact that sputum samples were not obtained
from the index case at a time that they were smear-positive (taking into account the potential
long duration of disease).
Although all children were screened for TB primarily because they were contacts of
adult MDR PTB, some did have clinical symptoms and signs compatible with TB disease.
The most significant of these was a documented failure to gain weight for a period of ~3
months and a history of cough for> 14 days. These are indicators for the diagnosis of TB used
by the World Health Organizarion."
Taking into account that a significant proportion of adults in this community probably
develop tuberculosis as a result of reactivation rather than reinfection.f the very high
infection rate in our childhood MDR TB contacts is disturbing. With poor chemoprophylaxis
and increasing HIV infection in the community, this may lead to an increasing pool of MDR
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TB-infected patients in the next generation who will develop MDR TB disease. It may
therefore be rewarding to concentrate on the childhood contacts of adult MDR TB cases with
regard to chemoprophylaxis and compliance. We would suggest that more attention be paid to
the drug susceptibility pattern of the adult case's M tuberculosis culture in choosing the
chemoprophylactic drugs in children.
In a study of MDR M tuberculosis isolated from adult patients in our area half of the
isolates were susceptible to isoniazid concentrations easily achieved in most children/"
Earlier studies in adults have also provided evidence of a clinical response to isoniazid in
patients with primary drug resistance.i" 28 whereas a slight but significant response was
reported recently in the early bactericidal activity of isoniazid despite primary isoniazid
resistance." These findings suggest that isoniazid may still be of value in chemoprophylaxis
and treatment despite documented isoniazid resistance. We do, however, suggest that a larger
daily dosage of 15 to 20 mg/kg be used and this is well-tolerated by young children.3o This
should be combined with pyrazinamide and one or two other drugs to which the adult strain is
susceptible, e.g. ethambutol (only 20% resistance in this study), ethionamide (tolerated better
in children than in adults) and/or a fluoroquinolone such as ofloxacin or ciprofloxacin.
Chemoprophylaxis should continue for at least 6 months and should be administered under
direct observation only. We preferred to keep the currently available fluoroquinolones in
reserve for the treatment of tuberculosis in that they are thought not to be ideal for the
sterilization of lesions." Although the fluoroquinolones are contraindicated for use in small
children, they are often used for treatment of resistant organisms. Serious adverse effects are
rare.32 A 30 month follow-up study of these patients is in progress.
This study documents the transmission of MDR M. tuberculosis to childhood contacts,
the development of disease in these contacts and the importance of knowing the index case's
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M tuberculosis susceptibility pattern in choosing a regimen for chemoprophylaxis or the
treatment for the childhood contact.
A further disturbing factor is the prevalence of 1.1% MDR TB among new adult cases of TB
pre-HIV, a situation that is likely to deteriorate as HIV-infected patients are increasingly
exposed to MDR TB. Preventive and curative therapy options for children exposed to adult
MDR TB cases_are quite limited and unresearched. Therefore the development of MDR TB in
adults and the subsequent transmission to children should be prevented. The first step to
achieve this is to identify new adult TB cases in the community and to give them combination
therapy under direct observation.
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Transmission of multidrug-resistant tuberculosis
Aim: To compare the Mycobacterium tuberculosis isolates of adult index cases with
multidrug-resistant (MDR) tuberculosis to the isolates obtained from their child
contacts.
Patients and methods: A 4-year prospective study in the Western Cape Province of
South Africa. We evaluated 149 child contacts of 80 adult MDR pulmonary
tuberculosis cases. This report includes those cases where a culture for M. tuberculosis
was obtained from both the adult source case and child contact. Isolates were compared
by drug susceptibility pattern and restriction fragment length polymorphism analysis.
Results: Six adult-child pairs with cultures for M. tuberculosis were identified. Two
children had contact with more than one adult tuberculosis case. One child received
previous isoniazid prophylaxis. Drug susceptibility pattern and restriction fragment
length polymorphism analysis were identical for five adult-child pairs. One child, with
no other known source case, had a strain different from that of the identified source
case, but the MDR M. tuberculosis strain with which he was infected was prevalent in
the community in which he resided. All children responded well to treatment.
Conclusion: This study confirms that most of the childhood contacts of adults with
MDR tuberculosis are likely to be infected by these MDR source cases despite their
exposure to other drug susceptible adults with tuberculosis in some instances. Child
contacts of adults with MDR tuberculosis should be treated according to the drug
susceptibility patterns of the likely source cases' M. tuberculosis strains unless their own
strain's susceptibility testing indicates otherwise. Contact tracing remains of
fundamental importance in identifying children at risk.
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INTRODUCTION
Drug-resistant Mycobacterium tuberculosis strains had been postulated to be less
infectious and to be less likely to cause disease than their drug-susceptible counterparts 1
but recent studies have shown them to cause infection and disease as often as drug-
susceptible organisms.i" It is further presumed that a person in contact with both drug-
susceptible and drug-resistant source cases will be less likely to develop drug-resistant
tuberculosis (TB).5 When young children develop drug-resistant TB, it is most likely
primary resistance caused by transmission.v' Studies have compared the characteristics of
M tuberculosis strains from children in contact with adults with single and multiple
(excluding rifampin) drug-resistant TB by drug susceptibility patterns only.2.3 These
studies found a high degree of correlation between the susceptibility patterns of the source
cases and the child contacts.
Restriction fragment length polymorphism (RFLP) analysis is a useful epidemiologic
tool to trace the transmission of particular strains of M. tuberculosis during investigations
of outbreaks mainly in large epidemiologic studies in adults.8•9 It has been used in a
nosocomial outbreak of TB in pediatric wards 10 and to prove adult to child transmission of
drug-susceptible TB.11 The aim of this study was to compare the isolates of adult index
cases with multidrug-resistant (MDR) TB and their child contacts by drug susceptibility
pattern as well as by RFLP analysis.
PATIENTS AND METHODS
This prospective study was conducted between April, 1994, and March, 1998, in the
Western Cape Province of South Africa, an area with a reported tuberculosis notification
rate of 589 new cases per 100 000 population per year in 1998 (data from Department of
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Health: Directorate Health Systems Research and Epidemiology). For the purpose of this
study an index case was defined as an adult > 15 years of age with a sputum culture
positive for MDR M. tuberculosis, i.e. resistance to at least isoniazid and rifampin. Child
contacts were defined as children who, at the time of diagnosis of the index case, had lived
in the same house or on the same residential plot as the index case for at least I month.
Adult-child pairs described in this report are those in whom a culture of M.
tuberculosis was obtained from both the index case and the child contact. Information
collected regarding the adult index cases included age, their relation to the childhood
contact, history of prior TB treatment, HIV status, results of acid-fast bacilli smear (AFB)
and culture for M tuberculosis and the drug susceptibility pattern of the M. tuberculosis
culture. Childhood contacts were evaluated regarding age at diagnosis, duration of contact
with the smear-positive index case, HIV status, treatment and outcome. Clinic records
were reviewed to ascertain whether other household members also had active pulmonary
tuberculosis.
Cultures from adult index cases and child contacts were obtained at different times
and in different laboratories. Drug susceptibility testing was performed by the economic
variant of the indirect proportion method by the South African Institute for Medical
Research and drug resistance was defined as 1% or more bacterial growth." Quality
assurance for drug susceptibility results is done locally with every batch and quarterly by
the national tuberculosis reference laboratory.
At a tertiary hospital in the province, 149 child contacts of 80 index cases were
evaluated during the study period and 2 gastric aspirates or sputum specimens were
obtained from each child for culture of M. tuberculosis. Eight children had confirmed TB.
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Seven children had a positive culture for M. tuberculosis of which one isolate was
contaminated and could not be processed further. The diagnosis was confirmed by Ziehl-
Neelsen stain of a lymph node biopsy in the remaining child, and no tissue was sent for
culture of M. tuberculosis.
Isolates from index cases and child contacts were genotyped by RFLP analysis
performed by the internationally standardized method based on the IS611 0-3' probe.12 To
enhance the accuracy of strain typing, especially in cases of low IS6110 copy numbers,
three additional probes were used (ECL labeled IS6110-5', DRr probe for Pvull digests
and 32P-Iabeled MTB484(1) probe for Hin!1 digests)."
Child contacts were treated for 9 to 18 months according to the adult index case's
susceptibility pattern with at least two drugs to which the index case was susceptible
(Table 1).
The study was approved by the Ethics Committee of the Faculty of Medicine of the
University of Stellenbosch. Written informed consent was obtained from the parents of the
children for inclusion in the study.
RESULTS
During the 4-year period six adult-child pairs were identified (Table 1).
Except for Case 1 all adult index cases lived in the same house and were related to
the child contact. The duration of contact of the child with the AFB smear-positive index
case varied from 2 months to >1 year. Two children had additional adult household
members with active TB. In Case 6 the child's uncle had MDR TB and the child's father
had AFB smear-positive drug-susceptible TB. In Case 5 where the child's maternal
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grandmother had MOR TB, the child's father had smear- and culture-positive TB, but no
drug susceptibility test was done on the isolate. The paternal grandmother in case 5 who
also lived in the same house had MOR TB with the same resistance pattern as the index
case and child.
The median age at diagnosis of TB in the child contacts was 32 months (range, 7.5
months to 15 years). All children received Bacillus Calmette-Guerin (BCG) at birth. Only
one child received prophylactic antituberculosis treatment 7 years before the diagnosis of
MOR TB. All children and the 4 adults in whom HW serology was done, were HW
negative.
The drug susceptibility and RFLP pattern of the M. tuberculosis isolates infecting
adult and child was the same in five of the six cases. The RFLP pattern was identical with
respect to both the number and molecular size of all bands using all four probes in five of
the six cases implying transmission of a multidrug-resistant M. tuberculosis strain from
adult to child in these five cases (Fig 1). In one case (Case 1) the adult was infected with a
different M tuberculosis strain resistant to isoniazid, rifampin and streptomycin, whereas
the organism infecting the child had in addition ethambutol and ethionamide resistance.
This implies that the child was infected by a different strain from an unknown source as
proved by RFLP (Fig 1, Lane 1). The use of three additional probes showed that the isolates
from Adult-Child Pair 1 are quite different from each other and that this is not simply a
gain or loss of one IS611 0 locus which may sometimes occur.
The one child with a different strain (Case 1) was inappropriately treated because the
child, owing to technical difficulties experienced with the drug resistance testing of the
child's strain, was treated according to the adult index case's results. The drug
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susceptibility pattern of the infecting strain was eventually found to be different, with the
child's isolate being resistant to more drugs than the strain of the suspected source case.
However, clinically and on chest radiography the child improved, and for this reason
further treatment was considered unnecessary. No relapse occurred during the 30 months
of follow-up.
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TABLE 1: Summary of adult-child pair data
Adult MOR Index Cases Child Contacts
Minimum
Same duration Other Age at Prior Mantoux Chest Chest RFLPAdult/Child Relationship
housel
smear- Resistance household diagnosis anti-TB result
Resistance radiograph Treatment Duration radiograph at patternPair to child plot positive pattern contacts (mo) drugs (mm) pattern
at follow-up last follow-up (pain)
contact with TB diagnosis
(mo)
I. Cm-CW Boarder Plot 2 H,R,S No 32 No 17 H,R,S,E, Hilar nodes + H, Z, E, Eth 30 Normal Different
Eth perihilar for9 mo
opacification
2. AH-MH Mother House 2 H,R,S No 7.5 No 15 H,R,S Perihilar H,R,Z,E, 36 Calcified hilar Same
opacification Eth for9 node
mo
3. RdV-EdV Father House >i2 H,R,S, No 180 Isoniazid Not done H,R,S,E, Cavities left H, Z, K, T 30 Fibrosis left Same
E,T prophy- T upper lobe o for8 upper lobe,
laxis mo+ residual
7 yr ago HZTO for pneumatoceles
8mo
4. NP-BP Aunt House iO H,R,S No 9.5 No 18 H,R,S Paratracheal H,Z,E, 18 Normal Same
+ hilar Eth, 0 for
nodes and 9mo
segmental
opacification
5. SdP-JdP Grandmother House >12 H,R,S Yes 54 No 14 H,R,S Perihilar H,Z,E, 30 Normal Same
opacification Eth,O for
6mo
(then
defaulted
treatment)
6. CA-RA Uncle House 3 H,R Yes 32 No 40 H,R Hilar nodes + H,Z,E, 30 Normal Same
segmental Eth, 0 for
lesion 12mo
H, Isoniazid; R, Rifampicin; S, streptomycin; E, ethmabutol; Eth, ethionamide; 0,olf1oxacin; T, thiacetazone; K, kanamycin
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FIG 1. RFLP (156110-3' probe) pattern of the infecting M. tuberculosis strain of six children
(first lane of each of six pairs) and the corresponding adult MOR TB source case (second
lane of each of six pairs). Lane R corresponds to the control strain MTB 14323.
None of the children had serious side effects from the antituberculosis drugs used.
Ethionamide caused some gastrointestinal side-effects, but in all five children in whom it
was used it could be continued for the full duration of treatment. Four children, of whom
three were <5 years of age, received ofloxacin (15 mg/kg/day) for 6 to 16 months with no
clinical side effects. All children were clinically well after their treatment and remained
so at median follow-up of 30 months.
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Three of the adult index cases died during the study (two of TB and one from a
gunshot), two were still culture-positive at the end of the study (both defaulting
treatment) and one was cured.
DISCUSSION
As far as we could determine this is the first prospective study making use of drug
susceptibility patterns and RFLP analyses to confirm transmission of MDR TB from
adult source cases to their childhood contacts.
In a study of 29 cases of isoniazid- and/or streptomycin-resistant TB in children
and/or their source cases, Steiner et al.2 found that the drug susceptibility patterns of
source cases and children were similar in 69% (n = 20). In our study 5 of 6 pairs (83%)
had the same multidrug-resistant M tuberculosis strain as shown by susceptibility and
RFLP analysis, and this despite the fact that in 2 households there were other adults with
presumably drug-susceptible TB. In the one case (Case 1) in which the strains were
different, no other source case could be identified even after a detailed social history. The
strain with which the child was infected is, however, part of a cluster of MDR TB strains
circulating in the community in which the child resides. This implies that transmission of
MDR tuberculosis to children can occur through unknown contact."
Four of the six adult-child pairs (Pairs 1 to 4) come from a well-studied community while
two pairs are from geographically distant communities. In the well-studied community,
only eleven five-bander isolates (during a 5-year period) have been detected with the
genotype presented, of which five are shown in this report. (unpublished data). For this
reason it is more likely that transmission occurred within the household than within the
community.
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The long duration of smear-positive contact in this study was probably a result of
insufficient contact tracing. It emphasizes the importance of contact tracing especially in
young children where the incubation period can be as short as 6 to 8 weeks and who are
in danger of developing disseminated and more severe forms of disease." Treatment for
infection and disease should be initiated as soon as possible."
Transmission of MDR TB from adults to their child contacts has important
implications for the management of these children. Young children ~5 years of age
should be considered for prophylactic therapy after active TB has been excluded'
Isoniazid is the only drug proven to be effective as prophylactic therapy, and rifampin is
recommended as an alternative in cases of isoniazid resistance.v" However, both these
drugs are probably of limited value in prophylactic therapy in MDR TB contacts. No
controlled trial has evaluated any prophylactic regimen for contacts of MDR TB cases. A
potential prophylactic regimen could be a combination of pyrazinamide and ethambutol
or pyrazinamide and a fluoroquinolone for a minimum period of 6 months.v"
The treatment of MDR TB in children is a controversial issue. It has been
postulated that persons exposed to several sources of M tuberculosis, including
infectious TB patients with drug susceptible M. tuberculosis, are less likely to have been
infected with a MDR strain than are those whose only known exposure to TB was to an
infectious MDR TB case.' The presumed intermediate to low risk has not been confirmed
by our study and we suggest that child contacts of infectious MDR index cases should be
treated according to the drug susceptibility pattern of the MDR TB index cases and not
the drug-susceptible source case. These children should be treated with at least two or
three drugs to which the M. tuberculosis strain of the child or adult source case is
susceptible. However, much uncertainty exists as to which drugs to use and for what
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duration. Ethionamide is much better tolerated in children than in adults and therefore
plays an important role in the treatment of MDR TB in children.' No serious side effects
were experienced by our patients. Ethambutol is a valuable drug in the treatment of drug-
resistant TB and no case of optic neuritis has been reported in a child." Eyesight should
still be tested when possible. On the grounds of the effect of the quinolones on cartilage
growth in animal studies, it is suggested that the quinolones should not be used in
children.l" We found no side effects in the four children treated with quinolones for up to
16 months.
The suggested duration of treatment in adults and children with MDR TB is 12 to
24 months.16,17 The number of M. tuberculosis organisms found in caseating lung lesions
in children is, however, much less than in the cavitatory lung disease of adults and
probably not many more than the number of organisms found in children who are
infected but do not have disease.l" In this study, we treated children without cavitatory
disease for 9 to 12 months, and they have had satisfactory weight gain and no sign of
relapse on chest radiograph after 18 to 36 months.
This study confirms that most of the childhood contacts of adults with MDR TB
are likely to be infected by these adult MDR source cases despite their exposure to other
drug-susceptible adults with TB in some instances. Contact tracing remains of
fundamental importance in identifying children at risk. We recommend that appropriate
samples for M tuberculosis cultures and susceptibility testing be taken from all children
in close contact with adults MDR pulmonary TB cases. However, if the child contact's
M. tuberculosis culture is not available, we suggest that children in contact with adults
who have MDR TB should be treated according to the drug susceptibility patterns of the
source cases' M tuberculosis strains.
Stellenbosch University http://scholar.sun.ac.za
130
ACKNOWLEDGEMENTS
We thank Glaxo Wellcome International Action TB Programme for financial support,
Ms. Sophia Carlini for preparing the M. tuberculosis cultures for RFLP, Ms. Collette
Booysen for interviewing patients and household members and the nursing and technical
staff of the TB Research Team of the University of Stellenbosch.
References:
I. Cohn ML, Davis CL. Infectivity and pathogenicity of drug-resistant strains of tubercle bacilli
studied by aerogenic infection of guinea pigs. Am Rev Respir Dis 1970; 102:97-100.
2. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculosis in children.
Correlation of drug-susceptibility patterns of matched patient and source case strains. Am J Dis
---
Child 1985;139:780-782.
3. Snider DE Jr., Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among
contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis
1985; 132: 125-132.
4. Schaaf HS, Vermeulen HAS, Gie RP, Beyers N, Donald PR. Evaluation of young children in
household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatr Infect Dis J
1999; 18:494-500.
5. Centers for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis.
MMWR 1992;41(RR-Il):59-71.
6. Rieder HL. Drug-resistant tuberculosis: Issues in epidemiology and challenges for public health.
Tuberc Lung Dis 1993;75:321-323.
7. Schluger NW, Lawrence RM, McGuiness G, Park M, Rom WN. Multidrug-resistant tuberculosis in
children: Two cases and a review of the literature. Pediatr Pulmonology 1996;21: 138-142.
8. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Fransisco. A
population-based study using conventional and molecular methods. N Engl J Med 1994;330: 1703-
1709.
Stellenbosch University http://scholar.sun.ac.za
131
9. Van Rie A, Warren RM, Beyers N, et al. Transmission of a multidrug-resistant Mycobacterium
tuberculosis strain resembling "Strain W' among noninstitutionalized, human immunodeficiency
virus-seronegative patients. J Infect Dis 1999; 180: 1608-1615.
10. Aznar J, Safi H, Romero J, Alejo A, Gracia A, Palomares JC. Nosocomial transmission of
tuberculosis infection in pediatrics wards. Pediatr Infect Dis J 1995; 14:44-48.
Il. Makristathis A, Stauffer F, Klein JP, Rotter ML, Wewalka G, Hirschi AM. Infant tuberculosis in
Austria - trend reversal since 1990? Infection 1998;26:42-44.
12. Van Embden JDA, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium
tuberculosis by DNA fingerprinting: Recommendations for a standardized methodology. J Clin
MicrobioI1993;31:406-409.
13. Warren R, Richardson M, Sampson S, et al. Genotyping of Mycobacterium tuberculosis with
additional markers enhances accuracy in epidemiological studies. J Clin Microbiol 1996;34:2219-
2224.
14. Van Rie A, Warren R, Richardson M, et al. The traditional classification of drug resistant
tuberculosis can be misleading in an epidemic area. Lancet (in press).
15. Starke JR, Correa AG. Management of mycobacterial infection and disease in children. Pediatr
Infect Dis J 1995;14:455-470.
16. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and
children. Am J Respir Crit Care Med 1994;149:1359-1374.
17. Swanson DS, Starke JR. Drug-resistant tuberculosis in pediatrics. Pediatr Clin North Am
1995;42:553-581.
Stellenbosch University http://scholar.sun.ac.za
132
CHAPTER6
Evaluation of young children in contact with adult multidrug
resistant pulmonary tuberculosis: A 30-month follow-up
H Simon Schaaf, Robert P. Gie, Magdalene Kennedy, Nulda Beyers,
Peter B Hesseling, Peter R. Donald
Department of Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University and
Tygerberg Children's Hospital, Western Cape Province, South Africa
Pediatrics 2002; 109:765-771.
Printed by copyright permission. Copyright © 2002 by American Academy of Pediatrics
Stellenbosch University http://scholar.sun.ac.za
133
Evaluation of young children in contact with adult multidrug resistant pulmonary
tuberculosis: A 30-month follow-up
Setting: The Western Cape Province of South Africa, an area with a high
tuberculosis (TB) incidence, where initial multidrug resistance (MDR) among adult
TB cases was 1.1% during 1992-1993.
Objective: To determine the long-term prevalence of TB infection and disease in
children in household contact with adults with MDR pulmonary TB, and to establish
the efficacy of chemoprophylaxis in preventing disease in these children.
Method: Children < 5 years old in contact with 73 MDR TB adults were evaluated.
Disease was treated by prescribing at least 2 drugs to which the adult's strain was
susceptible. The remaining children were classified as infected or noninfected and
received chemoprophylaxis according to the index's strain susceptibility or were
followed up and treated when indicated. All were followed up for 30 months.
Results: At the initial evaluation 125 children were seen, median age 27.5 months.
Of these, 119 were followed up. Fourteen (12%) had disease, 61 (51%) were
infected only and 44 (37%) were noninfected. By 30-month follow-up, 29 (24%) had
developed disease and 64 (54%) were infected only. Four adult-child pair M.
tuberculosis isolates were compared by DNA fingerprinting; 3 were identical. All
children who developed TB disease were clinically cured. Two (5%) of 41 children
who received appropriate chemoprophylaxis and 13 (20%) of 64 who did not,
developed TB during follow-up. (odds ratio: 4.97)
Conclusion: The study confirms MDR TB transmission to childhood contacts.
Seventy-eight percent of children were infected or developed disease. Appropriate
chemoprophylaxis may prevent disease in these children.
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INTRODUCTION
Tuberculosis (TB) contact tracing has produced a significant yield of new TB cases
and newly infected patients in the past. I Children in close contact with drug-susceptible
adult pulmonary TB have a high risk of becoming infected and developing disease.v' It
is generally accepted that 30 to 50% of household contacts of adults with infectious
forms of pulmonary TB will become infected.' The risk for young children with
untreated infection to develop TB is up to 43% in children <1 year of age and about 24%
for children 1 to 5 years of age.' Little is known, however, about the long-term outcome
of children in contact with multidrug-resistant (MOR) adult pulmonary TB cases.
Although studies in guinea pigs suggested that isoniazid-resistant strains are less
infectious and cause less disease than the drug-susceptible strains, this diminished
infectiousness and pathogenicity was not confirmed in human studies.4,s The
management of adults or children in contact with infectious MOR pulmonary TB cases is
still very uncertain and, although many suggestions for different regimens for MOR
chemoprophylaxis have been made, there are no prospective studies to verify their
effectiveness." Furthermore, the optimal duration of chemoprophylaxis with these drugs
is uncertain.Y On the other hand, the implications of not being able to give adequate
chemoprophylaxis to children infected with MOR strains of Mycobacterium tuberculosis
are serious, because about 10% or more of infected children will develop TB disease in
their lifetime, and they will have the potential to continue the transmission of MOR TB
in future.t
Drugs used in the treatment of MOR TB cases are generally much more toxic than
first line drugs. In children, the use of fluoroquinolones is not generally recommended. 9
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Although their safety in short and medium term treatment have been documented,
uncertainty still exists about the long-term treatment with the fluoroquinolones.t'"
The main purpose of this study was to determine the long-term prevalence of
tuberculous infection and disease in young children in household contact with adults with
MDR pulmonary TB in a geographical area with a high incidence of TB. An additional
aim was to establish whether chemoprophylaxis is effective in preventing active disease
in these children.
PATIENTS AND METHODS
Primary resistance was defined as resistance in M. tuberculosis cultures from
patients with no previous TB treatment. Initial resistance is drug resistance in new TB
patients but allowing for undisclosed previous TB treatment (i.e., primary resistance plus
undisclosed acquired resistance). Acquired resistance is resistance found in cultures from
patients who have had 1 or more previous TB treatment episodes. MDR is resistance to
isoniazid and rifampin with or without resistance to other anti-TB drugs. I I
A prospective study was conducted between April 1994 and January 2000 in the
Western Cape Province of South Africa, an area with a TB incidence of 589 new cases
per 100 000 population per year in 1998 (Department of Health: Directorate Health
Systems Research and Epidemiology). The rate of initial resistance to isoniazid
determined in adult tuberculosis cases in the Western Cape Province during 1992-1993,
was 3.9% (95% confidence intervals [Cl]: 3.3-4.6%) and initial resistance to both
isoniazid and rifampin was found in 1.1% of isolates (95% Cl: 0.7-1.4).12 Human
immunodeficiency virus (HIV) seroprevalence in women attending antenatal clinics in
the Western Cape Province rose from 1.16% (95% Cl: 0.76-1.56) to 5.21% (95% Cl: 3.2-
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7.2) from 1994 to 1998 (Department of Health: Directorate Health Systems Research and
Epidemiology).
An index case was defined as an individual >15 years of age with sputum culture
positive for M. tuberculosis, which was resistant to at least isoniazid and rifampin. The
sputum specimens were processed by the South African Institute for Medical Research in
Cape Town, which is responsible for the mycobacteriology services in the Western Cape.
Laboratory procedures for determining drug resistance were described previously. Il
Briefly, Middlebrook 7H12 (Bactec; Becton Dickenson and Company, Sparks, MD)
culture medium was used for isolation of mycobacterial strains. The niacin production
test was used to identify M. tuberculosis. Drug susceptibility testing was performed by
the indirect proportion method. The following drugs were tested at the indicated
concentrations: isoniazid 0.2 ug/rnl LJ; rifampin 30.0 ug/ml LJ; streptomycin 5 ug/rnl
LJ; ethambutol 2 ug/ml LJ; and ethionamide 20 ug/rnl LJ. Resistance was defined as 1%
or more bacterial growth. Quality assurance for drug susceptibility results is done locally
with every batch and quarterly by the national TB reference laboratory.
Index cases were resident in suburbs surrounding the Tygerberg Hospital, a tertiary
referral center for the area. Information collected regarding the adult index case included
gender and age, their relation to the childhood contact, whether their sputa were smear-
positive or smear-negative ...the susceptibility pattern of the M. tuberculosis culture, and
the index case's outcome after 30 months.
Childhood contacts were defined as children 5 years of age or less living and
sleeping in the same house or group of clustered houses/shacks on the same residential
site as the index case for at least one month. Il Parents or guardians were asked to bring
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these children to hospital for initial and follow-up evaluations, even if the parents
considered the child to be asymptomatic. All the children in these households were seen.
Initial evaluation included obtaining a history regarding previous TB
chemoprophylaxis or treatment and whether there were other adults in the same house
who had or had recently had TB. This information was verified by contacting the local
authority health clinics where patients reside. Evidence regarding recent weight loss or
failure to gain in weight and documentation of BeG immunization was obtained from the
patient's "Road to Health" clinic card or from clinic records.
Each child was subjected to an initial clinical examination, tuberculin skin test
(Mantoux test - 5TU [O.lml] Japanese purified protein derivative by intradermal injection
read after 48-72 hours), antero-posterior and lateral chest radiographs, and two early
morning gastric aspirates for M.tuberculosis cultures. I I The erythrocyte sedimentation
rate (ESR) was determined and HIV serology with enzyme-linked immunosorbent assay
was done in all children with written informed consent and after counselling of the
parent. An area of induration ~15mm in transverse diameter after Mantoux skin testing
was regarded as significantly positive in accordance with World Health Organization
criteria and National TB program guidelines as > 95% of children in this area receive
BeG at birth.13 Bronchoscopy was performed only when the chest radiograph was
persistently abnormal but was not diagnostic of TB. As part of the initial diagnostic
evaluation, children were seen again after 2 months when the relevant results of
investigations including cultures and, where indicated, follow-up chest radiograph were
available.
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Children were classified as noninfected, infected, or diseased. Noninfected children
were asymptomatic, had a nonsignificant «15mm induration) Mantoux test, normal
chest radiograph, and negative cultures for M.tuberculosis. Children with a Mantoux test
of ~ 15mm who were asymptomatic, had a normal chest radiograph or only calcifications
in the lung parenchyma or regional lymph nodes on the chest radiograph, and negative
cultures were regarded as having infection and not disease." Diseased children were
those who on chest radiograph had well-defined hilar or mediastinal adenopathy, miliary
TB or endobronchial TB (as evidenced by hilar or mediastinal adenopathy with bronchial
compression or segmental/lobar consolidation or both), those with adenopathy
compressing airways identified by bronchoscopy, acid-fast bacilli on biopsy histology
specimen or those with a positive culture for M. tuberculosis from any source. The chest
radiograph and bronchoscopy findings could be present with or without a positive
(z l Smrn) Mantoux test, and with or without positive cultures for M. tuberculosis. A
cough lasting >2 weeks, weight loss or failure to gain adequately in weight for ~3
preceding months, and an ESR of >50mmlhour Westergren substantiated the diagnosis of
disease but was not regarded in itself as confirming the presence of tuberculous disease.
All infected children and all children <2 years of age who had received no previous
treatment or chemoprophylaxis of any kind for TB were offered chemoprophylaxis with
high-dose isoniazid 15 to 20 mg/kg/d, pyrazinamide 25 to 35 mg/kg/d, ethionamide 10 to
15 mg/kg/d and/or ethambutol 15 to 20 mg/kg/d and/or ofloxacin 15 mg/kg/d for 6
months, the latter 2 drugs being included depending on the susceptibility of the MDR
M.tuberculosis strain of the adult index case. Children who had received previous TB
treatment or chemoprophylaxis with isoniazid with or without rifampinlpyrazinamide
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were not routinely prescribed another course of chemoprophylaxis except when it was
preferred by the parent rather than follow-up only.
Children who had TB disease received individualized treatment. This consisted of a
4- or 5-drug regimen (isoniazid, pyrazinamide, ethionamide, ethambutol, and ofloxacin)
that included at least 2 to 3 drugs to which the adult index case's isolate was susceptible.
Prescribed duration of treatment was for 6 to 12 months, determined by extent of disease,
eg, hilar adenopathy only was initially treated for 6 months (later 9 months), whereas
extensive pulmonary infiltrates were treated for 12 months.
All treatment and chemoprophylaxis was given as directly observed therapy.
Caregivers were expected to take the children to the local health clinic daily (5 days a
week) where health care workers had to observe the children taking their treatment.
When patients did not return for treatment, several home visits were made to motivate
caregivers to bring the children for treatment. If despite all efforts (including motivation
for hospital admission for treatment) children did not receive any treatment for> 1month,
treatment was discontinued. Follow-up visits were, however, continued.
Follow-up visits were arranged for all children at 4 months, 6 months and 6-
monthly thereafter to 30 months. Other evaluations occurred as were clinically indicated.
Evaluations at follow-up comprised a clinical examination, Mantoux skin testing if a
previous test was not significantly positive, and chest radiographs every 6 months or
more often, when clinically indicated. Culture for M. tuberculosis, lymph node biopsy
and bronchoscopy were done only when clinically or radiologically indicated.
In those cases where cultures of M. tuberculosis were obtained from both the adult
index case and the child contact, isolates were genotyped by restriction fragment length
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polymorphism (RFLP) analysis using the internationally standardized method (IS611 0-
3 ') and three additional probes as previously described.P:"
Children older than 5 years of age and adults were not assessed as part of this study,
but were referred to the local authority health clinics in their area.
Categorical data was analysed using the "I: test to compare groups and Fisher exact
test was applied where appropriate. Statistical analysis was done using Epi Info version
6.04 (Centers for Disease Control and Prevention, Atlanta, GA).
The study was approved by the Ethics Committee of the Faculty of Health Sciences of
the University of Stellenbosch and informed written consent was obtained from the
parent or guardian for participation in the study.
RESULTS
Seventy-three index cases and 125 childhood contacts <5 years of age were
identified and studied. Two index cases with 3 childhood contacts identified in the
original study were excluded because the 1 index case was not culture positive after the
birth of the 2 children, and the second index case was subsequently shown to have a drug
susceptible M tuberculosis strain. II
The median age of the index cases was 30 years (range: 16-63 years; mean: 33.1
years) and the male:female ratio was 1:1.2. Thirteen (18%) index cases had primary
drug-resistant TB. At 30-month follow-up, 24 (33%) of the index cases had died, in 2 of
whom the cause was not TB-related; 8 (Il %) were still smear- and/or culture-positive for
MDR M tuberculosis, and 5 (7%) were lost to follow-up. Thirty-six (49%) index cases
were alive and culture-negative.
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There was no significant age difference between the index cases of children who
developed disease (median: 32 years old; range: 19-62), had infection only (median: 32
years old; range: 16-63) and those that were not infected (median: 30 years old; range:
17-60).
Forty-one households (56%) affecting 57 (46%) children had >1 adult source case,
consisting of additional MOR TB source cases in 38 children (68%), drug-susceptible
source cases in 19 children (28%), and cases with unknown susceptibility in Il children
(16%).
At initial evaluation of all 125 childhood contacts there were 58 boys and 67 girls
with a median age of 28 months (range: 1-60 months). Of these, 14 (11%) children had
tuberculous disease, 66 (53%) were infected only and 45 (36%) were not infected. Six
(5%) children, 5 infected only and 1 noninfected, did not return for any follow-up and
were excluded from the analysis.
One hundred nineteen children attended follow-up visits, 116 (97%) of whom were
seen at the 30-month appointment. Except for the 4-month follow-up attendance of 71%,
all 6-monthly evaluations had an attendance of >90%. The median number of follow-up
evaluations per child was 6 (range: 1-16) with only 6 children having <4 follow-up
evaluations. Twenty-three (19%) children were followed up beyond 30 months.
On follow-up, an additional 15 children (12%) developed disease by 30 months.
Diagnosis at 6-month follow-up evaluations is summarized in Table 1. There was no
significant difference in the rate of infection or disease by age. Twelve (80%) of the 15
children that developed disease during the 30-month follow-up, were diagnosed by 12
months, and only 1 child developed disease between 18 and 30 months.
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Ninety-five (80%) children were in contact with an acid-fast bacilli smear-positive MDR
TB index case and 24 with a culture only confirmed index case. Of the smear-positive
contacts, 80 (84%) were infected of whom 27 (34%) developed disease and of culture
only positive contacts 14 (58%) were infected of whom 2 (14%) developed disease.
Infection occurred significantly more in the smear-positive group [P = .012; odds ratio
3.81 (95% Cl: 1.28-11.36)], but disease among those infected was not significantly more
frequent. (P = .21) Ten (40%) of 25 noninfected children had a smear-negative adult
index case.
Table 1. Diagnosis at follow-up evaluations*
TB diagnosis TB disease Infected only Noninfected Lost to follow-up
Initial evaluation 14(11%) 66 (53%) 45 (36%)
6-month evaluation 24 (19%) 58 (46%) 37 (30%) 6 (5%)
12-month evaluation 26 (21%) 62 (49%) 31 (25%) 6 (5%)
18-month evaluation 28 (22.5%) 63 (50%) 26 (21%) 8 (6.5%)
24-month evaluation 28 (22.5%) 65 (52%) 24 (19%) 8 (6.5%)
30-month evaluation 29 (23%) 64 (51%) 23 (19%) 9 (7%)
*0 = 125
Continued contact with the adult index case after the initial evaluation was shorter
for noninfected children (median: 2 months; range: 1-7 months) than for infected only (P
= .002; Kruskal-Wallis test) and diseased children (P = .04; both groups, median: 4
months; range: 1-30 months).
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Tuberculosis was confirmed in 6 (21%) of 29 children with disease, 5 by culture of
M tuberculosis and 1 by finding acid-fast bacilli on microscopy of a peripheral lymph
node biopsy. Drug susceptibility testing was done in 4 cases and these isolates were all
MDR. The 1 isolate not tested was contaminated and the histology specimen was
regrettably not submitted for culture. RFLP analysis was performed on 4 adult-child pair
isolates, 3 of which were identical. In 1 adult-child pair the drug susceptibility pattern
and RFLP were dissimilar, but both were MDR and a community infection was likely in
the child. II
Of the 29 children diagnosed with tuberculosis, 27(93%) had hilar
lymphadenopathy on chest radiography, 16 of whom had other parenchymal or pleural
changes. A Mantoux of ~15mm induration was present in 22 (76%), a cough for >2
weeks in 16 (55%) and documented weight loss or failure to gain weight in 12 (41%). In
3 children hilar lymphadenopathy compressing the airways was confirmed by
bronchoscopy. In 1 of these the chest radiograph did not clearly show hilar adenopathy.
The ESR was >50 mmlhour in both children who did not have hilar lymphadenopathy on
chest radiography. No child had disseminated disease.
At the initial evaluation, calcification was present on chest radiography in 10 (8%)
of 119 children, all of whom were tuberculin skin test-positive. Subsequently, a further
29 (24%) children developed calcification on chest radiograph. In 10 cases, in 2 of whom
the Mantoux test remained 0 mm, calcifications developed 6 to 18 months after diagnosis
of TB disease. In 4 children with infection only, the diagnosis was based solely on the
presence of calcifications on chest radiograph. In 3 of these cases, the Mantoux test
showed no reaction and in 1 an induration of 10mm was found.
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Tuberculin skin test results are summarized in Table 2. Only 1 child, whose
Mantoux test was 0 mm and was diagnosed as having TB disease, was HIV-infected.
Table 2. Mantoux test results during 30-month follow-up of children in contact with
adult MDR pulmonary TB cases. *
Induration 0-9mm 10-14 mm ~15mm
Initial evaluation 42 (35) 8 (7) 69 (58)
6-month evaluation 40 (34) 7 (6) 72 (60)
12-month evaluation 38 (32) 5 (4) 76 (64)
18-month evaluation 36 (30) 5 (4) 78 (66)
24-month evaluation 35 (29) 5 (4) 79 (67)
30-month evaluation 33 (28) 5 (4) 81 (68)
*n=119; % in parenthesis.
Individualized treatment according to the drug susceptibility pattern of the index
case was prescribed in 25 (86%) of 29 children that had disease. (Table 3) Fourteen
(56%) children completed a 4- to 5-drug regimen of 9 to 12 months, 6 (24%) children
defaulted from a 9-month treatment course after 4 to 8 months, and 5 (20%) children, all
with only hilar adenopathy on chest radiograph, completed a 6-month treatment regimen.
Of the 4 children who did not receive treatment, in 3, one of whom had received previous
TB treatment, the diagnosis was made retrospectively. These children were followed up
but no treatment was given. The remaining child missed his 6-month follow-up and was
diagnosed at the local authority health clinic and received isoniazid, rifampin and
pyrazinamide for 6 months. All 29 children were clinically and radiologically well after
30 months follow-up.
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Table 3. List of regimens used as chemoprophylaxis and treatment
Chemoprophylaxis regimens (n = 41) (%)
5 days a week for 6 months
HZEth 20 (49)
HZE 9 (22)
HEEth 4 (14)
EEth 2 (5)
HZE Eth 2 (5)
ZEEth 2 (5)
HZEthO 2 (5)
Treatment regimens (n = 25) (%)
6HZE Eth 4 (16)
6 H Z Eth 0 (4)
9 HZ E Eth 8 (32)
9HZEthO 2 (8)
9HZEEthO 4 (16)
6 H Z E 0/6 HZ E Eth* 1 (4)
12 H Z E Eth (4)
12 H Z Eth 0 1 (4)
12 H Z E Eth 0 3 (12)
H indicates isoniazid; Z, pyrazinamide; E, Ethambutol; Eth, Ethionamide; 0, ofloxacin.
·Ofloxacin was stopped because of arthralgia.
Forty-one children received prophylaxis for MDR TB. Three- or 4-drug
combinations for 6 months were prescribed. (Table 3) Isoniazid and pyrazinamide were
included in almost all regimens together with ethionamide and/or ethambutol or
ofloxacin. A comparison between the groups of children that did and those that did not
receive appropriate prophylaxis once they were identified as MDR TB contacts is
summarized in Table 4. Fifty-seven of these contacts had no other adult source case
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identified. None of the 29 children who received appropriate chemoprophylaxis and 6 of
28 children who did not, developed disease during follow-up (P = .01; Fisher exact). Of
the remaining 9 children who developed disease and did have other source cases, 6
source cases had MDR (including both cases in the chemoprophylaxis group), in 2 the
source cases' susceptibility patterns were unknown and one child had an additional drug-
susceptible contact.
Ethionamide was used in the treatment or prophylaxis of 61 (51%) children. Thirty
(49%) children experienced gastrointestinal side effects, and the drug had to be stopped
in 4 cases. There was no difference in the occurrence of side effects attributable to
ethionamide in children less or more than 2 years of age.
Ofloxacin, used mainly for treatment, was administered in 15 children for durations
of 6 to 12 months. Median age of onset of treatment with ofloxacin was 37 months with a
range of 7 to 63 months. In combination with ethionamide, it was not possible to
establish whether it caused gastrointestinal side effects. Only 1 child, a girl in whom
treatment was started at 19 months old, complained of pain in the knees after 6 months,
and ofloxacin was immediately stopped. The arthralgia cleared but it could not be
determined whether ofloxacin was the actual cause. No radiologic studies were done to
evaluate potential toxicity in any of these children.
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Table 4. Comparison of children who received and those who did not receive
appropriate chemoprophylaxis during this follow-up.
Characteristic Appropriate Prophylaxis
n = 41 (%)
No Prophylaxis
n = 64 (%)
Age (mo) Median: 19 (range: 1-60)· Median: 31 (range: 1-60)
average: 25 average: 31.5
Male:Female 20:21 27:37
Previous prophylaxis 10 (24)·
2 (5)·
32 (50)
16 (25)Previous TB treatment
Mantoux first evaluation
~15mm
5-14 mm
0-4mm
Adult index case
28 (68)·
5 (12)
8 (20)
33 (52)
4 (6)
27 (42)
Smear positive 39 (95) • 43 (67)
Duration of contact Median: 6 (range: 1-30) •
after first evaluation (mo)
Median: 2 (range: 1-30)
average: 9.15 average: 5.0
Initial diagnosis
Infected only 28 (68)·
13 (32)
33 (52)
31 (48)Noninfected
Outcome:
TB disease #
Confirmed
Probable
Infected only:
Noninfected:
2 (5)
o
2
34 (83)
5 (12)
13 (20)
3
10
31 (48)
20 (31)
• Group in which more disease is expected.
#p = 0.05; odds ratio: 4.97 (95% Cl: 1.06-23.33).
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DISCUSSION
Although TB contact tracing has produced a significant yield of new cases in the
past, the duration and value of long-term follow-up has been debated.F" Data from
previous studies suggest that contacts of smear-positive pulmonary TB and adult
pulmonary TB cases in socioeconomically deprived areas should be followed up after the
initial examination.I.17.18In several retrospective contact tracing studies, 90% or more of
TB cases were identified within the first 12 months after identification of the index
case.I.17.19Furthermore, studies have shown that drug-resistant organisms can be as
infectious as drug-susceptible M. tuberculosis, but no long-term follow-up of childhood
contacts of MDR TB index cases could be found.4.5 In this study 29 (23%) children
developed disease, 90% of whom were diagnosed as diseased by 12-month follow-up.
Tuberculous infection with or without disease was present in 78% of children by 30
months, 95% of whom were already infected by 12 months. The low yield after
completion of the first 12 months of follow-up is similar to findings in other studies.
It is generally accepted that between 30 and 50% of all household contacts of
infectious adults will have a positive tuberculin skin test.' In children 0 to 5 years of age
this infection rate was reported to be as high as 72% in earlier studies.2o.21The very high
infection rate in this study is therefore not unexpected. Possible explanations are that 80%
of the children had smear-positive adult index cases, MDR TB usually remains infective
for longer periods 4 and 46% of children had more than one adult household source case
with active pulmonary TB. Other studies of households with a drug-resistant index case
have shown similar high infection rates.22-24
Twenty percent of household contacts <5 years of age of mainly drug-susceptible
index cases developed TB disease during a 5-year follow-up in India.2 This is similar to
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the 15 (14%) cases that developed disease during follow-up in our study. The rate of
developing disease was the highest for children <5 years of age, but chemoprophylaxis
significantly reduced disease in this age group to 5% in the Indian study.' This is similar
to the group without appropriate chemoprophylaxis in our study in whom 20% developed
disease compared with the 5% who developed disease in the group given appropriate
chemoprophylaxis.
The age of the adult index cases of those children who developed disease and those
who did not was not significantly different. This is in contrast to the findings of Snider et
a1.4where adults with drug-resistant TB causing infection and disease amongst childhood
contacts were significantly younger. Nearly half of the children, however, had >1 adult
source case. This may influence results but it is a common problem in communities with
a high incidence of TB and complicates the management of these patients.25,26 Childhood
contacts of smear-positive adults were more likely to be infected than contacts of smear-
negative adults. This again emphasizes the importance of smear positivity as a
determinant of the transmission of infection.
DNA fingerprinting of M. tuberculosis isolates from 3 of 4 adult-child pairs that
were analysed by RFLP were identical which confirms transmission from adult index
case to the child contact.l"
All 29 children with TB disease had primary disease. It is known that a large
proportion of these children will improve even without treatment, 27 but effective
treatment remains important to prevent progression of disease especially in the very
young child. Furthermore, the eradication of live bacilli may prevent relapse with MDR
disease in future, which is an important consideration in the face of the rapidly spreading
Stellenbosch University http://scholar.sun.ac.za
150
HIV/AIDS epidemic. The optimal duration of anti-TB treatment in children even in cases
of drug-susceptible TB is still uncertain and many children are probably overtreated."
Although directly observed therapy is practiced mainly in the urban areas, it has
limitations, as the patients are expected to pay a daily visit to the local clinic. Children
are therefore dependent on their caregivers to take them for treatment. Problems arise
when this does not happen despite home visits by nursing staff. Resources at clinic level
are inadequate to treat children at home and if hospital admission is not possible,
treatment is stopped and patient declared a defaulter.
Isoniazid was given to almost all children either as treatment or chemoprophylaxis.
There is evidence that about half the patients with primary isoniazid resistance have low-
level resistance (minimal inhibitory concentration :::2.0 ug/ml.) and these serum levels
are easily achievable in children with a dose of 15-20 mglkgld.28,29 Furthermore, child
contacts in this study often had contact with> 1 adult source case, of whom a number had
either drug susceptible TB or their susceptibility pattern was unknown.
Ethambutol has been accepted as first-line agent in TB and can even be
recommended in children aged 5 years or more for routine treatment. Reviews of clinical
trials in children <5 years of age did not reveal any serious ocular complications during
treatment with ethambutol at a dose of 15 mglkgld.30,31 It is an essential drug in the
treatment ofMDR TB cases, even for younger children.9, 30,31
Of the second-line anti- TB drugs, ethionamide has significant activity against
tubercle bacilli but causes considerable gastrointestinal discomfort. It seems to be better
tolerated in children than in adults and therefore plays an important role in the treatment
of MDR TB in children. About half of the 61 children who received ethionamide in this
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study experienced gastrointestinal side effects but by dividing the daily dose, drug-
induced nausea and vomiting subsided so that it could be continued once again as a
single dose in all but 4 patients.
The fluoroquinolones are generally not recommended for use in children because of
their possible effect on cartilage growth in immature animals following long-term
administration." A number of reports have shown low rates of side effects with arthralgia
episodes in only 1,3 to 3,5% of children even when used for periods of 150-300
days.lo,32,33Three women who were receiving ofloxacin treatment became pregnant but
no adverse effects were noted in their infants." Ofloxacin has a higher early bactericidal
activity of 0.32-0.39 against M. tuberculosis compared with the early bactericidal activity
of 0.205 of ciprofloxacin, and the pharmacokinetic profile of ofloxacin is better than that
of ciprofloxacin.35-37 Ofloxacin is therefore the fluoroquinolone preferred by many
experts in the treatment of MOR TB.34,38Arthralgia was experienced in only 1 of 15
children receiving ofloxacin for 6 to 12 months in our study. Because of the
gastrointestinal discomfort caused by ethionamide, it was difficult to evaluate this side
effect of ofloxacin in these children.
Chemoprophylaxis was successfully administered to 41 children, and 64 children
received no appropriate chemoprophylaxis. This was, however, not a randomized,
controlled study and results should therefore be interpreted with caution. The children
who received chemoprophylaxis were clearly the group with the higher risk for
developing disease since they were significantly younger, had more sputum smear-
positive index cases, had a higher rate of infection and had had previously received
treatment or chemoprophylaxis less often (Table 4). Despite the higher risk for disease,
they developed significantly less disease than those that did not receive
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chemoprophylaxis, This is particularly true of the children that had no other adult TB
source case. Several combinations have been advocated such as pyrazinamide and
ethambutol, pyrazinamide and a tluoroquinolone, a tluoroquinolone alone, and
ethionamide and cycloserine.V We have used several combinations according to the drug
resistance pattern of the index case, but most children received a combination of
isoniazid, pyrazinamide and ethionamide with good effect.
The optimal duration of chemoprophylaxis for MOR TB contacts is uncertain. Our
experience suggests that 6 months may be adequate if not optimal. Twelve months
chemoprophylaxis has been advised in at least 2 official recommendations.v' An
alternative strategy to chemoprophylaxis, because of the lack of data, is regular follow-up
without chemoprophylaxis, an option which was also offered to our patients.' However,
with the high incidence of infection and disease in our study we believe that giving
chemoprophylaxis should be the preferred management. In areas with a high burden of
disease and in poorly resoureed countries where treating smear-positive TB cases is the
priority, 6 months of directly observed chemoprophylaxis may be more appropriate than
giving 12 months of unsupervised chemoprophylaxis to MOR TB contacts.
CONCLUSION
This study confirms the transmission of TB infection from MOR adult index cases to
children in close household contact and the subsequent development of disease in these
children. The incidence of infection and disease was comparable to that occurring in
children in contact with drug-susceptible adult index cases. Our results suggest that in
resource limited situations the follow-up of such children with a view to detecting the
development of disease can be limited to 12 months, as only a minority of children
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developed disease after this period. Appropriate chemoprophylaxis, taking into account
the resistance profile of the index case, seemed to be effective in preventing the
development of disease. There is, however, an urgent need for a multicenter, randomized,
controlled trial to identify the most effective drug combinations and the optimal duration
of chemoprophylaxis in contacts of MOR pulmonary TB adults.
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Clinical pharmacokinetics of isoniazid in children with tuberculosis
7.1 LITERATURE REVIEW
Historical perspective
Fifty years after its introduction as an antituberculosis agent, I isoniazid (INH)
continues to form the basis of all first-line antituberculosis regimens. Furthermore, INH
is the agent of choice for the prevention of tuberculosis and is the only agent that has
been evaluated in randomised controlled trials for the prevention of tuberculosis in
children.v '
Isoniazid has a potent bactericidal action against Mycobacterium tuberculosis (M.
tuberculosis) organisms, especially against actively multiplying bacilli such as those
found in the walls of cavities. There is also evidence that INH suppresses the growth of
non-multiplying organisms and that prolonged exposure of these organisms to supra-
minimal inhibitory concentrations results in bacteriolysis." 5
Efficacy of INH
a) Minimal inhibitory concentration (MIe)
The efficacy of INH is largely dependent on the MIe of INH against the M.
tuberculosis organism. Susceptible strains are usually classified as organisms that have a
MIe of :S;0.2mg/L (break point)." The majority of susceptible strains will, however, have
a MIe of approximately 0.05 mg/L or less. 6 Not all INH-resistant strains are equally
resistant and strains with an MIe :S;5.0mg/L are particularly likely to occur in patients
with primary drug resistance.Ï: 8
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b) Concentration vs. time of exposure (exposure integrals [mg L-I hI)
There is at present some uncertainty as to what pharmacokinetic parameters
correlate best with INH efficacy against M. tuberculosis. One opinion is that the peak
INH concentration following an oral INH dose provides the best correlation with
efficacy." The views referred to should, however, be interpreted with caution for reasons
that will be discussed in context (vide infra).
Although peak serum INH concentrations achieved by oral administration are only
slightly lower in fast acetylators compared to slow acetylators," the systemic INH levels
decrease much more rapidly in the fast acetylators because of a shorter half-life. Both the
INH concentration versus time integral (AVC), and by implication the time that optimal
concentrations in excess of the MIC are maintained, are significantly reduced in fast
acetylators. The time available to penetrate effectively into the different body fluid
compartments and TB lesions is reduced leading inevitably to lower peak concentrations
where they are most needed. II
It is likely that not only is the peak concentration important but also a level near the
peak concentration maintained for some time. Although INH diffuses freely into caseous
lesions and cells, the peak concentrations in the lesions are likely to be somewhat lower
and flatter than in the serum as a result of diffusion.V It has also been shown in vitro that
it takes several hours for INH to reach an intracellular plateau.V' 13
INH has no post antibiotic effect (PAE) like other antituberculosis drugs such as
rifampicin and streptomycin, and any escape from the influence of the drug in vitro leads
to diminished efficacy." Even among drug susceptible M. tuberculosis strains, bacilli
differ in their response to INH; some bacilli need higher concentrations and/or longer
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duration of exposure for INH to have a bacteriostatic or bacteriocidal effect.ls The effect
of exposing a M tuberculosis culture to INH is proportional to the product of the
concentration and the duration of exposure. 14
On the other hand Awaness and Mitchison 16 and others have also shown that a
single daily dose with higher peak levels is better than divided doses with smaller peak
levels.17 Since INH does not exhibit a PAE, the observed improvement of efficacy is due
either to an improvement in the exposure of the M. tuberculosis organism to INH
(balance between concentration and exposure time) or to better penetration of INH to the
sites of antimycobacterial action. M. tuberculosis organisms exposed to high
concentrations of INH for relatively short periods of time are thought to suffer damage
that requires an adequate period of time to repair. If the time needed to effect these
repairs is greater than the dosage interval, initial bacteriostasis followed by ultimate
bacteriolysis ensues. In fast acetylators not receiving an optimal dose of INH, the balance
between effective INH concentration in relation to an adequate period of time may be
lost, with a consequent loss of efficacy.
Burman 6 cautions that in vitro and in vivo activity of drugs, and specifically
antituberculosis agents, are not always comparable and that MIC, MIC/Cmax and serum
half-life are often not relevant predictors of clinical outcome. Given the complexity of
mycobacterial disease this observation is not surprising. However, it is rational to
assume that both therapeutic efficacy and INH related toxicity are primarily determined
by exposure to INH. Both the maximal systemic concentration and the elimination half-
life determine the exposure of organism and host to INH and are relevant. The extent to
which the two separate factors contribute to efficacy and toxicity remain to be better
defined. IS
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The apparent volume of distribution (Vd, vol.mass") of a medicinal agent is the
apparent volume of aqueous medium into which the agent distributes after absorption has
taken place. This apparent volume is determined with reference to the concentration of
the agent in the plasma and varies from agent to agent. In computational terms Vd =
DICo, in which D and Co represent the administered dose (mass) and subsequent
elevation in concentration (mass.vol"), respectively.
The volume of distribution (Vd) of a drug is a basic pharmacokinetic parameter
required for the determination of therapeutic concentration versus time exposure integrals
at the site of therapeutic action. In the context of the use of !NH in the treatment of
tuberculosis, the systemic concentration of !NH should be high enough to exceed the
MIC of the M. tuberculosis organism wherever it is located or sequestered.
As !NH has no PAE, it is necessary to maintain concentrations at the target site for
as long as practically possible, while taking into account possible toxicity. Since the MIC
of non-resistant M. tuberculosis organisms is low (0,05 to 0.2 mglL) therapeutic
concentrations are easily achieved and adequately maintained in the well-perfused central
compartment (brain, heart and lungs) in most instances.
The M. tuberculosis organism may, however, invade any tissue, no matter how
peripheral, and enhance its survival by forming impenetrable clusters in denatured and
necrotic tissue. The therapeutic challenge from a pharmacokinetic perspective should
thus not be viewed solely in terms of MIC-values, but rather in terms of the
pharmacokinetic imperatives required to ensure adequate exposure integrals of !NH at
peripheral sites where blood perfusion is poor, or wherever organisms may lurk in
sequestered lesions.
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The area under the time versus concentration curve (AVC) or "exposure integral"
of INH is the most informative basic therapeutic parameter, since it allows assessment of
the mean effective concentration of INH within a dosage interval. The mean
concentration embodies both elements of therapeutic importance: 1) the magnitude of the
therapeutic concentrations and 2) the length of time during which effective therapeutic
concentrations are maintained.
c) Pharmacodynamics
The aim of antituberculosis treatment, as with any other antibiotic treatment, is to
achieve adequate drug concentrations at the site of the infection for an appropriate length
of time in order to ensure the eradication of the organisms and optimise clinical
success." This desired outcome depends not only on the pharmacokinetics of the agent,
but also on the characteristic of the pathogen, e.g., microbial susceptibility, and host
related factors.
A new approach to this problem seeks to combine the microbiologic activity with
antibacterial pharmacokinetic data into a discipline called pharmacodynamics. The best
pharmacodynamic parameter is the minimum effective antimicrobial action in an area
under the inhibitory titre (AVIC), which is calculated as the 24-hour serum AVC divided
by the MIC of the pathogen/" According to Schentag the minimum effective action is an
AVIC of 125, but this is mainly of value in extracellular organisms (personal
communication). This target can be achieved by a single antibiotic or by the sum of
AVIC-values of two or more antibiotics. This could possibly explain why, even in the
event of low INH doses in adults or children or in fast acetylators, patients still have a
good clinical outcome with combination therapy.
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d) Early bactericidal activity (EBA)
The rate at which an antituberculosis drug kills rapidly metabolising and
multiplying bacilli during the first two days of therapy is termed the early bactericidal
activity (EBA). EBA can be used to determine the lowest effective dose size of these
drugs.i' In an evaluation of the EBA of!NH there was a significant drop in the EBA in
adult patients receiving 300 mg (6 mg/kg body weight) compared to those receiving a
dose of 150 mg (3 mg/kg body weight), while there was no further increase in the EBA at
a dose of 600 mg (12 mg/kg). This would imply that 3 mg/kg body weight is a less
effective dose for the killing of metabolically active organisms. In these same patients the
mean 3-hour !NH serum concentration dropped from 6.05 mg/L to 1.22 mg/L at doses of
12 mg/kg and 3 mg/kg, respectively. It would therefore appear that a mean !NH
concentration of between 3.0 to 3.7 mg/L at 3 hours, as could be expected from a dose of
6 mg/kg body weight, would provide an optimal response."
e) Potential impact of polymorphic metabolism on efficacy
There are contradictory reports in the literature in respect of the extent to which
pre-systemic or first-pass extraction of!NH takes place. Some investigators have found
the differences between polymorphic subtypes to be marginal, ro, 13,22 whilst others have
found the differences to be considerable and significant.V' 23 The apparent contradiction
may be easily explained in terms of recently generated data in which it was shown that
the metabolism of isoniazid is saturable, consistent with Michaelis-Menten concepts.22, 24
Furthermore, the polymorphic acetylator subtypes all share the same Vmax-value (about
10 mg L-I h-I), but have distinctly different Km-values and hence affinities for !NH
substrate: Km fast (FF) = 6.57 mg/L; Kmintermediate (FS) = 14.43 mg/L; Kmslow (SS) =
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32.82 mglL.25 It is clear from these data that fast and intermediate acetylators have a far
greater affinity for INH substrate than do slow acetylators. Consequently, the pre-
systemic extraction fraction of INH will be maximal in fast (FF) acetylators receiving a
low dose of INH (e.g., 3 mg kg") in whom absorption is retarded (for whatever reason),
and minimal in slow (SS) acetylators receiving a high dose ofINH (e.g., 10 mg kg"), and
in whom absorption is rapid; intermediate acetylators would appear to resemble fast
acetylators, rather than slow acetylators, in this regard. It is clear from the foregoing that
the pre-systemic absorption of INH cannot validly be assessed in the absence of
corresponding Cmax and Tmax pharmacokinetic parameters.
Simplistic approaches to a complex problem will thus fail to shed light on the most
appropriate pharmacokinetic parameter with which to correlate antimycobacterial
efficacy. However, it is rational to assume that a parameter that reflects the total
exposure of the M. tuberculosis organism to the pharmacodynamic effects of isoniazid,
with due regard to the MIC applicable to the specific organism, would be most
appropriate. The area under the isoniazid concentration versus time curve (a direct
measure of exposure) is precisely such a parameter and should be determined as
accurately as possible when assessing the antimycobacterial activity of INH in the
research setting.
An instance of therapeutic failure in a fast acetylator being treated for tuberculous
meningitis with an INH containing regimen, has recently been reported. II Because the
patient was being treated with a regimen comprising higher than usual dosages of
isoniazid and rifampicin, and the infecting M. tuberculosis organisms had been shown to
be susceptible to both isoniazid and rifampicin, the reason for the therapeutic failure was
not immediately apparent. However, subsequent investigation showed that the patient
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was a fast acetylator of INH. The INH dosage was increased and thereafter therapeutic
progress was uneventful and the child progressed to cure. The authors expressed the
view that the most likely cause of therapeutic success was the increase in the dosage of
INH, which was large enough to compensate for the rapid elimination. This report
suggests that acetylator status assessment may be valuable in the face of unexplained
therapeutic difficulties. Furthermore, and equally important, whenever higher than usual
dosages of INH are contemplated, for whatever reason, acetylator status should be
determined in order to allow assessment of the individual risk of dose-related INH
induced toxicity. Several authors have expressed the view that INH dosage should be
adjusted to allow for, or accommodate, the acetylator capacity of the individual, in order
to ensure optimal treatment and limit toxicity.'?' 26
Pharmacokinetics of isoniazid in adults
The pharmacokinetic characteristics of INH have been studied extensively in
adults." However, data in respect of children, and especially in children younger than 6
years of age, are limited.26,27 INH is well absorbed from the gastrointestinal tract but is
subject to first-pass metabolism, which may impact on the systemic concentrations of the
parent compound. INH does not bind appreciably to plasma proteins and distributes to
the total body water compartment; it crosses membranes readily despite its high water
solubility and has a volume of distribution in adults of 0.67 L/kg_28Very little parent
compound is excreted unchanged in the urine and the greater proportion is acetylated (in
the liver and the small intestine) to acetyl isoniazid prior to excretion in the urine.
Although the initial work on the pharmacokinetics of INH seemed to indicate that
INH is bimodally eliminated, and that alleles coding for slow acetylation are recessive to
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the fast wild type, it has now been established that !NH is eliminated in accordance with
a trimodal distribution of subtypes [fast (FF), intermediate (FS) and slow (SS)], and that
fast (F) and slow (S) alleles are in fact co-dominant.f This knowledge, coupled with
developments in modem analytical technology, allows for rapid and accurate assessment
ofpharmacokinetic parameters, and their potential impact on therapy.
Pharmacokinetics of isoniazid in children
Observations, perceptions and practical experience of research-orientated clinicians
seem to indicate that the pharmacokinetic parameters for !NH differ in children and
adults. Furthermore, the extent of these differences should probably be taken into account
when determining the most appropriate dosage regimen of!NH in the paediatric patient.
Finally, certain practical aspects of paediatric patient management also have a direct
bearing on the clinical pharmacokinetics of isoniazid in this age group. These factors are
summarised briefly below:
a) Elimination rate and metabolism
It has been shown that children eliminate !NH faster than adults despite having
similar acetylation phenotypes.i'" 30 This may be due to the relatively larger size of the
liver in children." Calculations based on body surface area indicate that younger children
need higher doses than adults do to achieve an equivalent exposure to the agent."
b) Volume of distribution
The total body water in children and the extracellular fluid make up a larger
percentage of the total body weight than in adults and the volume of distribution in
children might therefore be increased." 30, 32
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c) Absorption of INH
Concurrent food intake decreases the bioavailability of INH.33 It is difficult in
practice to keep a hungry child from eating for two or three hours in order to improve
drug absorption. Furthermore antituberculosis drugs will often be administered together
with something sweet to eat or to drink.
d) Isoniazid toxicity: Children vs. adults
Advancing age is a risk factor for the development of INH-induced toxicity.l" 35
According to some reports, even children receiving INH at 20 mg/kg daily together with
other hepatotoxic drugs such as rifampicin, pyrazinamide and ethionamide during
treatment for tuberculous meningitis, show relatively low rates of hepatotoxicity. 36 There
are, however, reports from different populations in which children who were treated with
INH 15-20 mg/kg together with rifampicin had very high rates of hepatotoxicity.Vj" INH
toxicity seems to be dose-related with very little hepatotoxicity at 8-10 mg/kg, and INH
without rifampicin also has a lower rate of hepatotoxicity.V'"
The reason for the lower risk of toxicity in children has never been explained
satisfactorily but may be due to metabolism related causes. INH itself has little (if any)
toxic potential but is biotransformed in the liver and a variety of toxic metabolites are
generated, most notably hydrazine and mono-acetyl hydrazine.
Hepatotoxicity is the most senous risk factor limiting the upper extremes of
isoniazid dosage regimens. Mono-acetyl hydrazine is thought to be the most important
mediator of hepatotoxicity and is converted by the cytochrome mixed function oxidase
enzymes into a highly reactive hepatotoxic acylating agent.
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The cytochrome mixed function oxidase system is comprised of a large variety of
oxidative isoenzymes, all of which are easily inducible. Both the induction profile (the
specific isoenzymes induced) and the extent of the induction are very variable, and
depend upon inducing substrate(s) involved and the duration and extent of the exposure
of the enzymes to the substrate. It is possible that the cytochrome system of adults is
more mature (and hence has a greater capacity and wider metabolic variety) than is the
case in children. It is possible that conversion of non-toxic mono-acetyl hydrazine to a
highly reactive acylating agent is more efficient and extensive in adults and that the
higher incidence of hepatotoxicity is due to this factor.
It has been demonstrated that hydrazine levels in the plasma of adults are on
average higher than those in children following a comparable dose for mass." The reason
for this difference has never (to date) been satisfactorily explained and these elevated
levels of toxic hydrazine in adults may be of greater significance in the pathogenesis of
hepatotoxicity than has previously been supposed. This aspect should be investigated in
depth at the molecular level.
e) Pathology related considerations
Young children are more prone to the lymphohaematogenous dissemination of
organisms and the development of extrapulmonary TB than are adults. Furthermore,
children in the South African population are being infected by the human
immunodeficiency virus at an escalating rate. HIV -infected patients (both adults and
children) who contract TB also have a greater predisposition to extrapulmonary TB.41
Consequently, as indicated elsewhere appropriate therapeutic !NH concentrations should
not be viewed simplistically in terms only of MIC-values, the well-perfused central
compartment, and the concentrations achieved in the blood, but rather in terms of levels
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achieved and maintained (as far as this is possible) in peripheral tissue and in tissues
protected by physiological barriers (e.g. the blood brain barrier).
t) Population differences in acetylation type
It is well known that acetylation type varies widely in different populations.
Caucasians (Europeans) are mainly slow acetylators compared to white North Americans
who have more or less equal numbers of slow and fast acetylators. Japanese, Chinese,
Eskimos and African blacks are mainly fast acetylators." In the Western Cape Province,
fast and intermediate acetylators constituted 65% of the population studied and 35% were
slow acerylators.f Acetylation phenotype may have a role in determining the optimal
INH dose for children. Although children seem to metabolise INH more rapidly than
adults, this is not related to the acetylator status, which is genetically determined, and
which matures early." Acetylation type is, however, not the only consideration in
choosing appropriate dosage regimens, as within each acetylator group the range of
recommended doses can vary widely." According to Rey et al. 26 dose can be calculated
by use of the inactivation index method. (vide infra)
Dosage regimens of INH in general
a) Inactivation index (13). 13
When an individual is given different doses of oral INH in mg/kg, the resulting 3-
hour INH serum levels (y-axis) plotted against the mg/kg oral dose (x-axis) will result in
a straight line if the points are connected. This line will, however, not pass through the
point of origin (zero on both axis) but will be displaced to the right because of the first
pass effect on INH. Although the slope of the straight line will be different for each
individual patient (a way in which acetylation type can be determined), the intersection
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Figure 1: Correlation between 3h INH concentrations and INH oral dose (3
estimations, different doses, same patient). Straight line passes through at -0.6
(constant), cx: is the angle of the line that varies from patient to patient.
of the straight line with the y-axis has been shown to be a well-defined average value that
can be fixed at -0.6. From this information the index of inactivation of INH (h) was
developed. The index is calculated by the equation:
13 = C3h + 0.6 / D (mg/kg) (C = concentration of INH; D = dose in mg/kg)
The inactivation index has since been used to adjust individual children's INH
dosages and to determine optimal INH dosages for the different acetylation types.26, 42 To
achieve this it was necessary to accept that the efficacious therapeutic plasma
concentration of INH should range from 1 to 2 mg/L, three hours after oral
administration as previously suggested." The advantage of this index is that only a single
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serum specimen at 3 hours after an INH dose is necessary to calculate the "optimal
dose".
b) Reference integral
According to the literature 5 mg/kg of INH in an appropriate antituberculosis
regimen yields satisfactory treatment results in patients with INH-susceptible M.
tuberculosis organisms." 44-46A satisfactory outcome implies that the patient responds
satisfactorily to treatment, that treatment is not associated with undue toxicity, that
treatment is completed within the scheduled time frame (six months), and that the
incidence of relapse is acceptably low (2-4%) on follow_up.45,47 Caution is, however,
necessary in accepting the appropriateness of a dose of 5 mg/kg of INH since
publications emanate from populations in which slow and intermediate acetylator
phenotypes are predominant. The minority fast acetylator phenotypes in these
populations probably are at a relative therapeutic disadvantage as to the most appropriate
dose of INH. They may nevertheless respond satisfactorily to treatment because of the
synergistic potential of the treatment regimen as a whole.
The apparent satisfactory response of fast acetylators should not however be cause
for complacency, as the relative disadvantage may be exposed in circumstances in which
other negative factors play a role: poor absorption of INH itself as well as other
components of the regimen - most notably rifampicin; non-compliance with the
therapeutic regimen, and protected organisms sequestered in lesions in poorly perfused
tissues. II,48,49
In populations in which fast acetylators are predominant, the dosage
recommendations for INH appear to be somewhat higher, and 7-10 mg/kg is apparently
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not perceived by clinicians as excessive (Japanese Tuberculosis Society, personal
communicationj." Their use of a higher dosage is presumably the result of clinical
experience that evolved in a natural way, rather than on true experimental data. From the
foregoing it seems reasonable to assume that fast acetylator phenotypes may benefit from
an upward adjustment of the dosage of INH, although the extent to which the dosage
should be adjusted, if at all, is a matter to be investigated.
For purposes of rational assessment of an appropriate dose of INH, a reference
standard should be set in terms of a firm pharmacokinetic base. The most appropriate
pharmacokinetic parameter is the area under the concentration versus time curve. Since a
5 mg/kg dose is universally accepted as being appropriate and adequate in slow
acetylators the AUe applicable to slow acetylators following this dose would seem to be
a rational reference parameter.
If 5 mg/kg of INH is administered to a slow acetylator once daily, and rapid and
complete absorption of INH and a volume of distribution for INH of 0.67 Llkg 28is
assumed, then the following parameters will apply:
Cmax = [INH]o
[INH]24h
= 7.5 mg/L
0.006 mg/L
37.3 mg/L'h
1.56 mg/L'd
e24h =
AUe (O-och)
[INH](ave,O-24h)
=
=
Dosage regimens of isoniazid appropriate to children.
a) Current practice
A review of currently suggested INH doses for children shows wide variations.
(Table 1) The World Health Organization" and the International Union against
Stellenbosch University http://scholar.sun.ac.za
173
Tuberculosis and Lung Disease52.53recommend an INH dose (daily) of 4 to 6 mg/kg body
weight, while the American Academy of Pediatrics (AAP)50 advises 10 to 15 mg/kg. In
TBM the suggested dose ranges from 15 to 20 mg/kg daily with a maximum total dose of
between 300 and 500 mg. None of these dosing schedules take into account either the
acetylation phenotype of the patient or the incidence of primary INH resistance in the
community involved.
b) Childhood INH dosage regimens: The potential role of INH in the
management of primary INH-resistant TB
The dosages of INH that are used in regimens in the treatment of tuberculosis in
children have largely been derived from and reflect the regimens used in adults. This
tendency continues to the present time and is cause for some concern. Optimal INH
dosage regimens in adults are still a matter of lively debate and considerable uncertainty,
and the constitutional differences between adults and children may impact on the most
appropriate dosage regimens applicable to children." These uncertainties, and related
relevant factors, require careful appraisal. Although earlier studies in adults and children
should be taken into account, newer technological developments allow for more accurate
assessment of INH pharmacokinetics and genetic analysis.
INH-resistant and multidrug-resistant TB has become a global problem. This
development compromises the usefulness of INH in these patients both in
chemoprophylaxis and in treatment.54-56However, it has been shown that about half of
the primary INH-resistant bacilli have low-level INH resistance (vide supra Chapter 3,
Results: Degree of isoniazid resistance)," 8 and consequently the potential role of INH in
the management of primary INH-resistant M. tuberculosis infected patients should be
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assessed. The implications would be far-reaching if it could be shown that appropriate
INH dosage regimens contribute to the eradication of partially resistant M. tuberculosis
organisms. 57 Such information would better define the most appropriate use of INH and
prolong the usefulness of this invaluable agent in tuberculosis control programs,
particularly in resource poor countries.
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Table 1: Recommended daily isoniazid dosage for use in children
INn dosage (mg/kg) Recommended Year Population Reference
Dosage Maximum by:
5 (3-6) NTCP 2000 South Africa Dept of Health
20 ifTBM South Africa 200058
5 (4-6) IUATLD 1991 International IUATLD 1991 52
& IUATLD 2000 53
2000
5 WHO 1996 International WHO 199651
5 300 V. Seth, India 1997 India Seth V 1997 59
7-10 300 Japan Anti- 2000 Japan Japan Anti-
tuberculosis tuberculosis
Association Association 2000*
10-15 300 American 2000 North America AAP 2000 50
Academy of
Pediatrics (AAP)
10-20 300 Nelson and 2000- International Nelson & Bradley
Bradley 2001 200060
10 300 Frank Shann, 2001 Australia, Shann 2001 61
15-20 TBM 500 Australia International
10-20 300 American 1993 North America Ad Hoc Committee
Thoracic Society ATS 199562
Ad Hoc
Committee
NTCP = National Tuberculosis Control Programme
IUATLD = International Union Against Tuberculosis and Lung Disease
WHO =World Health Organization
ATS = American Thoracic Society
• Japan Anti-tuberculosis Association Guidelines. 2000 (Personal communication)
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7.2 EVALUATION OF CLINICAL PHARMACOKINETICS OF ISONIAZID IN
CHILDREN, AND ISONIAZID'S POTENTIAL ROLE IN PRIMARY
ISONIAZID-RESISTANT TB IN CHILDREN
STUDY OBJECTIVE
The study was undertaken in order to assess:
1.) the potential role ofJNH in patients with low-level JNH resistance;
2.) JNH pharmacokinetics in children, making use of improved analytical technology
and advances in the understanding of the polymorphism governing JNH metabolism;
3.) the potential impact of the polymorphism governmg JNH metabolism, on
therapeutic outcome.
METHODS
Patients:
Children less than 13 years of age of mixed 22 and black race were enrolled in this
study. All children were diagnosed with primary tuberculosis and were included
randomly on the basis of being available for study on a Thursday.
Ethical approval was obtained from the Institutional Ethical Authority and
parents/guardians had to give written informed consent.
The age, gender and weight of each child were recorded and a detailed clinical
history was taken. In addition, the presence or absence of extrapulmonary tuberculosis
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was established, the extent of the pulmonary disease was assessed and recorded, and the
human immunodeficiency virus (HIV) status was determined.
Inclusion criteria: As above.
Exclusion criteria: Children with stage 2 or 3 tuberculous meningitis or severely
sick children.
Dosage and Sampling:
All children participating in the trial were hospitalised for the required procedures.
Those children not already hospitalised (for other than trial related reasons) were
admitted for the morning on which the procedures were scheduled.
The !NH used for this study was standard pharmaceutical grade in powder form
from Fluka Chemie AG (Buchs, Switzerland). The dose of!NH was accurately weighed
at 10 mg/kg according to the child's exact weight the previous day. !NH powder was
dissolved in 5-10 ml of water and administered orally with a syringe or, in the case of
very young children, through a nasogastric tube, and washed down with water. The drug
was given by one of two people between 07:00 and 07:30 a.m. after abstaining from
solids from the previous evening. A light breakfast was served between 08:00 and 08:30.
Blood samples were drawn at 2, 3, 4, and 5 hours post !NH dose. After collection
into EDTA-coated tubes, the blood samples, 1 to 1.5 ml in all instances, were chilled and
delivered to the laboratory on ice for determination of the !NH levels in plasma using the
HPLC-method of Seifart et a1.63 A further single sample of 3 to 4 ml was collected into
an EDTA-coated tube from each child for DNA analysis and the HIV status was
determined in those children where it was not previously known.
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Pharmacokinetic Parameters:
a) Determination of first-order elimination rate constant (k, hoi)
The apparent first-order elimination rate constants (discriminant for
phenotypification) were calculated over the interval 2 to 5 hours after the dose (k, h-I) for
all children from the linear regression of InCt and t in the range 2, 3, 4 and 5 hours, InCt
being the natural logarithm of the concentration at time t.
b) Concentration at zero time post dose (Co, mg/L)
The maximal increase was measured as the concentration (Co, mg/L) at time
designated zero, i.e., the time at which the test dose of medication was administered. Co
was determined from back-extrapolation to the ordinate of the best fit linear regression
line in respect of the natural log of the concentration of!NH as a function of time, over
the time range 2 to 5 hours after the dose (involving four concentrations vs. time data
pairs).
Co was also calculated for each individual making use of the population data in
respect of Vd as follows: Co = Vd (population data) divided by the dose/kilogram that
each individual received.
c) Determination of volume of distribution (Vd)
The volume of distribution (Vd) of!NH was determined in each patient from the
maximal increase in the !NH concentration following an accurately weighed oral test
dose. The maximal increase was measured as the concentration (Co, mglL) at time
designated zero, i.e., the time at which the test dose of medication was administered. Vd
was calculated by dividing the!NH dose (D) by Co (Vd = DICo L/kg)
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d) First-order elimination rate constant (k, h-I) related variables
First-order elimination rate constant was compared to age (in groups: 0 to 2 years,
>2 to 5 years and >5 to 13 years) by analysis of variance (Anova). First-order elimination
rate constant was compared separately by student t-test for independent samples (with
Levene's test for homogeneity of variances) to gender, ethnicity, human
immunodeficiency virus (HIV) status and the presence of abdominal TB to determine
whether there were any significant differences or whether all results could be compiled.
e) Vd-related variables
The influence of age-related variation in physical development on the magnitude of
Vd (if any), and the potentially distorting effect of polymorphic INH elimination on the
determination of Vd (vide supra), was assessed prior to determination of truly
representative paediatric population Vd data. Regression analysis between these variables
and Vd was done. Population data in respect of Vd was calculated after excluding values
deviating more than one standard deviation from the mean if Vd was not influenced by
the above mentioned variables.
t) Area under the time concentration curve (AVC)
AVC (zero to infinity) for each individual was determined by dividing the
calculated Co-value of each child by its first-order elimination rate constant (k, h-1).
g) Phenotypification
Slow acetylator phenotype was defined as a first-order elimination rate constant of
S;0.31h-1 and intermediate (FS) to fast (FF) acetylator status as >0.31 h-1•22
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h) Statistical Methods
Statistical methods used are described in each section. Statistica version 5, 1997
edition, was used for all statistical analysis.
RESULTS
Demographics and clinical profile of participants
INH levels were determined in 65 children, of which one was excluded because of
unreliable laboratory results due to technical problems. Of the remaining 64 children, 44
were of mixed race and 20 were black children. There were 36 boys and 28 girls, and
median age was 3.75 years with a range ofO.6 to 13 years.
All children had primary tuberculosis, although a number had progressive or
disseminated disease. The clinical features, including age, HIV -status and
extrapulmonary TB status, are summarised in table 2.
Dosage commentary and INH concentrations versus time data
The mean dose of INH administered was 10.14 mg/kg with a standard deviation of
± 0.70 mg/kg.
The raw data of age, gender, dose in mg/kg, actual post dose time of each specimen
and INH concentration at that time is summarised in table 3. (Addendum)
INH concentrations corrected for exact post dose times of 2,3,4 and 5 hours were
calculated and are presented in table 4. (Addendum)
Stellenbosch University http://scholar.sun.ac.za
181
Derived pharmacokinetic parameters of individuals
a) First-order elimination rate constant (k, h-I)
The results for each individual are presented in table 5. (Addendum) There was no
statistical difference when first order elimination rate constant was compared to age
groups (p = 0.81) (Figure 2), ethnicity (p = 0.69), gender (p = 0.50), HIV status (p =
0.56) and presence or absence of abdominal TB (p = 0.53).
Age vs. elimination rate constant
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Figure 2: First order elimination rate constant compared by age group
0-2 >5-13
I ±Std.Dev.
e=] ±Std. Err.
o Mean0.2
(Anova: p = 0.82)
b) Concentration at zero time post dose (Co,mgIL)
The results of both the extrapolated and calculated concentrations at zero time post-
dose are presented in table 5. (Addendum)
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c) Calculated volume of distribution (Vd, L/kg)
The calculated Vd values for each individual patient are summarised in table 5.
(Addendum)
d) Area under the concentration versus time curve (AUC, mg r' h)
The AVe (time zero to infinity) values of each individual is presented in table 5.
(Addendum)
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Table 2. Clinical features and special investigation results of the study children
Clinical feature or Number Percentage
special investigation n =64
Age groups
0-2 years 18 28%
>2-5 years 24 38%
>5-13 years 22 34%
Weight loss 50 78%
Weight <3rd percentile 31 48%
Cough >2 weeks 39 61%
Household TB contact 35 55%
Mantoux tuberculin test:
0-4mm 13 (7 = HIV-infected) 20%
5-14 mm 6 9%
;::::I5mm 41 (6 = HIV-infected) 64%
Not done 4 6%
HIV -infected 13 20%
Chest radiograph
Lymphadenopathy 44 69%
Collapse/opacification 33 52%
Pleural effusion 14 22%
Miliary 8 13%
Extra pulmonary TB
Peripheral lymph node 14 22%
Pleural effusion 14 22%
Miliary 8 13%
TB meningitis stage 1 4 6%
Pericardial effusion 1 2%
Culture or histology 41 64%
confirmed tuberculosis
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Variables with potential to impact directly or indirectly on Vd
Age: The calculated Vd values were plotted as a function of age (years) as shown
in figure 3. Inspection of the distribution of the data reveals that age per se did not
influence the magnitude of Vd over the paediatric age range (birth to adolescence) (p =
0.082). It is also evident that there were a number of outliers but that these were
randomly distributed over the entire age-range and hence due to experimental variation
only.
First order elimination rate constant: The calculated Vd values were plotted as a
function of the first order elimination rate constant (k, l/h) as shown in figure 4.
Inspection of the distribution of the data reveals that the rate constant per se did not
influence the magnitude ofVd as calculated over the paediatric age range (p = 0.84). It is
also evident that there were a number of outliers but that these were randomly distributed
over the entire range of first order rate constants and hence due to experimental variation
only.
Derived pharmacokinetic population parameters
a) Population first-order elimination rate constant (k, h-I)
Twenty-four (37.5%) children were slow and 44 (62.5%) were intermediate to fast
acetylators of INH. The populations' mean first-order elimination rate constant for slow
acetylators was 0.2433 ± standard deviation (SO) of 0.0341 h-I, with a range of 0.1731 -
0.3085 h-I.The populations' mean for the faster acetylators was 0.5654 ± SO 0.1295 h-I with
a range 0 0.3317-0.9715 h-I. There was no clearly distinctive antimode between the
intermediate and fast acetylator groups.
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Figure 3: Volume of distribution vs. age in years. Correlation not significant (p =
0.082)
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Figure 4: Volume of distribution vs. first-order elimination rate constant.
Correlation not significant (p = 0.84)
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b) Volume of distribution (Vd, L/kg)
The mean (0.7962 L/kg) and standard deviation (0.3439 L/kg) of the Vd values of
the entire population was calculated as a point of departure, since the magnitude of this
factor was not influenced either by age or by acetylator capacity. Values deviating from
the mean by more than one standard deviation (n = 8) were then identified and excluded,
followed by calculation of a corrected mean (0.6876) and its standard deviation (0.1646
L/kg), in order to approach more accurately truly representative population values.
Population data in respect ofVd used was therefore 0.6876 +/- 0.1646 Llkg. The data in
respect of the entire population and of the modified population are shown in table 5.
Dosage comparisons and assessment relative to experimental data
a) Isoniazid Inactivation Index
The inactivation index using the 3-hour !NH concentration was calculated for each
individual according to Vivien's formula (see introduction and table 6).13If a 3-hour !NH
concentration of 1.5 mg/I is accepted as optimal,13,2617 (27%) children, all of whom are
classified as fast acetylators, would need an INH dosage regimen containing >7mg/kg/d.
The mean and sn INH dose for the slow acetylators according to this method of
calculation would be 3.2 mg/kg ± 0.8 mg/kg/d, while the mean dose for the faster
acetylators would be 7.2 mg/kg ± 2.9 mg/kg/d.
b) Isoniazid Exposure Integrals
If it is assumed that 5 mg/kg/d of!NH is the optimal dose for an average adult slow
acetylator (k-value 0.2 h-1), the AVe would be 37.3 mg/llh.(see introduction) At 10
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mg/kg 5 (8%) children had an AUC of <20 mg/Llb and a further 23 (36%) had an AUC
of between 20-30 mg/Llh (table 5). The mean AUC for the faster acetylators was only
27.578 mg/LIb, while the slow acetylators had a mean AUC of61.182 at 10 mg/kg INH.
Results of HIV -infected children compared with HIV -uninfected children
Thirteen (20%) children were HIV-infected, of whom 6 had clinical category Band
7 had clinical category C infection according to the Centers for Disease Control and
Prevention 1994 revised classification system for HIV-infected children <13 years of
age." There was no statistically significant difference between the first order elimination
rate constant (k-values) of the HIV-infected children compared with the HIV -un infected
children (p = 0.56) The mean and standard deviation (SD) of the 2- and 3-hour corrected
INH-concentrations, k-value and AUC are presented in table 7. No significant difference
in INH-Ievels was found and the marginally higher mean-AUC in the HIV-uninfected
group most likely reflects the slightly lower mean k-value (slower acetylation) in this
group.
Table 7: Comparison of mean (±SD) of corrected INH-concentrations, k-values and
AVCs in HIV-uninfected and HIV-infected children
HIV -uninfected children HIV -infected children
n= 51 n = 13
Mean (±SD) Mean (±SD)
2-h INH-concentration (mglL) 6.21 (± 2.73) 6.26 (± 2.34)
3-h INH-concentration (mgIL) 4.30 (± 2.43) 4.12 (±2.02)
k-value (hol) 0.4376 (± 0.1933) 0.4721 (± 0.1723)
AVC (mg.rl.h) 41.18 (± 18.93) 36.24 (± 14.86)
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DISCUSSION
The primary aim of the experimental work was to assess the pharmacokinetics of
!NH in children in the context of practical antituberculosis chemotherapy. This objective
was approached in two ways: (l) a prospective accurate determination of !NH
concentrations versus time data and the standard pharmacokinetic parameters deriving
therefrom; (2) a comparison of the experimental data with existent data. Existent data are
limited, fragmentary and in many respects outdated.
Although it was demonstrated that the pharmacokinetics of!NH in children reflect
the pharmacokinetic profiles applicable to adults to a large extent, there are differences in
children that should be taken into account in practical pharmacotherapy. The
experimentally determined pharmacokinetic parameters, which reflect the profiles
applicable to children, are discussed for completeness prior to the discussion of the
practical therapeutic implications.
Volume of distribution: Although the volume of distribution of isoniazid was
marginally higher in children than in adults (0.69 vs. 0.67 Llkg, respectively), the
difference was smaller than anticipated" 32 With a Vd of 0.67 Llkg (adults), isoniazid
appears to distribute into the total body water compartment. The similarity in distribution
between children and adults would seem to indicate that the total body water is a stable
compartment and does not vary markedly with age. However, it should be borne in mind
that the Vd data generated in our trial is in respect of lean body mass, since all our
patients were suffering from tuberculosis with its inevitable impact in this regard.
First order elimination rate constant: The elimination rate constant (k; h-I) of the
children in the trial group ranged from 0.1731 to 0.9715 h-I. There was clear phenotypic
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separation between the slow acetylators and the intermediate and fast acetylators.
Although the fast and intermediate acetylators formed a single composite group, the fast
and intermediate individuals tended to cluster together in separate domains. Since there is
a clear separation of phenotypes in adults, using the k-values as discriminant.f the non-
separation of phenotypes in children is probably a reflection either of a degree of
developmental immaturity or of the relatively high test dose (INH 10 mg/kg) that was
used in most instances.
Since the first order elimination rate constant (k; h-I) is the complete primitive of
clearance (Cl = kVd, Vol fl), it follows that the individual k-value may be used as a
means of individualising INH dosaging if, and when necessary. In this regard the
considerable variation between individual children, as in the case of adults, should be
taken into consideration when planning an optimal INH containing dosage regimen. How
best this should be done remains a matter of conjecture rather than controversy.
Area under the isoniazid-concentration versus time curve (AUe mgL-1h): The
AUC of INH following a standard oral dose (INH 10 mg/kg) varied in accordance with
the k-value as was to be expected.r' As in adults, the magnitude of the differences in
children was extensive and varied from 14.97 to 85.78 mgl.i'b. This, in the presence of
polymorphic metabolism, implies irrevocably that this variation will carry over to
differences in overall antimycobacterial efficacy and therapeutic response, and risk of
INH-induced toxicity following a standard INH dose.
The finer nuances of these differences have never successfully been demonstrated,
presumably because of the complexity of antituberculosis treatment (application of
multiple component dosage regimens over extended [months] periods of treatment).
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However, basic pharmacological principles and good clinical practice would seem to
serve as motivation that appropriate (to best knowledge) dosage adjustment be effected in
order to confer comparable, if not equal, therapeutic efficacy/toxicity risk profiles on
each individual patient.
In adult TB patients, it seems as if a dose of 4 to 6 mg/kg daily in a population of
mainly slow acetylators will be sufficient for the majority of patients, specifically if used
in combination with other antituberculosis drugs. This will give a concentration at time
zero (Co), calculated as dose per kg divided by Vd (0.67 for adults), of 5.97 to 8.96 mg/I.
The AVC for an average slow acetylator (k = 0.2 h-I) will therefore be between 29.9 and
44.8 mg/l/h, From the calculations of AVC in our study, it is clear that the mean AVC
for fast acetylators in children will fall below the optimal AVC for adults even at a dose
of 10 mg/kg and an elevation of dosage may be required, while the majority of slow
acetylators will have exceeded the desired AVC at 10 mg/kg body weight.
It seems therefore that in children the dose will vary for slow and fast acetylators
and that the optimal dose will vary between 5 to 10 mg/kg daily in most cases, taking
into account that toxicity may increase considerably with doses of more than 10 mg/kg in
slow acetylators.Ï' 50
In an area where the majority of tuberculosis occurs in the ethnic populations that
are intermediate to fast acetyl ators , and taking into consideration the factors discussed
that could negatively affect JNH-concentrations in children, it seems appropriate to
advise that children should receive a higher dose of JNH of between 6 to 10 mg/kg body
weight compared to the WHO and IUATLD recommended dose of 4 to 6 mg/kg (table
1).51-54
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Inactivation Index (13): Although the dosage adjustment according to the 3-hour
!NH concentration and the inactivation index formula 13 has the advantage of making use
of a single !NH concentration point, there are now more accurate methods available to
determine the dose requirements for individual patients. However, when the inactivation
index and the 3-hour !NH concentration was used to calculate the dose requirement for
our patients, using the accepted therapeutic 3-hour level of 1.5 mg/L,I3·26 the required
dosages (approximately 4 mg/kg for slow acetylators and approximately 7 mg/kg for
intermediate to fast acetylators) were similar to the AVC-derived dosages (table 6).
What constitutes an optimal INH dosage regimen?: In attempting to determine
optimal !NH dosage regimens, suitable for general application to large populations of
children, the characteristics of the specific population should properly be taken into
account. Our target population is comprised of a preponderance of fast acetylators in the
ratio slow:fast of 33-35%:65-68% (own data and Parkin et al.).22 Furthermore, a
considerable percentage of this population is HIV -infected (8.7%; 95% Cl: 6.0-11.4% in
the Western Cape province, antenatal survey 2000, Department of Health), and the
primary !NH-resistant rate as determined by our study (chapter 3) was about 7%, half of
which will probably have low-level !NH resistance (MIC =::;;2mg/L).
The optimal dosage regimen should consequently contain the highest dose of !NH
that can safely be given to slow acetylators who are at the highest risk of developing
toxicity. In our children a dose of 10 mg/kg is well tolerated provided that there is no
underlying hepatic pathology. Directly observed therapy (DOT) should be applied in the
treatment of all patients. With DOT hepatic toxicity (nausea, jaundice, hepatic
tenderness) can be adequately assessed. If such an approach is adhered to, maximal
therapeutic benefit may be achieved in large populations in field conditions. If however
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!NH at this dosage is ineffective or toxicity ensues, the specific needs of the patient need
to be assessed, e.g. toxicity in slow acetylator needing a reduced dose or a fast acetylator
needing an increased dose.
The use of INH in primary INH-resistant or MDR children: Resistance of M.
tuberculosis to !NH is usually defined as a MIC of >0.2 mg/1. Studies have shown varying
degrees of resistance to !NH, but when the MIC is >5.0 mg/L, resistance is complete.
In approximately half the patients who present with primary !NH resistance, the
bacilli have low-level resistance of between 0.2 and 2.0 mg/L. 7,8 This was confirmed in a
small study sample in our study (Chapter 3). Victor et al.65 showed that up to 50% of
strains of a large number of random specimens had a MIC of ~5 mg/L.
The use of !NH in the treatment of !NH-resistant patients remains a matter of
conjecture. This issue becomes more relevant as the incidence of primary !NH and
multi drug resistance rises in communities, and specifically developing communities with
restricted resources. Devadatta et al.66 showed a significantly beneficial response to high-
dose !NH (14 mg/kg) in patients with low-level !NH resistance and Tripathy et al.8
agreed that primary !NH resistance should not be regarded as an indication for stopping
further treatment with the drug.
Mitchison 57 discovered that the efficacy of an !NH-only regimen increased as the
dose was increased. His explanation was that it seemed likely that an increased dose of
!NH is more efficacious because it suppresses the growth of mutants with lower degrees
of resistance.
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Even in retreatment cases with low-level INH resistance (MIC between 0.2 to 1.0
mg/L), the addition of high dose (16 to 20 mg/kg) INH may be advantageous if given
together with other drugs to which the organisms are susceptible.V No advantage was,
however, shown when the normal dose of 300 mg INH was used in addition to a similar
regimen in another study.68
In a recent experimental study in mice a marked reduction in low-level (MIe ::;;5
mg/L) INH-resistant M. tuberculosis bacilli was achieved (although significantly less
than in an INH-susceptible strain) with INH at 25 mg/kg. However, INH at 100 mg/kg
was not more active than INH at 25 mg/kg against the low-level INH-resistant strain of
M. tuberculosis.69
Considering the relative low toxicity rate of INH in children, it should be possible
to use INH at increased doses (15 to 20 mg/kg) in selected cases, such as children with
primary INH resistance or TBM. In our study of childhood contacts of adult MDR TB
cases, none of 62 children who had received either chemoprophylaxis or treatment that
included INH at 15 to 20 mg/kg daily, developed jaundice because of therapy. (Chapter
6, table 3) Furthermore, only one of 38 children treated with INH 20 mg/kg together with
three other antituberculosis drugs for TBM developed significantly raised liver enzymes
and bilirubin levels."
Mean INH peak serum concentrations of 19.1 mg/l +/- SD 4.2 mg/l have been
achieved by giving INH doses of 20 mg/kg, which is approximately 10 times the MIC of
2 rug/ml." A Cmax often times the MIC should have an effect on these low-level resistant
organisms even though the AUC will be significantly decreased and an AUIC of 125
may not be achieved. In the case of INH, if even smaller pulses that in themselves may
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not have a detectable effect, are followed on successive days by further small pulses, the
overall effect, measurable by bactericidal activity or lag in growth, is cumulative.l" It is
therefore advisable that INH treatment should be given daily if added to a drug-resistant
treatment regimen.
In this study we have shown that even at a dose of only 10 mg/kg, 51 (80%)
children had an 3-hour INH-concentration of >2 mg/L. All children with 3-hour INH-
concentrations <2 mg/L were phenotypically fast (n = Il) and intermediate (n = 2)
acetylators. Furthermore 28 (44%) children, including all the slow acetylators, had INH-
levels of >2 mg/L at 5-hours post INH administration. Therefore, in an area where
primary INH resistance is high, a dosage of 10 mg/kg of INH may contribute to the
efficacy of treatment regimens in low-level INH-resistant cases mainly in the slow
acetylators. An increased INH-dosage of 15-20 mg/L in the faster acetylators will most
likely have a similar effect in this group. INH should, however, not be given as a
replacement drug for other antituberculosis drugs to which the bacilli are susceptible, but
as an additional drug to such a regimen.
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Table 3: Raw data tabulation of age, gender and INH levels at 2 to 5 hours post dose.
Patient Age (years) Gender INH 2-hour 2-hour 3-hour 3-hour 4-hour 4-hour 5-hour 5-hour
ID d/kg time concentration time concentration time concentration time concentration
1 9.00 Male 10 2 4.8354 3.016 2.6118 4 1.8244 5.0333 1.0217
2 11.17 Male 10.26 2.0667 8.4644 3 5.942 4.0833 3.9603 5.1167 2.1134
3 2.25 Male 10 2.0167 10.6173 3.1167 7.7778 4.0333 5.8908 5.0833 4.2015
4 2.92 Male 10 1.9667 9.1346 3 7.5492 4 5.8439 5.0833 4.4007
5 3.92 Male 13.27 1.95 2.1831 2.9833 2.9833 3.95 2.3518 5.1 1.2816
6 4.00 Female 10 1.9166 7.1133 2.883 4.3116 3.9 2.761 4.933 1.7673
7 6.75 Male 10 1.917 5.9251 2.966 2.7138 3.9 1.5153 5 0.862
8 3.92 Male 10 2.067 6.2507 3.1 3.8725 4.1 2.4194 5.1 1.4257
9 7.83 Female 10 2 2.7367 3 1.1041 4.05 0.5406 5.034 0.2724
10 2.75 Female 10 3 5.6697 4 4.3157 5 3.1516
11 4.67 Male 10.87 2.083 6.3389 3 5.5548 4.083 4.3228 5.033 3.7504
12 2.08 Male 10 2.033 7.7387 3.083 5.811 4.083 4.2697 5.117 2.9883
13 4.00 Male 10.2 2 5.1221 3 2.3443 4 1.3305 5 0.6558
14 2.50 Male 10 1.983 7.8519 2.9667 5.4469 4 3.9141 4.9667 3.3263
15 0.83 Male 10 1.95 6.7381 2.967 4.9591 4 3.9855 4.9667 3.1764
16 4.08 Male 10 2.0833 2.6211 3.0667 1.1771 4 0.6139 5.233 0.3681
17 3.58 Female 10 2.134 5.5043 3 3.1869 4 1.7639 5 0.9862
18 1.25 Male 10.41 3.1 6.1663 3.9667 5.1647 5.2667 3.6099
19 11.08 Female 10 2 7.7494 3 4.944 4.0167 2.8028 5.0167 1.9554
20 0.75 Male 9.75 2.133 5.3125 3 3.108 4.05 1.9052 5.08 1.1928
21 4.00 Female 14.49 2 9.8829 3 7.7941 4 5.5386 5 4.7665
22 3.08 Male 10 2 2.3697 3.016 1.0929 4.05 0.6156 5.07 0.3153
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Table 3: Raw data tabulation of age, gender and INH levels at 2 to 5 hours post dose. (continued)
Patient Age (years) Gender INH 2-hour 2-hour 3-hour 3-hour 4-hour 4-hour 5-hour 5-hour
ID d/kg time concentration time concentration time concentration time concentration
23 3.00 Female 10.1 2 2.5745 2.96 1.6594 3.95 1.0031 5.03 0.6994
24 10.92 Male 10 1.933 6.5805 3.05 3.6765 4 1.9654 4.98 1.0322
25 0.67 Female 10 2.016 4.2066 3.016 2.3474 4.016 1.2339 5 0.8863
26 9.00 Male 10 1.95 7.9327 2.967 6.0954 3.967 4.9336 4.95 4.0782
27 4.92 Female 10 2.4 2.4829 3.05 1.3441 4 0.6138 5.1 0.2833
28 9.92 Female 10 1.9167 4.4031 2.9167 2.374 3.9333 1.3348
29 1.42 Female 10 1.9 3.2558 2.983 1.3365 3.967 0.7797 4.95 0.4579
30 10.50 Male 10 2.05 7.9379 3.083 4.4433 4.067 2.5537 5 1.7132
31 8.17 Male 10 1.867 7.1961 3.033 5.1931 4.05 4.2569 4.9667 3.2884
32 3.17 Female 10 2.25 4.3195 2.967 2.6136 4.133 1.7953
33 5.33 Male 10 1.933 1.7752 2.95 0.9256 4 0.5128 4.95 0.4001
34 2.58 Female 10 2 6.3807 2.883 5.1362 3.917 3.9759 4.917 3.3156
35 3.33 Female 10 1.967 3.3596 2.867 1.7548 3.95 0.9478 4.967 0.5197
36 7.67 Male 10 2.033 7.3902 3 4.743 4.0333 2.9218 5.0167 1.734
37 2.67 Female 10 2 6.5268 2.9666 4.1383 4 2.5305 5 1.394
38 9.92 Female 10 1.85 10.8406 2.9833 7.47 3.9833 5.751 5 4.3066
39 1.25 Female 10 1.95 7.2519 3.0166 6.0108 4 4.3918 5 3.8142
40 0.58 Male 10 1.933 7.0375 3.05 5.0144 4.083 3.9572 5.1166 3.0972
41 1.17 Female 10 2.033 6.6676 3.0833 4.4643 4.1 3.0454 5.1333 1.9997
42 12.58 Female 10 2.0667 8.3661 2.95 6.8566 3.95 5.5876 4.9667 3.9842
43 2.33 Male 10 1.9833 3.4724 2.95 1.5588 4.0667 0.6029 4.95 0.2799
44 11.00 Male 10 2.0333 4.8809 3.0333 2.7867 3.9833 1.9601 4.9666 1.3518
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Table 3: Raw data tabulation of age, gender and INH levels at 2 to 5 hours post dose. (continued)
Patient Age (years) Gender INH 2-hour 2-hour 3-hour 3-hour 4-hour 4-hour 5-hour 5-hour
ID d/kg time concentration time concentration time concentration time concentration
45 4.58 Female 10 1.95 12.6101 3.0833 9.4362 4.0833 7.4746 5.0333 6.1358
46 4.00 Female 10 2.1667 5.6127 2.95 3.9965 4.0833 2.1316 5 1.3159
47 6.58 Male 10 2 1.9065 3 1.0087 4.1166 0.5962 5 0.379
49 10.08 Male 10.08 2.0833 6.5786 3 4.4561 4.1667 2.7025 4.9 1.9557
50 0.58 Male 10 1.8833 7.2402 3.0167 5.5783 4.0833 4.216 5.05 3.374
51 1.58 Male 10 2 4.7023 2.95 2.7473 4.1 1.3843 4.95 0.8361
52 12.17 Male 10 2 11.4861 3 10.1876 4.033 8.3527 4.95 6.9322
53 1.00 Male 10 2.3166 3.4932 3.2 3.048 4.1667 2.4248
54 2.00 Male 10 2.1 3.9257 2.95 2.2925 4.0333 1.2554 4.95 0.7348
55 3.42 Female 10 2.1333 4.6051 3.0167 2.7607 4.05 1.574 5.0667 0.8525
56 6.25 Female 10 2 10.7708 3.0167 8.6152 3.95 7.0946 4.9667 5.7846
57 0.83 Male 10 2.1167 2.4584 2.9833 1.3779 4.0167 0.7065 4.9833 0.4031
58 11.42 Female 10 1.8833 7.9778 3 4.7749 3.9667 3.214 4.9333 2.0815
59 1.58 Male 10 2 8.5183 3.0833 6.5491 4.0333 5.1388 5.0333 4.16
60 1.92 Female 10 1.9167 4.663 3.0167 2.382 3.9833 1.3725 5 0.8047
61 6.47 Female 10 2.0167 8.3002 2.9833 6.8854 4 5.4259 4.9667 3.878
62 11.25 Male 10 1.95 12.3481 3.0167 9.712 4.0333 7.3508 4.9837 6.1418
63 1.08 Female 10 2.016 3.1033 3.1333 1.0303 4.0333 0.4378
64 1.39 Female 10 2.1167 6.5204 3.0667 4.6814 4.0833 3.2884 5 2.5097
65 1.40 Male 9.73 2.05 3.823 3 1.7435 4.067 0.8474 4.9667 0.4627
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Table 4: INH concentrations corrected for times 2 to 5 hours post dose.
Patient Age (years) Gender INH d/kg Corrected 2h Corrected 3h Corrected 4h Corrected 5h
ID concentration concentration concentration concentration
1 9.00 Male 10 4.6800 2.8431 1.7272 1.0493
2 11.17 Male 10.26 9.1252 5.8360 3.7324 2.3870
3 2.25 Male 10 10.7757 7.9621 5.8831 4.3470
4 2.92 Male 10 9.2816 7.3268 5.7836 4.5655
5 3.92 Male 13.27 4.6785 3.1261 2.0888 1.3957
6 4.00 Female 10 6.6763 4.2193 2.6665 1.6852
7 6.75 Male 10 5.2814 2.8283 1.5146 0.8111
8 3.92 Male 10 6.5467 4.0284 2.4788 1.5252
9 7.83 Female 10 2.5326 1.1867 0.5560 0.2605
10 2.75 Female 10 7.6575 5.7093 4.2567 3.1737
11 4.67 Male 10.87 6.5037 5.4090 4.4986 3.7414
12 2.08 Male 10 7.9646 5.8504 4.2974 3.1566
13 4.00 Male 10.2 4.9391 2.5191 1.2848 0.6553
14 2.50 Male 10 6.5075 5.0909 3.9827 3.1157
15 0.83 Male 10 6.5075 5.0909 3.9827 3.1157
16 4.08 Male 10 2.4736 1.3252 0.7100 0.3804
17 3.58 Female 10 5.8864 3.2347 1.7776 0.9768
18 1.25 Male 10.41 8.2301 6.4134 4.9978 3.8946
19 11.08 Female 10 7.6968 4.8255 3.0253 1.8967
20 0.75 Male 9.75 5.4238 3.2864 1.9913 1.2066
21 4.00 Female 14.49 9.8139 7.6209 5.9180 4.5956
22 3.08 Male 10 2.3704 1.1893 0.6230 0.3263
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Table 4: INH concentrations corrected for times 2 to S hours post dose. (continued)
Patient Age (years) Gender INH d/kg Corrected 2h Corrected 3h Corrected 4h Corrected Sh
ID concentration concentration concentration concentration
23 3.00 Female 10.1 2.5172 1.6262 1.0506 0.6787
24 10.92 Male 10 6.5863 3.5733 1.9387 1.0518
25 0.67 Female 10 4.0660 2.3828 1.3963 0.8183
26 9.00 Male 10 7.7068 6.1793 4.9545 3.9725
27 4.92 Female 10 3.2386 1.4540 0.6528 0.2931
28 9.92 Female 10 4.1548 2.2990 1.2721 0.7039
29 1.42 Female 10 2.8061 1.4863 0.7873 0.4170
30 10.50 Male 10 7.9502 4.7044 2.7837 1.6472
31 8.17 Male 10 6.8937 5.3839 4.2047 3.2838
32 3.17 Female 10 4.7384 2.7921 1.6453 0.9695
33 5.33 Male 10 1.6821 0.9226 0.5060 0.2776
34 2.58 Female 10 6.3036 5.0255 4.0065 3.1942
35 3.33 Female 10 2.7389 1.4803 0.8001 0.4324
36 7.67 Male 10 7.6226 4.6975 2.8948 1.7839
37 2.67 Female 10 6.6920 4.0157 2.4097 1.4460
38 9.92 Female 10 10.2098 7.6366 5.7119 4.2723
39 1.25 Female 10 7.2278 5.7946 4.6457 3.7245
40 0.58 Male 10 6.7666 5.2415 4.0601 3.1450
41 1.17 Female 10 6.7853 4.6069 3.1279 2.1237
42 12.58 Female 10 8.6765 6.7499 5.2510 4.0850
43 2.33 Male 10 3.4558 1.4787 0.6327 0.2707
44 11.00 Male 10 4.6882 3.0452 1.9779 1.2847
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Table 4: INH concentrations corrected for times 2 to S hours post dose. (continued)
Patient Age (years) Gender INH dlkg Corrected 2h Corrected 3h Corrected 4h Corrected Sh
ID concentration concentration concentration concentration
45 4.58 Female 10 12.3168 9.7471 7.7135 6.1041
46 4.00 Female 10 6.2890 3.7449 2.2300 1.3279
47 6.58 Male 10 1.8285 1.0752 0.6322 0.3718
49 10.08 Male 10.08 6.8357 4.4454 2.8909 1.8800
50 0.58 Male 10 7.0659 5.5400 4.3435 3.4055
51 1.58 Male 10 4.7412 2.6368 1.4665 0.8156
52 12.17 Male 10 11.7552 9.8867 8.3153 6.9936
53 1.00 Male 10 3.7686 3.0919 2.5368 2.0813
54 2.00 Male 10 4.0949 2.2842 1.2742 0.7108
55 3.42 Female 10 4.9769 2.8095 1.5860 0.8953
56 6.25 Female 10 10.7173 8.6925 7.0502 5.7182
57 0.83 Male 10 2.5987 1.3811 0.7340 0.3901
58 11.42 Female 10 7.5239 4.8564 3.1346 2.0232
59 1.58 Male 10 8.4745 6.6790 5.2639 4.1486
60 1.92 Female 10 4.3503 2.4597 1.3908 0.7864
61 6.47 Female 10 8.6191 6.6758 5.1706 4.0048
62 11.25 Male 10 12.1887 9.6380 7.6210 6.0262
63 1.08 Female 10 3.1352 1.1867 0.4492 0.1700
64 1.39 Female 10 6.5204 4.6814 3.2884 2.5097
65 1.40 Male 9.73 3.8230 1.7435 0.8474 0.4627
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Table 5: Calculated pharmacokinetic parameters
Patient Age Gender Calculated 3h k h-I Phenotypification Co (mgIL) Co (mgIL) Vd (Llkg) AUCO-oc,
ID (years) concentration extrapolated calculated individual (mgIL/h)
1 9 Male 2.8431 0.4984 Intermed 12.6808 14.5433 0.7886 29.180
2 11.17 Male 5.836 0.447 Intermed 22.3101 14.9215 0.4599 33.381
3 2.25 Male 7.9621 0.3026 Slow 19.7369 14.5433 0.5067 48.061
4 2.92 Male 7.3268 0.2365 Slow 14.8951 14.5433 0.6714 61.494
5 3.92 Male 3.1261 0.4032 Intermed 10.479 19.2990 1.2663 47.865
6 4 Female 4.2193 0.4589 Intermed 16.7159 14.5433 0.5982 31.692
7 6.75 Male 2.8283 0.6245 Fast 18.4153 14.5433 0.543 23.288
8 3.92 Male 4.0284 0.4856 Intermed 17.2905 14.5433 0.5784 29.949
9 7.83 Female 1.1867 0.7581 Fast 11.5357 14.5433 0.8669 19.184
10 2.75 Female 5.7093 0.2936 Slow 13.7755 14.5433 0.7259 49.534
11 4.67 Male 5.409 0.1843 Slow 9.4024 15.8086 1.1561 85.776
12 2.08 Male 5.8504 0.3085 Slow 14.7612 14.5433 0.6775 47.142
13 4 Male 2.5191 0.6733 Fast 18.9877 14.8342 0.5372 22.032
14 2.5 Male 5.1825 0.2678 Slow 13.3912 14.5433 0.7468 54.307
15 0.83 Male 5.0909 0.2455 Slow 10.633 14.5433 0.9405 59.240
16 4.08 Male 1.3252 0.6241 Fast 8.6182 14.5433 1.1603 23.302
17 3.58 Female 3.2347 0.5987 Fast 19.4929 14.5433 0.513 24.291
18 1.25 Male 6.4134 0.2494 Slow 13.5528 14.5433 0.7379 58.313
19 11.08 Female 4.8255 0.4669 Intermed 19.582 15.1396 0.5316 32.425
20 0.75 Male 3.2864 0.501 Intermed 14.773 14.5433 0.6769 29.029
21 4 Female 7.6209 0.2529 Slow 16.2745 14.1796 0.599 56.068
22 3.08 Male 1.1893 0.6466 Fast 8.2742 21.0732 1.7512 32.591
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Table 5: Calculated pharmacokinetic parameters (continued)
Patient Age Gender Calculated 3h k, h-I Phenotypification Co (mgIL) Co (mgIL) Vd (Llkg) AUCO-oc
ID (years) concentration extrapolated calculated individual (mgIL/h)
23 3 Female 1.6262 0.4369 Intermed 6.0312 14.5433 1.658 33.287
24 10.92 Male 3.5733 0.6115 Fast 22.3762 14.6888 0.4513 24.021
25 0.67 Female 2.3828 0.5344 Intermed 11.8397 14.5433 0.8446 27.214
26 9 Male 6.1793 0.2209 Slow 11.9879 14.5433 0.8342 65.837
27 4.92 Female 1.454 0.8008 Fast 16.0664 14.5433 0.6224 18.160
28 9.92 Female 2.299 0.5918 Fast 13.57 14.5433 0.7369 24.575
29 1.42 Female 1.4863 0.6355 Fast 10.0021 14.5433 0.9979 22.885
30 10.5 Male 4.7044 0.5247 Fast 22.7053 14.5433 0.4404 27.717
31 8.17 Male 5.3839 0.2472 Slow 11.3023 14.5433 0.8848 58.832
32 3.17 Female 2.7921 0.5289 Fast 13.6467 14.5433 0.7328 27.497
33 5.33 Male 0.9226 0.6006 Fast 5.5916 14.5433 1.7884 24.215
34 2.58 Female 5.0255 0.2266 Slow 9.9177 14.5433 1.0083 64.180
35 3.33 Female 1.4803 0.6153 Fast 9.3761 14.5433 1.0665 23.636
36 7.67 Male 4.6975 0.4841 Intermed 20.0719 14.5433 0.4982 30.042
37 2.67 Female 4.0157 0.5107 Fast 18.5842 14.5433 0.5381 28.477
38 9.92 Female 7.6366 0.2904 Slow 18.2497 14.5433 0.548 50.080
39 1.25 Female 5.7946 0.221 Slow 11.2451 14.5433 0.8892 65.807
40 0.58 Male 5.2415 0.2554 Slow 11.2774 14.5433 0.8867 56.943
41 1.17 Female 4.6069 0.3872 Intermed 14.7192 14.5433 0.6794 37.560
42 12.58 Female 6.7499 0.2511 Slow 14.3367 14.5433 0.6975 57.918
43 2.33 Male 1.4787 0.8489 Fast 18.8752 14.5433 0.5298 17.132
44 Il Male 3.0452 0.4315 Intermed 11.1123 14.5433 0.8999 33.704
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Table 5: Calculated pharmacokinetic parameters (continued)
Patient Age Gender Calculated 3h k h-I Phenotypification Co (mgIL) Co (mgIL) Vd (Llkg) AUCO-cc,
ID (years) concentration extrapolated calculated individual (mgILlh)
45 4.58 Female 9.7471 0.234 Slow 19.6675 14.5433 0.5084 62.151
46 4 Female 3.7449 0.5184 Intermed 17.7362 14.5433 0.5638 28.054
47 6.58 Male 1.0752 0.531 Intermed 5.2882 14.5433 1.891 27.389
49 10.08 Male 4.4454 0.4303 Intermed 16.1636 14.6597 0.6236 34.069
50 0.58 Male 5.54 0.2433 Slow 11.4947 14.5433 0.8699 59.775
51 1.58 Male 2.6368 0.5867 Fast 15.328 14.5433 0.6524 24.788
52 12.17 Male 9.8867 0.1731 Slow 16.6181 14.5433 0.6018 84.017
53 1 Male 3.0919 0.1979 Slow 5.5985 14.5433 1.7862 73.488
54 2 Male 2.2842 0.5837 Fast 13.1594 14.5433 0.7599 24.916
55 3.42 Female 2.8095 0.5718 Fast 15.6176 14.5433 0.6403 25.434
56 6.25 Female 8.6925 0.2094 Slow 16.2918 14.5433 0.6138 69.452
57 0.83 Male 1.3811 0.6321 Fast 9.2001 14.5433 1.0889 23.008
58 11.42 Female 4.8564 0.4378 Intermed 18.0598 14.5433 0.5537 33.219
59 1.58 Male 6.679 0.2381 Slow 13.6435 14.5433 0.7329 61.081
60 1.92 Female 2.4597 0.5702 Fast 13.6079 14.5433 0.7349 25.506
61 6.47 Female 6.6758 0.2555 Slow 14.3677 14.5433 0.696 56.921
62 11.25 Male 9.638 0.2348 Slow 19.4941 14.5433 0.513 61.939
63 1.08 Female 1.1867 0.9715 Fast 21.8828 14.5433 0.457 14.970
64 1.39 Female 4.6814 0.3317 Intermed 12.8978 14.5433 0.7753 43.845
65 1.4 Male 1.7435 0.7219 Fast 15.8388 14.1507 0.6313 19.602
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Table 6: Dose adjustments according to the inactivation index (13)
Patient ID K-value Corrected 3-h Inactivation Indexj, 13-adjusted dose 13-adjusted dose
cone (13) (3-h INH cone, = 1.5 mg/L) (3-h INH conc. = 2.0 mg/L)
1 0.4984 2.8431 0.3443 6.10 7.55
2 0.447 5.836 0.6273 3.35 4.14
3 0.3026 7.9621 0.8562 2.45 3.04
4 0.2365 7.3268 0.7927 2.65 3.28
5 0.4032 3.1261 0.2808 7.48 9.26
6 0.4589 4.2193 0.4819 4.36 5.39
7 0.6245 2.8283 0.3428 6.13 7.58
8 0.4856 4.0284 0.4628 4.54 5.62
9 0.7581 1.1867 0.1787 11.75 14.55
10 0.2936 5.7093 0.6309 3.33 4.12
Il 0.1843 5.409 0.5528 3.80 4.70
12 0.3085 5.8504 0.6450 3.26 4.03
13 0.6733 2.5191 0.3058 6.87 8.50
14 0.4263 5.1825 0.5783 3.63 4.50
15 0.2455 5.0909 0.5691 3.69 4.57
16 0.6241 1.3252 0.1925 10.91 13.51
17 0.5987 3.2347 0.3835 5.48 6.78
18 0.2494 6.4134 0.6737 3.12 3.86
19 0.4669 4.8255 0.5426 3.87 4.79
20 0.501 3.2864 0.3986 5.27 6.52
21 0.2529 7.6209 0.5673 3.70 4.58
22 0.6466 1.1893 0.1789 11.74 14.53
23 0.4369 1.6262 0.2204 9.53 11.80
24 0.6115 3.5733 0.4173 5.03 6.23
25 0.5344 2.3828 0.2983 7.04 8.72
Stellenbosch University http://scholar.sun.ac.za
211
Table 6: Dose adjustments according to the inactivation index (13) (continued)
Patient ID K-value Corrected 3-h Inactivation Indexj, I3-adjusted dose I3-adjusted dose
cone (13) (3-h INH cone. = 1.5 mglL) (3-h INH conc. = 2.0 mglL)
26 0.2209 6.1793 0.6779 3.10 3.84
27 0.8008 1.454 0.2054 10.22 12.66
28 0.5918 2.299 0.2899 7.24 8.97
29 0.6355 1.4863 0.2086 10.07 12.46
30 0.5247 4.7044 0.5304 3.96 4.90
31 0.2472 5.3839 0.5984 3.51 4.34
32 0.5289 2.7921 0.3392 6.19 7.66
33 0.6006 0.9226 0.1523 13.79 17.08
34 0.2266 5.0255 0.5626 3.73 4.62
35 0.6153 1.4803 0.2080 10.09 12.50
36 0.4841 4.6975 0.5298 3.96 4.91
37 0.5107 4.0157 0.4616 4.55 5.63
38 0.2904 7.6366 0.8237 2.55 3.16
39 0.221 5.7946 0.6395 3.28 4.07
40 0.2554 5.2415 0.5842 3.59 4.45
41 0.3872 4.6069 0.5207 4.03 4.99
42 0.2511 6.7499 0.7350 2.86 3.54
43 0.8489 1.4787 0.2079 10.10 12.51
44 0.4315 3.0452 0.3645 5.76 7.13
45 0.234 9.7471 1.0347 2.03 2.51
46 0.5184 3.7449 0.4345 4.83 5.98
47 0.531 1.0752 0.1675 12.54 15.52
49 0.4303 4.4454 0.5005 4.20 5.19
50 0.2433 5.54 0.6140 3.42 4.23
51 0.5867 2.6368 0.3237 6.49 8.03
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Table 6: Dose adjustments according to the inactivation index (13)(continued)
Patient ID K-value Corrected 3-h Inactivation Index3h 13-adjusted dose 13-adjusted dose
conc (13) (3-h INH cone, = 1.5 mg/L) (3-h INH cone, = 2.0 mg/L)
52 0.1731 9.8867 1.0487 2.00 2.48
53 0.1979 3.0919 0.3692 5.69 7.04
54 0.5837 2.2842 0.2884 7.28 9.01
55 0.5718 2.8095 0.3410 6.16 7.63
56 0.2094 8.6925 0.9293 2.26 2.80
57 0.6321 1.3811 0.1981 10.60 13.12
58 0.4378 4.8564 0.5456 3.85 4.77
59 0.2381 6.679 0.7279 2.89 3.57
60 0.5702 2.4597 0.3060 6.86 8.50
61 0.2555 6.6758 0.7276 2.89 3.57
62 0.2348 9.638 1.0238 2.05 2.54
63 0.9715 1.1867 0.1787 11.75 14.55
64 0.3317 4.6814 0.5281 3.98 4.92
65 0.7219 1.7435 0.2409 8.72 10.79
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CHAPTER8
General Conclusions
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General Conclusions
A. Background to drug-resistant tuberculosis
Soon after the discovery of the first antituberculosis agents it became clear that the
development of drug resistance was not uncommon, and that it could lead to failure of
both individual antituberculosis treatment and tuberculosis control programmes.l"
Combination therapy introduced in the mid-1950s appeared to overcome most of the
problems with antituberculosis drug resistance.t"
The first twenty to twenty-five years after the introduction of antituberculosis
treatment saw the development of most of the antituberculosis agents currently in use, as
well as research on the mechanisms and effects of drug resistance. So effective was the
introduction of combination treatment regimens that research in the field of tuberculosis
in general, but more specifically drug-resistant tuberculosis, halted almost completely in
the early 1970s.
Despite warnings by experienced researchers such as Canetti' and Horne", this lack
of interest continued into the late 1980s, at which time the incidence of tuberculosis
started to rise in developed countries after many years of steady decline." 10 This was
mainly due to the effect ofHIV/AIDS, but also as a result of increased immigration from
the developing countries where tuberculosis had never really been controlled.f''!' The
severity of the new epidemic only struck home, however, when large outbreaks of MOR
TB started to occur in developed countries such as the United States.12,13
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B. Background to childhood drug-resistant tuberculosis
Tuberculosis in children has been a very neglected field of research, as it was
thought to be of relatively little epidemiologic importance." This is, however, an
incorrect assumption, because when a child presents with a M. tuberculosis infection or
tuberculous disease, it usually implies recent transmission from an adult with active
pulmonary tuberculosis in the community.15-17These infected children, even if they do
not immediately develop disease, may undergo reactivation during adolescence or
adulthood and so contribute to the infectious pool. This has become a particularly serious
possibility in the era of HIV and AIDS.
For many years the dogma that INH-resistant tubercle bacilli are less infectious and
less pathogenic than INH-susceptible tubercle bacilli was accepted. This was based on
. I di . . I 18-21b ti d i h di 1522-26Mexpenmenta stu les In amma s, ut was not con irme In uman stu les.' any
researchers still hold this view, and the infectiousness and pathogenicity of MDR TB for
immunocompetent children still had to be proven.
With the rise in the incidence of drug-resistant tuberculosis in adults in cities such
as New York, it was noticed that a similar increase in drug-resistant tuberculosis in
children soon followed.27-29Apart from a few surveys in the USA,28,30,31very little is
known about the incidence of drug-resistant tuberculosis in children. Furthermore,
despite much debate on the management of adults in contact with MDR TB cases,
children have received little attention, and no prospective studies have been recorded to
date to evaluate the management of these childhood contacts.32-34Many reports describe
the treatment and outcome of adults with MDR TB, but, once again, the treatment of
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children with MDR TB is based on a number of case reports, and experience in the
treatment of adults with MDR TB.28,35-37
The role of individual antituberculosis agents in the management of MDR TB in
children needs to be clarified.34,38Several reports speculate on the possible therapeutic
role of INH in primary INH-resistant tuberculosis, which would include the majority of
children with drug-resistant TB.39-42 Although failure of INH as a single
chemoprophylactic agent against INH-resistant strains has been reported,22,43.44it is
possible that, with partial or low-level resistance to INH, this agent can still be a valuable
adjunct to the treatment regimen. Furthermore, the second line antituberculosis agents,
which are known to be less effective and to cause more adverse events than the first line
drugs, need to be evaluated in the long-term treatment in children.
c. Drug-resistant TB in children as a measure of transmission of drug-resistant
TB in the community.
Although the primary aim of any TB control program or service should be to
optimise treatment (short course chemotherapy, directly observed) for drug-susceptible
cases, the surveillance, either continuous or periodic, of the magnitude of the drug
resistance problem remains essential." Trends in primary or initial drug resistance
provide an indication of the effectiveness of treatment regimens, while acquired drug
resistance rates can indicate failure in the management of disease."
The surveillance of drug-resistant TB in children may be beneficial for several
reasons. Firstly, it is often difficult to establish whether adults had received previous
antituberculosis treatment, and thus whether they actually have primary drug
resistance.V" Young children, because of their age, usually have primary drug resistance
Stellenbosch University http://scholar.sun.ac.za
217
and previous antituberculosis treatment is much easier to exclude with certainty.l"
Secondly, even when it is established that previous TB treatment had been received by an
adult, it has been shown by DNA fingerprinting of M. tuberculosis strains that in a high
TB incidence area, MDR TB is still more often transmitted (i.e. reinfection from an index
case with MDR TB) rather than acquired through non-compliance with antituberculosis
drug treatment.Y Finally, few high TB-burden countries have the resources to do
susceptibility testing on all M. tuberculosis isolates or even to do cultures for M.
tuberculosis on each patient with suspected TB. Sampling is, therefore, often done, the
results of which could easily be distorted by testing mainly those who are at higher risk
of having drug-resistant TB.45 Drug susceptibility testing of all M. tuberculosis isolates
obtained from children may thus be a cost effective alternative.
We have shown that prospective susceptibility testing of M. tuberculosis isolates
from children with TB in a specific geographic drainage area yielded results of drug
resistance comparable with results obtained from an adult study that had been done in the
same area. This was despite the number of childhood cases being much smaller than the
number of cases in the adult study." When study limitations were removed, 5.6% of
children had primary INH resistance and 1.0% MDR TB compared to a rate of 3.9% and
1.1%, respectively, in adults.
If the total study population was included in the analysis, however, the increase in
drug resistance evident in the childhood surveillance study (6.9% INH resistance and
2.3% MDR) could be explained in several ways (see chapter 3, discussion), of which the
most likely reasons are a bias because the childhood study was hospital-based and
therefore probably represents the worst case scenario," or because the childhood study
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truly reflects transmitted drug resistance in a high incidence area as demonstrated by the
DNA fingerprint study of van Rie et a1.47
In conclusion, our findings show that the incidence of drug-resistant TB in children in
the Western Cape Province is low. The study probably reflects the level of primary drug
resistance amongst organisms currently circulating in our community.
Recommendation: This surveillance study should be repeated on a larger scale to
include all the secondary and tertiary hospitals in the Western Cape area. The data should
again be compared to current surveillance studies in adults in the same area. If these
results are again similar, it will strengthen the case for children's drug susceptibility
results to be used as a cost effective, continuous, surveillance method for primary
(currently circulating) drug resistant TB organisms in the total population in an area.
D. Infection and disease in childhood contacts of adult MDR pulmonary TB cases
One of the main study objectives was to determine prospectively the short-term
prevalence and the long-term incidence of tuberculous infection and disease in young
children in household contact with adult MDR pulmonary TB, and therefore the
importance of contact tracing in this group of patients. A further aim was to confirm
transmission of MDR M tuberculosis organisms to children in contact with adult MDR
pulmonary TB cases by evaluating drug susceptibility patterns and RFLP analysis.
Although the absence of a prospective control group was a limitation of this study,
the initial evaluation (0 to 2 months) was compared with a similar study of children <5
years of age who had been in contact with mainly drug-susceptible cases in the same
geographical area." The infection rate (63%) at the first evaluation was significantly
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higher (P < .02) than in the child contacts of the drug susceptible cases (48%), but the
disease rate was much less (12% versus 34%, respectively). Snider et a1.24had similar
results regarding the infection rate in a controlled trial of INH- and/or streptomycin-
resistant contacts compared to drug-susceptible contacts. This could be because adults
with drug-resistant TB remain infectious for longer periods. A complicating factor in our
study was that many children had more than one adult TB contact, not all of whom were
multidrug-resistant.
On follow-up to 30 months, a first of its kind for childhood MDR TB contacts,
many more children became infected or developed disease. As was previously found in
several contact tracing studies, 90% of those who developed disease did so within the
first 12 months of follow_up.50-52This implies that follow-up beyond 12 months is
probably not cost effective in resource poor areas.
Seventy-eight percent of children had developed infection by 30-month follow-up,
which is higher than the generally reported infection rate of childhood contacts 0-5 years
of age of 30_72%.29,53,54Although a number of explanations can be given (Chapter 6,
discussion), this demonstrates that MDR TB is not less infectious than drug-susceptible
TB. Despite some children receiving chemoprophylaxis, 24% of the children eventually
developed disease, which is again similar to the expected disease incidence in childhood
contacts <5 years of age of infectious drug-susceptible adult pulmonary TB cases.29
Six adult-child pairs were identified in whom both the adult source case's M.
tuberculosis strain and the child's strain were obtained. Four of these were included in
the initial follow-up study and two further child contacts of adult MDR TB cases for
which both isolates were available, were subsequently identified. Susceptibility patterns
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as well as RFLP analysis were identical in 5 adult-child pairs. In one child, although also
infected with a MDR M. tuberculosis strain, the strain was different both in susceptibility
pattern as well as RFLP analysis. The results confirmed transmission of MDR M.
tuberculosis strains from adult source cases to their child contacts in most cases, and
confirm previous results found in INH-resistant cases by Steiner et a1.25
Recommendation: Specimens for M. tuberculosis culture and susceptibility testing
should be taken from all children in close contact with adult MDR pulmonary TB cases.
However, if the child's M. tuberculosis strain is not available, the child in contact with
the MDR source case should be treated according to the drug susceptibility pattern of the
source case's strain.
E. Treatment and chemoprophylaxis in childhood MDR TB disease and contacts
No prospective evaluation of treatment of children with MDR TB or
chemoprophylaxis for children in contact with adult MDR TB cases has been reported.
An additional aim of this study was therefore to establish the role of treatment in children
with MDR TB and whether chemoprophylaxis is effective in preventing active disease in
the childhood contacts.
Although children with primary uncomplicated TB will often improve without
treatment.f it is imperative that they should receive treatment because of the risk of
progression or dissemination of disease specifically in young children with death or
disability the outcome. The possibility of later HN infection and its propensity to
activate dormant organisms is a further cause for concern. In our series of 29 children
diagnosed as having disease, 25 (86%) received appropriate antituberculosis treatment
according to the drug-susceptibility pattern of the adult source cases' M. tuberculosis
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isolate. Prescribed treatment regimens consisted of two to three drugs to which the source
case's isolate was susceptible and antituberculosis drugs used were INH (see below),
pyrazinamide, ethambutol (EMB), ethionamide and ofloxacin. The duration of treatment
was generally shorter than that prescribed for adult type cavitary disease, as most
children were identified and treated before progression of disease occurred. It is known
that the lesions of uncomplicated primary TB contain a much smaller population of
organisms than cavitary or disseminated lesions, and that TB in childhood in the absence
of cavitation or dissemination is therefore probably overtreated.Y'
All children treated for MDR TB were clinically and radiologically well after
completion of treatment, despite some children defaulting treatment after as little as 4
months. All treated children were followed up for 30 months and no clinical or
radiological relapse occurred in these patients.
The reason for including INH at a high dose of 15 to 20 mg/kg/d in all treatment
regimens was that about half of the primary INH-resistant M. tuberculosis isolates
probably have low-level INH resistance of ~2 mg/L. (See below) EMB, which is used as
first line drug in the treatment of children with drug-susceptible TB in some developing
countries, is a relatively safe drug with optic neuritis the main adverse reaction.56,57 When
used at the recommended dosage, this adverse event is very rare and EMB is therefore an
essential drug in the treatment of MDR TB cases, including young children,
Ethionamide was the most commonly used second line antituberculosis drug in our
study. Although about half the children receiving the drug experienced gastrointestinal
adverse events, most of these could be overcome by temporarily splitting the daily dose,
and only in 4 (7%) of 61 children did the drug have to be discontinued.
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The fluoroquinolones are not generally recommended for use in children because of
their possible harmful effect on cartilage growth.i" Many reports of the safety of these
drugs in children in short- and medium-term treatment have been published.58-6o In our
experience of 17 children (including 2 children from chapter 5 not included in chapter 6),
ofloxacin for a duration of 6 to 12 months was well tolerated. Possible arthralgia due to
the drug occurred in one (6%) child after 6 months of treatment. This is similar to
previous reports of arthralgia occurring in 1.3 to 3.5% of children, following 150 to 300
days of treatment. 58-60 Although we used ofloxacin mainly for the treatment of children
with MDR TB, it could probably also be recommended for use in MDR
chemoprophylaxis in children. The adverse effects of long-term fluoroquinolone use in
children needs further study.
An interesting observation during the follow-up of child contacts of adults with
infectious MDR TB was that TB disease occurred significantly less often in children that
received appropriate chemoprophylaxis (according to the drug susceptibility pattern of
the adult source case's isolate). Although this was not a randomised controlled trial, the
group that received chemoprophylaxis during the follow-up period was at higher risk for
developing disease. This has definite implications for the prevention of TB in MDR
contacts in so far as that these children should receive appropriate chemoprophylaxis
with at least two drugs to which the infectious source case's strain is susceptible.
Recommendation: A prospective, randomised controlled study is necessary to
evaluate the best drug combinations, their safety in long-term treatment, and the optimal
duration of such chemoprophylactic regimens.
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F. Isoniazid and its possible role in primary isoniazid-resistant TB cases
Relatively little is known about the pharmacokinetics of INH in children.
This study was undertaken to determine whether a dose of 10 mg/kg INH would
provide adequate therapeutic exposure even in children with low-level INH resistance
who are fast or intermediate acetylators of INH. Low-level INH resistance occurs in
about half the cases with primary INH resistance (Chapter 3).7.40
In our study, using only aIO mg/kg dose, phenotypic separation could be effected
between slow and 'fast' acetylators, but clear separation between fast and intermediate
acetylators, as in adults, could not be demonstrated." A high percentage (>60%) of this
population is intermediate or fast acetylators (Chapter 7).61 On studying the exposure
integrals and adjusted dosage regimens for INH according to Vivien's inactivation
index,62 it seems likely that in a population with mainly fast acetylators, and because
children in general having a lower propensity to toxicity, an INH dosage regimen of 6-1 0
mg/kg/d is more appropriate than the 4-6 mg/kg/d suggested by the IUATLD and
WHO.63.64 Supervision for adverse events, although rarely expected at this dose, can be
done together with directly observed therapy.
Our results also suggest that peak levels of 10 times the MIC of low-level (~2
mg/L) INH-resistant organisms can be achieved in most patients by giving higher
dosages of INH. In case of low-level resistance to INH the optimal management will be
to determine both the MIC of the INH-resistant M. tuberculosis strain as well as the
acetylator status of the individual in case of INH-resistant TB. This is however, often not
possible. Under these circumstances, knowing or suspecting (because of adult drug-
resistant contact) that a child has primary INH- or multi drug-resistant TB, a high dose of
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!NH (15-20 mg/kg/d) with close supervision for side effects, may be beneficial in up to
50% of cases.
Further studies with regard to the use of !NH in !NH-resistant cases are needed.
!NH may for example improve the function of other antituberculosis drugs even though
the organism is resistant to !NH itself. A long-term follow-up study in adults with
primary MDR TB treated with regimens with and without !NH to specifically look at the
speed with which sputum smears and cultures become negative, and remain negative,
may resolve this problem.
Recommendation: We propose that !NH at higher dosages of 15-20 mg/kg/d
(maximum 500 mg) should remain part of the treatment regimen of children with MDR
TB, especially in developing countries where second line drugs are less freely available.
Treatment should be given under direct supervision and include observation for adverse
events such as hepatotoxicity. Pyridoxine can be added specifically in older children to
prevent peripheral neuropathy.
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